atazanavir sulfate has been researched along with HIV Coinfection in 726 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 278 (38.29) | 29.6817 |
| 2010's | 406 (55.92) | 24.3611 |
| 2020's | 42 (5.79) | 2.80 |
| Authors | Studies |
|---|---|
| Bunglawala, F; Cottura, N; Denti, P; Fabrega, F; Howarth, A; Kinvig, H; Lloyd, A; Montanha, MC; Siccardi, M; Waitt, C | 1 |
| Badell, ML; Best, BM; Browning, R; Capparelli, EV; Chakhtoura, N; Denson, K; George, K; Mirochnick, M; Momper, JD; Paul, ME; Powis, KM; Rungruengthanakit, K; Shapiro, DE; Stek, A; Wang, J | 1 |
| Adankie, BT; Aklillu, E; Amogne, W; Engidawork, E; Shibeshi, W; Tadesse, WT | 1 |
| Barboza, JJ; Castañeda-Sabogal, A; Geldres-Molina, F; Hilario-Gómez, MM | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Al-Abed, Y; Fan Cheng, K; He, M; VanPatten, S | 1 |
| Castelnuovo, B; Lumu, I; Musaazi, J | 1 |
| Brummel, SS; Chadwick, EG; Huo, Y; Jacobson, DL; Jao, J; Kacanek, D; Kahlert, CR; Patel, K; Powis, KM; Seage, GR; Shiau, S; Sultan-Beyer, L; Williams, PL; Yee, LM; Zash, R | 1 |
| Rana, V; Sethi, S | 1 |
| Campisi, J; Desprez, PY; Hughes, JB; Kuehnemann, C; Melov, S; Wiley, CD | 1 |
| Abbot, V; Kapila, I; Sharma, A; Sharma, P | 1 |
| Bamford, A; Burger, DM; Bwakura-Dangarembizi, M; Chabala, C; Colbers, A; Denti, P; Doerholt, K; Gibb, DM; Griffiths, AL; Makumbi, S; McIlleron, HM; Monkiewicz, LN; Mulenga, V; Mumbiro, V; Musiime, V; Nangiya, J; Szubert, AJ; Waalewijn, H; Wasmann, RE; Wiesner, L | 1 |
| Beltrami, M; Cattaneo, D; Gervasoni, C; Micheli, V; Pagano, S | 1 |
| Brunel, V; Malval, B; Massy, N | 1 |
| Cecka, F; Cerveny, L; Huliciak, M; Martinec, O; Staud, F; Vokral, I | 1 |
| Akelo, V; Aweeka, F; Aziz, M; Berzins, B; Cohn, SE; Coombs, RW; Coughlin, K; Cramer, YS; Friedman, RK; Gingrich, D; Godfrey, C; Moran, LE; Rosenkranz, SL; Scarsi, KK; Swaminathan, S; Zorrilla, CD | 1 |
| Bani-Sadr, F; Berger, JL; Brunet, A; Favarel-Garrigues, M; Hentzien, M | 1 |
| Anastos, K; Aouizerat, BE; Bacchetti, P; French, AL; Gange, S; Greenblatt, RM; Gustafson, DR; Huang, Y; Hysi, PG; Kassaye, S; Nowicki, MJ; Tamraz, B | 1 |
| Adamson, L; Akkina, R; Blake, K; Burgunder, EM; Devanathan, AS; Garcia, JV; Kashuba, ADM; Kovarova, M; Luciw, P; Pirone, JR; Remling-Mulder, L; Rosen, EP; Schauer, AP; Srinivas, N; Sykes, C; White, NR | 1 |
| Biasiotto, G; Bonito, A; Calza, S; Castelli, F; Quiros-Roldan, E; Vezzoli, M; Zanella, I | 1 |
| Cenderello, G; Di Biagio, A; Magnasco, L; Rizzardini, G | 1 |
| Castagna, A | 1 |
| Atzori, C; Baldelli, S; Cattaneo, D; Cozzi, V; Filice, C; Fusi, M; Gervasoni, C; Micheli, V | 1 |
| Mejias, A; Peeples, ME; Ramilo, O; Teng, MN | 1 |
| Cassola, G; Del Puente, F; Pontali, E; Torresin, A | 1 |
| Boccara, F; Costagliola, D; Cotte, L; de Castro, N; Duval, X; Duvivier, C; Grabar, S; Katlama, C; Lang, S; Mary-Krause, M; Partisani, M; Potard, V; Raffi, F; Ronot-Bregigeon, S; Simon, A; Tattevin, P; Weiss, L; Zucman, D | 1 |
| Siedner, MJ; Triant, VA | 1 |
| Basilua, JM; Pochart, P | 1 |
| Foresto, RD; Kirsztajn, GM; Reghine, ÉL | 1 |
| Auclair, M; Capeau, J; Fellahi, S; Garcia, M; Guénantin, AC | 1 |
| Bulmahn, JC; He, GS; Kutscher, HL; Mahajan, SD; Prasad, PN; Singh, A | 1 |
| Aweeka, F; Baker, P; Berzins, B; Cohn, SE; Coombs, R; Coughlin, K; Cramer, YS; Gingrich, D; Godfrey, C; Haas, DW; Moran, LE; Rosenkranz, SL; Scarsi, KK; Zorrilla, CD | 1 |
| Cottrell, ML; Deeks, SG; Hatano, H; Hoh, R; Hunt, PW; Kashuba, ADM; Lee, SA; Liegler, TJ; Savic, RM; Somsouk, M; Stephenson, S; Telwatte, S; Yukl, S | 1 |
| El Kamari, V; Hileman, CO; Kosco, J; Mccomsey, GA | 1 |
| Avelino-Silva, VI; Fonseca, FF; Pascom, ARP; Pereira, G; Perini, FB; Pinho, RGG | 1 |
| Bonora, S; Calcagno, A; De Benedetto, I; Guastamacchia, G; Trunfio, M | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Stray-Pedersen, B; Zvada, S | 1 |
| Adrian, S; Beghetto, B; Erlandson, KM; Feng, H; Guaraldi, G; Lake, JE; Ligabue, G; Miao, H; Milic, J; Nardini, G; Roncaglia, E; Scherzinger, A | 1 |
| Chan, WW; Li, M; Zucker, SD | 1 |
| Cazzaniga, A; Galli, M; Maier, J; Rusconi, S; Scrimieri, R | 1 |
| Agide, FD; Mohraz, M; Nikfar, S; Tigabu, BM | 1 |
| Andersson, LM; Edén, A; Eriksen, J; Gisslén, M; Mellgren, Å; Nilsson, S; Thalme, A; Treutiger, CJ; Tyrberg, E | 1 |
| Abideen, G; Adewumi, OO; Agbaje, EO; Akanmu, AS; Akinleye, MO; Akinyede, A; Busari, AA; Hassan, OO; Kadri, MR; Oreagba, IA; Usman, SO | 1 |
| Baziboroun, M; Mardani, M; Sharifi-Razavi, A; Sheibani, S | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S | 1 |
| Hatleberg, CI; Ryom, L; Sabin, C | 1 |
| Chawana, TD; Gandhi, M; Katzenstein, D; Kuncze, K; Louie, A; Metcalfe, J; Nathoo, K; Ngara, B; Nhachi, CFB; Okochi, H | 1 |
| Chaudhary, NS; Funderburg, N; Irvin, MR; Kind, T; Overton, ET; Saag, MS; Shrestha, S; Wiener, HW; Willig, AL | 1 |
| Best, BM; Capparelli, E; Chakhtoura, N; Eke, AC; Kreitchmann, R; Mirochnick, M; Shapiro, D; Stek, A; Wang, J | 1 |
| Arduino, G; Ariaudo, A; Bonora, S; Calcagno, A; Carcieri, C; D'Avolio, A; Di Perri, G; Marinaro, L; Pagani, N; Tettoni, MC; Trentini, L | 1 |
| Belmonti, S; Castagna, A; Cauda, R; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Abdel-Maboud, M; Abushouk, AI; Ahmed, H; Attia, A; Elmaraezy, A; Gadelkarim, M; Ismail, A; Menshawy, A; Menshawy, E; Negida, A | 1 |
| Boffito, M; Dicker, IB; Grasela, D; Hüser, A; Hwang, C; Keicher, C; Krystal, M; Lataillade, M; Ravindran, P; Ray, N; Schürmann, D; Sevinsky, H; Sobotha, C; Xiao, H | 1 |
| Antoniou, T; Bayoumi, AM; Burchell, AN; Cooper, C; Hogg, RS; Klein, MB; Loutfy, M; Machouf, N; Montaner, JS; Raboud, J; Szadkowski, L; Tsoukas, C; Walmsley, S; Wong, A | 1 |
| Centeno-Tablante, E; Cotton, MF; Frigati, L; Lazarus, E; Nicol, L; Nicol, S; Penazzato, M; Violari, A | 1 |
| Amara, A; Boffito, M; Elliot, ER; Else, L; Higgs, C; Khoo, S; Moyle, G; Pagani, N; Schoolmeesters, A | 1 |
| Antunes, F | 1 |
| Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Nicolè, S; Rigo, F; Vento, S | 2 |
| Chawana, TD; Gandhi, M; Horng, H; Katzenstein, D; Louie, A; Metcalfe, J; Nathoo, K; Ngara, B; Nhachi, CFB | 1 |
| Angarano, G; Bellacosa, C; Bellazzi, LI; Celesia, BM; Chirianni, A; Cicalini, S; Corsi, P; Grilli, E; Ladisa, N; Leone, A; Maggi, P; Martinelli, C; Maserati, R; Ricci, ED; Sozio, F; Viglietti, R; Volpe, A | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Chatelut, E; Delobel, P; Gandia, P; Metsu, D; Toutain, PL | 1 |
| Hughes, CA; Phillips, EJ; Seet, J; Tseng, A; Wu, J | 1 |
| Broadhurst, R; Gugsa, S; Heller, T; Hosseinipour, MC; Lim, R; Ngongondo, M; Ongubo, DM; Phiri, S; Speight, C; Stanley, CC; Tembo, P; Tweya, H | 1 |
| Bress, AP; Crook, J; LaFleur, J; Myers, J; Ritchings, C; Rosenblatt, L; Sax, PE | 1 |
| Couraud, PO; Hauser, KF; Jahr, FM; Leibrand, CR; McClay, JL; McRae, M; Palasuberniam, P; Patel, S; Weksler, B | 1 |
| Bonito, A; Bonora, S; Calcagno, A; Casari, S; Castelli, F; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Simiele, M; Trentini, L | 1 |
| Ard, KL; Beckman, JA; Milian, J; Prenner, JC; Price, CN; Sax, PE; Solomon, DA; Wood, BR; Zuflacht, JP | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Joly, V; Landman, R; Marcelin, AG; Perrier, M; Todesco, E; Visseaux, B; Yazdanpanah, Y | 1 |
| Baker, P; Chirwa, S; Erdem, H; Haas, DW; Leger, P; Leonard, M; Nwogu, JN; Olson, L; Richardson, DM; Turner, M | 1 |
| Chen, JS; DiMeglio, LA; Geffner, ME; Jacobson, D; Jao, J; Karalius, B; McFarland, EJ; Miller, TL; Mirza, A; Patel, K; Silio, M; Van Dyke, RB; Yu, W | 1 |
| Hunt, PW; Lim, J; McComsey, GA; Messing, S; Morse, GD; Venuto, CS | 1 |
| Hanna, GJ; Joshi, SR; Krystal, M; Lataillade, M; Lee, S; Stock, DA; Zhou, N | 1 |
| Cambilargiu, D; Correll, TA; Cotton, MF; Gonzalez-Tome, MI; Klauck, I; Liberty, A; Lissens, J; Pikora, C; Torres-Escobar, I; Zaru, L | 1 |
| Correll, TA; Eley, T; Pikora, C; Sevinsky, H; Wang, R; Xu, X; Zaru, L | 1 |
| Lundgren, J; Mocroft, A; Ryom, L | 1 |
| Cetin, I; Dalzero, S; Degli Antoni, A; Floridia, M; Francisci, D; Frisina, V; Liuzzi, G; Maccabruni, A; Masuelli, G; Ravizza, M; Sansone, M; Simonazzi, G; Tamburrini, E; Tassis, B | 1 |
| Cattaneo, D; Formenti, T; Fossati, A; Gervasoni, C; Meraviglia, P; Minisci, D; Resnati, C | 1 |
| Baldelli, S; Castagna, A; Cattaneo, D; Clementi, E; Colella, E; Galli, L; Galli, M; Lazzarin, A; Rusconi, S; Spagnuolo, V | 1 |
| Altman, RB; Alvarellos, M; Guillemette, C; Klein, TE | 1 |
| Chatzidimitriou, D; Chatzopoulou, F; Margariti, A; Metallidis, S; Papaioannou, M; Pilalas, D; Skoura, L; Tsachouridou, O; Zebekakis, P | 1 |
| Antinori, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Avino, A; d'Ettorre, G; De Luca, A; Del Pin, B; Di Giambenedetto, S; Fabbiani, M; Focà, E; Francisci, D; Gagliardini, R; Grima, P; Latini, A; Lombardi, F; Madeddu, G; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Gohel, S; Kumar, A; Letendre, S; Patel, AK; Patel, KK | 1 |
| Amiel, C; Chaix, ML; Charpentier, C; Delaugerre, C; Descamps, D; Dufayard, J; Flandre, P; Grude, M; Guinard, J; Lambert-Niclot, S; Le Guillou-Guillemette, H; Maillard, A; Marcelin, AG; Mirand, A; Montes, B; Morand-Joubert, L; Mourez, T; Reigadas, S; Rodallec, A; Vallet, S | 1 |
| De Wit, S; Delforge, M; Demeester, R; Florence, E; Goffard, JC; Lacante, P; Lacor, P; Moutschen, M; van Frankenhuijsen, M; Van Wijngaerden, E; Vandekerkhove, L; Vandercam, B | 1 |
| d' Arminio Monforte, A; Dabis, F; De Wit, S; El-Sadr, W; Fontas, E; Hatleberg, CI; Kirk, O; Law, M; Lundgren, JD; Mocroft, A; Phillips, A; Reiss, P; Ryom, L; Sabin, C; Weber, R | 1 |
| Bonito, A; Bonora, S; Calcagno, A; Castelli, F; Castelnuovo, F; Cusato, J; D'Avolio, A; Di Perri, G; Domenighini, E; Focà, E; Quiros Roldan, E; Trentini, L | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Castagna, A; Cauda, R; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Bandera, A; Clerici, M; Fenizia, C; Giannattasio, C; Gori, A; Maloberti, A; Masetti, M; Muscatello, A; Sabbatini, F; Soria, A; Squillace, N; Trabattoni, D | 1 |
| Crespo, M; Esteban, H; Gutiérrez, F; Hernández-Quero, J; Iribarren, JA; Mariño, A; Pasquau, J; Pérez-Molina, JA; Pérez-Valero, I; Rivero, A; Rubio, R; Santos, J; Sanz, J; Terrón, A | 1 |
| Borghetti, A; Castelli, F; Izzo, I; Lombardi, F; Maggiolo, F; Magro, P; Quiros-Roldan, E; Raffetti, E; Saracino, A | 1 |
| Chu, GJ; Evans, L; Henderson, C; Howlin, K; Murad, A | 1 |
| Ho, RJY; Koehn, J; Kraft, JC; McConnachie, LA; Perazzolo, S; Shen, DD; Shireman, LM | 1 |
| Brogan, AJ; Davis, AE; Goodwin, B | 1 |
| Firląg-Burkacka, E; Grycner, E; Horban, A; Kowalska, JD; Matłosz, B; Pietraszkiewicz, E | 1 |
| Espinosa, N; Fernandez-Magdaleno, T; García, C; Gutierrez-Valencia, A; López-Cortés, LF; Milanés-Guisado, Y; Pasquau, J; Viciana, P | 1 |
| Avihingsanon, A; Bowonwattanuwong, C; Chuasuwan, B; Duereh, M; Gatechompol, S; Hiransuthikul, A; Karachot, B; Manamuti, C; Ruxrungtham, K; Sawpitiporn, M; Sophonphan, J; Techatanawat, I; Thammajaruk, N | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| Antinori, A; Carrara, S; Cozzi Lepri, A; D'arminio Monforte, A; Dentone, C; Di Biagio, A; Fenoglio, D; Filaci, G; Giacometti, A; Lichtner, M; Marchetti, G; Sighinolfi, L | 1 |
| Coetsee, M; Cohen, K; Dunn, L; Hislop, M; Kengne, AP; Leisegang, R; Maartens, G; Maharaj, S; Meintjes, G; Stewart, A; van Zyl, G | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Chmielinska, JJ; ElZohary, L; Kramer, JH; Mak, IT; Weglicki, WB | 1 |
| Butterton, JR; Caro, L; Chu, X; de Hoon, JN; De Lepeleire, I; Denef, JF; Du, L; Dunnington, K; Fandozzi, C; Feng, HP; Fraser, IP; Guo, Z; Hanley, WD; Huang, X; Iwamoto, M; Jumes, P; Marshall, WL; Martinho, M; Mitselos, A; Panebianco, D; Talaty, J; Valesky, R; Vandermeulen, C; Yeh, WW | 1 |
| Bonora, S; Carosella, S; Castagna, A; Cattelan, A; De Socio, GV; Di Giambenedetto, S; Galli, L; Gulminetti, R; Ladisa, N; Mazzola, G; Mena, M; Poli, A; Quiros-Roldan, ME; Riva, A; Rusconi, S | 1 |
| Castelnuovo, B; Kaimal, A; Kiragga, A; Laker, EAO; Lamorde, M; Musubire, A; Nabaggala, MS; Nalwanga, D; Ratanshi, RP | 1 |
| Bruno, E; Gaston, TL; Gilles, P; Joe, MB; Laurent, C; Patrick, LM; Philippe, P; Roland, L; Sawoo, O | 1 |
| Adenuga, BA; Rennie, TW | 1 |
| Avihingsanon, A; Bunupuradah, T; Burger, DM; Chetchotisakd, P; Emery, S; Kiertiburanakul, S; Punyawudho, B; Ruxrungtham, K; Singkham, N; Thammajaruk, N | 1 |
| Becker, KJ; Budoff, M; Burkholder, GA; Chow, FC; Crane, HM; Delaney, JAC; Drozd, DR; Eron, JJ; Geng, E; Heckbert, SR; Ho, EL; Huffer, A; Hunt, PW; Kalani, R; Kim, HN; Kitahata, MM; Mathews, WC; Moore, RD; Nance, RM; Ritchings, C; Rosenblatt, L; Saag, MS; Tirschwell, DL; Whitney, BM; Wood, BR; Zunt, JR | 1 |
| Adams, JL; Corbett, AH; Dumond, JB; Forrest, A; Jennings, SH; Kashuba, AD; Kendrick, RL; Malone, S; Patterson, KB; Prince, HM; Sykes, C; Wang, R; White, N | 1 |
| Antunes, MV; Callegari-Jacques, SM; Caminha, LI; Linden, R; Luz, AJ; Poeta, J; Sprinz, E | 1 |
| Bertz, RJ; Chung, E; Grasela, D; McGrath, D; Persson, A; Zhang, J; Zhu, L | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Parienti, JJ; Taburet, AM; Vigan, M; Vrijens, B | 1 |
| Bonfanti, P; Bonizzoni, E; Croce, D; Foglia, E; Porazzi, E; Restelli, U; Ricci, E; Rizzardini, G; Scolari, F | 1 |
| Burger, DM; Colbers, EP; Jansen, A; Richter, C; Rockstroh, JK; van der Ven, AJ; van Luin, M; Wasmuth, JC | 1 |
| Anderson, PL; Erlandson, KM; Schoen, JC | 1 |
| Cahn, P; Sued, O | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; Callebaut, C; Cheng, AK; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, Y; Moyle, G; Rhee, MS; Rizzardini, G; Szwarcberg, J; Zhong, L | 1 |
| Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Culley, CL; Ensom, MH; Gilchrist, SE; Kiang, TK | 1 |
| Barlet, MH; Brockmeyer, NH; Esser, S; Jimenez-Exposito, MJ; Michalik, C; Nakonz, T; Pugliese, P; Svedhem-Johansson, V; Thalme, A | 1 |
| Daudon, M; de Lastours, V; Ferrari Rafael De Silva, E; Loze, B; Molina, JM; Porcher, R; Sauvageon, H | 1 |
| Alnouti, Y; Balkundi, S; Fox, HS; Gautam, N; Gendelman, HE; Guo, D; Lamberty, B; Liu, XM; McMillan, J; Morsey, B; Puligujja, P; Roy, U; Smith, N | 1 |
| Cabrera, F; Isasti, G; Moreno, T; Palacios, R; Pérez, I; Santos, J | 1 |
| Balkundi, S; Bronich, T; Edagwa, BJ; Gendelman, HE; Kabanov, AV; Kendrick, L; Li, T; Liu, XM; McMillan, J; Puligujja, P; Smith, N; Veerubhotla, RS | 1 |
| Back, D; Boffito, M; Else, L; Gazzard, B; Jackson, A; Karolia, Z; Moyle, G; Ringner-Nackter, L; Seymour, N; Yapa, MH | 1 |
| Cane, PA; Dolling, DI; Dunn, DT; Mbisa, JL; Parry, CM; Pillay, D; Post, FA; Sabin, CA; Sutherland, KA | 1 |
| Angel, JB; Blitz, SL; Burdge, D; Cohen, J; Conway, B; de Pokomandy, A; Gough, K; Haase, D; Klein, MB; la Porte, CJ; Loemba, H; Loutfy, MR; Pick, N; Raboud, J; Rachlis, AR; Smaill, FM; Trottier, S; Tseng, AL; Walmsley, SL | 1 |
| Dewhurst, S; DiFrancesco, R; Gelbard, HA; Gendelman, HE; Hochreiter, JS; Ma, Q; Maggirwar, SB; Morse, GD; Peterson, DR; Schifitto, G | 1 |
| Barreiro, P; Fernández-Montero, JV; Labarga, P; Soriano, V; Vispo, E | 1 |
| Bertz, R; Botes, M; Conradie, F; Eley, T; Hardy, H; Huang, SP; Josipovic, D; McGrath, D; Osiyemi, O; Zorrilla, CD | 1 |
| Baril, JG; Dufresne, S; Laprise, C; Trottier, H | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Teruya, K | 1 |
| Antinori, A; Castagna, A; d'Arminio Monforte, A; Galli, L; Gianotti, N; Lazzarin, A; Maserati, R; Quiros-Roldan, E; Salpietro, S; Torti, C | 1 |
| Duncan, A; Mills, J | 1 |
| Bertz, R; Bifano, M; Grasela, D; Hartstra, J; Hwang, C; Kandoussi, H; Oosterhuis, B; Sevinsky, H; Tiessen, R; Velinova-Donga, M | 1 |
| Atrio, JM; Chen, KT; Posada, R; Rodriguez Caprio, G; Sperling, RS | 1 |
| Feldt-Rasmussen, B; Gerstoft, J; Helleberg, M; Kronborg, G; Larsen, CS; Obel, N; Pedersen, C; Pedersen, G; Rasch, MG | 1 |
| Guaraldi, G; Santoro, A; Stentarelli, C; Zona, S | 1 |
| Arai, M; Satoh, M; Tanaka, H; Tomoda, Y; Wada, T; Yago, K | 1 |
| Braman, V; Cheng, C; Harbeson, S; Tung, R; Vedananda, S; Wu, L | 1 |
| Ananworanich, J; Avihingsanon, A; Burger, DM; Cooper, DA; Gorowara, M; Kerr, SJ; Lange, JM; Phanuphak, P; Punyawudho, B; Ruxrungtham, K; van der Lugt, J | 1 |
| Lee, V; Phillips, M; Saxon, C | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Castillo-Ferrando, JR; Espinosa, N; Gutierrez-Valencia, A; Lopez-Cortes, LF; Ruiz-Valderas, R; Torres-Cornejo, A; Viciana, P | 1 |
| Bhavani, PK; Chandrasekaran, C; Hemanth Kumar, AK; Raja, K; Ramachandran, G; Srinivasan, R; Sudha, V; Swaminathan, S; Venkatesh, S | 1 |
| Lambert, JS; Macken, A; Mallon, PW; O'Halloran, JA; O'Halloran, RM; Sheehan, GJ; Tinago, W | 1 |
| Apesteguia, AF; Domeque, N; Lozano, R | 1 |
| Angel, JB; Baril, J; Conway, B; Ferko, N; Giguère, P; Hollmann, S | 1 |
| Deeks, ED | 1 |
| Degli Antoni, A; Fiscon, M; Floridia, M; Francisci, D; Giacomet, V; Liuzzi, G; Marconi, AM; Martinelli, P; Masuelli, G; Pinnetti, C; Ravizza, M; Spinillo, A; Tamburrini, E | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Shimbo, T | 1 |
| David, SG; Osterberg, EC; Rosoff, JS; Wang, LC | 1 |
| Bernardino, JI; Carton, JA; Curran, A; Domingo, P; Ferrer, E; Gatell, JM; Gonzalez-Cordon, A; Gutierrez, F; Martinez, E; Murillas, J; Negredo, E; Peraire, J; Perez, I; Pich, J; Podzamczer, D; Portilla, J; Santos, I | 1 |
| Haberl, A; Johnson, M; Walmsley, S | 1 |
| Antoniadou, A; Detsika, M; Hatzakis, A; Katsarolis, I; Panagopoulos, P; Papadopoulos, A; Paraskevis, D; Petrikkos, G; Protopapas, K; Sypsa, V | 1 |
| Amadasi, S; Casari, S; Castelli, F; Cerini, C; Foca, E; Lonati, L; Nasta, P; Odolini, S; Panzali, A; Pezzoli, MC; Quiros-Roldan, E | 1 |
| DeGrosky, M; Farajallah, A; Hardy, H; McGrath, D; Moyle, GJ | 1 |
| Desjeux, JF; Dossou-Yovo, F; Eto, B; Limas-Nzouzi, N; Mamadou, G; Miantezila, J; Soudy, ID | 1 |
| Autran, B; Caby, F; Carcelain, G; Costagliola, D; Fourati, S; Guiguet, M; Guihot, A; Hattab, S; Katlama, C; Marcelin, AG | 1 |
| Bendayan, R; Kis, O; Walmsley, SL | 1 |
| Castillero-Manzano, M; Escoto-Delgadillo, M; Flores-Soto, M; Gálvez-Gastelum, F; Mata-Munguía, C; Torres-Mendoza, B; Vázquez-Torres, M; Vázquez-Valls, E; Viniegra-Osorio, A | 1 |
| Acosta, EP; Armstrong, WS; Arrendale, RF; Delille, CA; Easley, KA; Lennox, JL; Marconi, VC; Ofotokun, I; Pruett, ST; Sheth, AN; Vunnava, A | 1 |
| Bastow, B; Borowski, L; Kearney, M; Mailliard, RB; McKinnon, JE; Mellors, JW; Rinaldo, CR; Roper, JM; Swindells, S; Wiegand, A; Wilkin, TJ | 1 |
| Back, DJ; Brennan, M; Coulter-Smith, S; Else, LJ; Jackson, V; Khoo, SH; Lambert, JS | 1 |
| Bhatti, L; DeJesus, E; Edelstein, H; Margolis, DA; Ross, LL; Shaefer, MS; Small, CB; Weinberg, WG; Wohl, DA; Zhao, HH | 2 |
| Arends, JE; Burger, DM; de Kanter, CT; Hoepelman, AI; Jacobs, BS; van Elst-Laurijsen, DH; van Maarseveen, EM; Verwey-van Wissen, CP | 1 |
| Ferrer, E; Podzamczer, D; Van den Eynde, E | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Burger, D; Colbers, A; Giaquinto, C; Gingelmaier, A; Hawkins, D; Hidalgo-Tenorio, C; Ivanovic, J; Kabeya, K; Lambert, J; Moltó, J; Rockstroh, J; Sadiq, ST; Taylor, G; van der Ende, M; Weizsäcker, K; Wyen, C | 1 |
| Bonora, S; Calcagno, A; Concia, E; Di Perri, G; Lanzafame, M; Lattuada, E | 1 |
| Antinori, A; Carini, E; Castagna, A; D'Arminio Monforte, A; Di Biagio, A; Galli, L; Lazzarin, A; Montella, F; Nozza, S; Rusconi, S; Spagnuolo, V; Vinci, C | 1 |
| Bigliano, P; Bonora, S; Calcagno, A; Colella, E; D'Avolio, A; Di Perri, G; Galli, M; Marinaro, L; Mercadante, S; Orofino, G; Rusconi, S; Tettoni, MC; Trentini, L; Vigano, O | 1 |
| Aoki, T; Gatanaga, H; Hamada, Y; Honda, H; Joya, A; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsuchiya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Audagnotto, S; Baietto, L; Bonora, S; Calcagno, A; D'Avolio, A; De Rosa, FG; Di Perri, G; Pagani, N; Simiele, M | 1 |
| Collier, AC; Daar, ES; Fischl, M; Ma, Q; Mollan, K; Morse, GD; Sax, PE; Smith, KY; Tierney, C; Venuto, CS | 1 |
| Batard, ML; Bernard-Henry, C; Cheneau, C; De Mautort, E; Fafi-Kremer, S; Gantner, P; Koeppel, C; Muret, P; Partisani, M; Priester, M; Rey, D; Sueur, C | 1 |
| Aldrovani, G; Fenton, T; Fletcher, CV; Graham, B; Kiser, JJ; Mathew, M; Mofenson, LM; Rutstein, RM; Samson, P; Smith, E | 1 |
| Cattaneo, D; Clementi, E; Galli, M; Gervasoni, C; Riva, A; Rizzardini, G | 1 |
| Aweeka, F; Baugh, BP; Benson, CA; Brown, TT; Cohn, SE; Currier, JS; Fichtenbaum, CJ; Godfrey, C; Haas, DW; Koletar, SL; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Patterson, KB; Presti, RM; Ribaudo, HJ; Rooney, JF; Sagar, M; Seekins, D | 1 |
| Farajallah, A; Hardy, H; Kaplita, S; McGrath, SJ; Moyle, GJ; Ward, D | 1 |
| Anderson, J; Bradshaw, D; Brook, G; Byrne, L; Chan, SY; de Ruiter, A; Dhairyawan, R; Hawkins, D; Hay, P; Mandalia, S; Naftalin, C; Natha, M; Noble, H; Offodile, N; Perry, M; Poulton, M; Rodgers, M; Roedling, S; Samuel, M; Sarner, L; Shah, R; Short, CE; Smith, K; Taylor, G; Zhou, J | 1 |
| Bamford, A; Foster, C; James, M; Walters, S; Xiang, N | 1 |
| Bertz, R; Jariwala, N; Ravindran, P; Sevinsky, H; Sims, K; Tao, X; Wang, R; Xu, X | 1 |
| Baldelli, S; Castoldi, S; Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Fucile, S | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Daudon, M; De Sousa, B; Fourn, E; Katlama, C; Lafaurie, M; Lapidus, N; Molina, JM; Ponscarme, D; Rioux, C; Weiss, L | 1 |
| Bagella, P; Bonfanti, P; Carenzi, L; Celesia, BM; De Socio, GV; Dentone, C; Di Biagio, A; Franzetti, M; Libertone, R; Madeddu, G; Maggi, P; Martinelli, C; Orofino, G; Parruti, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Abgrall, S; Cain, LE; Casabona, J; Costagliola, D; Dabis, F; Esteve, A; Fehr, J; Hernán, MA; Jose, S; Justice, A; Logan, R; Meyer, L; Monge, S; Moreno, S; Muga, R; Olson, A; Paparizos, V; Pérez-Hoyos, S; Phillips, A; Reiss, P; Robins, JM; Sabin, C; Seng, R; Sterne, JA; Tate, J; Touloumi, G; van Sighem, A; Vandenhende, MA; Young, J | 1 |
| Azwa, I; Boettiger, DC; Bui, HV; Durier, N; Heng Sim, BL; Law, M; Nguyen, VK; Ruxrungtham, K | 1 |
| Costarelli, S; Di Giambenedetto, S; Di Pietro, M; Lorenzotti, S; Maggiolo, F; Postorino, MC; Prosperi, M; Quiros-Roldan, E; Saracino, A; Sighinolfi, L; Torti, C | 1 |
| Chan, JY; Cheng, BH; Fung, KP; Lau, CB; Leung, PC; Lin, HQ; Or, PM; Wan, DC; Wang, Y; Wang, YF; Zhou, X | 1 |
| Anthony, P; Kovacs, A; Louie, S; Mordwinkin, N; Neely, M; Thuvamontolrat, K; Xu, J | 1 |
| Campbell, L; Cheserem, E; Engler, B; Hamzah, L; Naftalin, C; Post, FA; Taylor, C; Wandolo, E | 1 |
| Minaeva, SV; Moshkovich, GF | 1 |
| Aweeka, F; Baugh, BP; Brown, TT; Cohn, SE; Currier, JS; Godfrey, C; Kuritzkes, DR; Landovitz, RJ; Leavitt, RY; Lennox, JL; McComsey, GA; Na, LH; Ofotokun, I; Para, MF; Patterson, KB; Ribaudo, HJ; Sagar, M; Villasis-Keever, A | 1 |
| Amiel, C; Caseris, M; Charpentier, C; Descamps, D; Desnoyer, A; Farnoux, C; Lassel, L; Lê, MP; Pain, JB; Peytavin, G; Pialoux, G | 1 |
| Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Ferraris, L; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Minisci, D; Molinari, L; Riva, A; Rizzardini, G | 1 |
| Borghetti, A; Cauda, R; Ciccarelli, N; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Mondi, A | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, R; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO | 1 |
| Bianic, F; Cure, S; Espinas, C; Hardy, H; Juday, T; Rosenblatt, L | 1 |
| Brown, TT; Currier, JS; Dubé, MP; Kelesidis, T; McComsey, GA; Moser, C; Murphy, RL; Ribaudo, HJ; Rothenberg, J; Stein, JH; Yang, O | 1 |
| Adeyemo, T; Akanmu, AS; Awolola, A; Bello, FO; Kanki, PJ; Lesi, F; Ogunsola, FT; Okonkwo, P; Okwuegbuna, K; Oloko, K | 1 |
| Frederick, T; Hazra, R; Himes, SK; Huestis, MA; Huo, Y; Rice, ML; Siberry, GK; Sirois, PA; Williams, PL | 1 |
| Araínga, M; Dash, P; Gendelman, HE; Gorantla, S; McMillan, J; Mosley, RL; Palandri, D; Poluektova, L; Puligujja, P | 1 |
| Warpakowski, A | 2 |
| Anderson, PL; Caraway, P; Gardner, EM; Kerr, B; MaWhinney, S; Meditz, AL; Palmer, C; Predhomme, J; Searls, K; Seifert, S | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Arce, PM; Biguenet, S; Cambilargiu, D; Correll, T; Donati, AP; Hardy, H; Lissens, J; Strehlau, R; Yang, R | 1 |
| Armstrong, DA; Brummel, SS; Kacanek, D; Lester, BM; Marsit, CJ; Rich, K; Seage, GR; Spector, SA | 1 |
| Ascoli-Bartoli, T; Bellelli, V; Bianchi, L; Ceccarelli, G; d'Ettorre, G; De Girolamo, G; Giustini, N; Mastroianni, CM; Serafino, S; Vullo, V; Zaccarelli, M | 1 |
| Henry, K; LaMarca, A; Ross, LL; Schneider, S; Shaefer, MS; Squires, KE; Tashima, K; Young, B; Zhao, HH | 1 |
| Bonora, S; Bracchi, M; Calcagno, A; Cusato, J; D'Avolio, A; Di Perri, G; Galli, M; Lanzafame, M; Marinaro, L; Rusconi, S; Siccardi, M; Trentalange, A; Viganò, O | 1 |
| Abram, ME; Andrade-Villanueva, JF; Antunes, F; Arastéh, K; Cao, H; Chetchotisakd, P; DeJesus, E; Fehr, J; Gallant, JE; Koenig, E; Liu, HC; Rizzardini, G; Szwarcberg, J | 1 |
| Anderson, J; Barbour, A; Conway, K; Dermont, S; deRuiter, A; Dwyer, E; Flanagan, S; Hawkins, D; Hay, P; McKendry, A; Mulka, L; Perry, ME; Rodgers, M; Roedling, S; Sabin, CA; Sarner, L; Shah, R; Stevenson, J; Taylor, GP; Williams, E; Wood, C | 1 |
| Ding, Y; Duan, J; Freeling, J; Ho, RJ; Koehn, J | 1 |
| Cattaneo, D; Di Cristo, V; Gervasoni, C; Micheli, V; Milazzo, L | 1 |
| Avihingsanon, A; Burger, D; Lewin, SR; Matthews, G; Punyawudho, B; Ruxrungtham, K; Thammajaruk, N; Thongpeang, P | 1 |
| Flandre, P | 1 |
| Araínga, M; Ciborowski, P; Dash, PK; Gelbard, HA; Gendelman, HE; Goodfellow, VS; Gorantla, S; Guo, D; Haverland, NA; Knibbe-Hollinger, J; Liu, XM; Martinez-Skinner, A; McMillan, JM; Poluektova, LY; Wiederin, JL; Wysocki, BJ; Wysocki, TA; Zhang, G | 1 |
| Antinori, A; Baakili, A; Gatell, JM; Girard, PM; Klauck, I; Osiyemi, O; Pozniak, A; Serrano, O; Sevinsky, H; van Lunzen, J | 1 |
| Booth, JW; Post, FA | 1 |
| Brouillette, M; Farr, AM; Johnston, SS; Ritchings, C; Rosenblatt, L | 1 |
| Arribas, JR; Elbirt, D; Girard, PM; Hadacek, MB; Hill, A; Marcelin, AG; Paton, N; Winston, A | 1 |
| Araínga, MA; Baldridge, HM; Edagwa, BJ; Gendelman, HE; Martinez-Skinner, AL; McMillan, JM; Mosley, RL; Palandri, DL; Puligujja, P | 1 |
| Aghokeng, AF; Bertagnolio, S; Carmona, S; Chua, A; De Oliveira, T; Fitzgibbon, JE; Fokam, J; Frenkel, LM; Gallant, JE; Gupta, RK; Hamers, RL; Hosseinipour, MC; Jordan, MR; Kantor, R; Katzenstein, D; Mukui, I; Ndembi, N; Parkin, N; Raizes, E; Rhee, SY; Richman, DD; Rinke de Wit, TF; Schapiro, JM; Schito, M; Shafer, RW; Tang, M; Van Zyl, GU; Wainberg, MA; Wallis, CL; Wensing, AM; Yang, C; Zeh, C | 1 |
| Cottrell, M; Dumond, JB; Forrest, A; Francis, O; Hudgens, MG; Malone, S; Mollan, K; Patterson, KB; Prince, HM; Sharpless, NE; Sykes, C; Torrice, C; Trezza, C; Van Dam, C; Wang, R; White, N | 1 |
| Ande, A; Kumar, A; Kumar, S; Li, J; Li, W; Nookala, AR; Vaidya, NK; Wang, L | 1 |
| Chaves, GC; Hasenclever, L; Oliveira, MA; Osorio-de-Castro, CG | 1 |
| Fux, CA; Kirk, O; Lundgren, JD; Mocroft, A; Monforte, Ad; Moranne, O; Morlat, P; Reiss, P; Ross, M; Ryom, L | 1 |
| Alfaro, RM; Calderón, MM; Kovacs, JA; Kumar, P; McManus, M; Pau, AK; Penzak, SR | 1 |
| Ando, A; Baumer, Y; Byron, MM; Chow, D; Kallianpur, KJ; Keating, S; Kohorn, L; Ndhlovu, L; Shikuma, C; Souza, S | 1 |
| Chang, SC; Chang, SY; Hung, CC; Kuo, CH; Lin, SW; Liu, WC; Su, YC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR | 1 |
| Caniglia, EC; Hernán, MA; Hernandez-Diaz, S; Huo, Y; Jacobson, DL; Kapetanovic, S; Patel, K; Rich, KC; Seage, GR; Sirois, PA; Williams, PL | 1 |
| Bharti, S; Hirsch, B; Malhotra, P | 1 |
| Anderson, PL; Andrade, A; Aquilante, CL; Baheti, G; Campbell, TB; Castillo-Mancilla, JR; Firnhaber, C; Fletcher, CV; Haas, DW; Kumarasamy, N; LaRosa, AM; MaWhinney, S; Smeaton, LM; Wempe, MF | 1 |
| Antela, A; Jiménez-Expósito, MJ; Knechten, H; Kuhlmann, B; Rocha-Pereira, N; Santos, J; Teófilo, E | 1 |
| Colella, E; Di Cristo, V; Franzetti, M; Galli, M; Giacomelli, A; Oreni, L; Ridolfo, AL; Rusconi, S | 1 |
| Baugh, BP; Coate, B; Dayaram, YK; De La Rosa, G; Overton, ET; Perniciaro, A; Ryan, R; Tebas, P | 1 |
| Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A | 1 |
| Berenguer, J; Blanco, JR; Estrada, V; Gómez-Garre, MD; Martínez, E; Masiá, M; Monge, S; Portilla, J; Sobrino, P; Viladés, C | 1 |
| Buclin, T; Bugnon, O; Cavassini, M; Csajka, C; Fuchs, A; Rotzinger, A; Schneider, MP | 1 |
| Antinori, A; Bigoloni, A; Borderi, M; Caramatti, G; Castagna, A; D'Arminio Monforte, A; Di Biagio, A; Di Giambenedetto, S; Galli, L; Gibellini, D; Guaraldi, G; Lazzarin, A; Montella, F; Rusconi, S; Spagnuolo, V | 1 |
| Back, D; Gibbons, S; Khoo, S; Marzolini, C | 1 |
| Durante, W; Durante, ZE; Liu, XM; Peyton, KJ | 1 |
| Bowman, VQ; Daar, ES; Diamond, C; Dube, MP; Goicoechea, M; Haubrich, RH; Jain, S; Karris, MY; Kemper, C; Kerkar, S; Morris, S; Rieg, G; Sun, X | 1 |
| Barber, X; Gutiérrez, F; Lidón, F; Masiá, M; Padilla, S; Sanchis, M; Terol, G | 1 |
| Díez-García, LF; Gálvez-Contreras, MC; Romero-León, JM | 1 |
| Assoumou, L; Benalycherif, A; Cabié, A; Costagliola, D; Duvivier, C; Girard, PM; Joly, V; Lambert-Niclot, S; Landman, R; Marcelin, AG; Peytavin, G; Pialoux, G; Samri, A; Slama, L; Valin, N | 1 |
| Ferretti, F; Mora-Peris, B; Stevens, E; Taylor, S; Underwood, J; Winston, A | 1 |
| Arif, S; Dbeibo, L; Gupta, SK; He, F | 1 |
| Jones, R; Levy, JB; Milburn, J | 1 |
| Cavadas, C; Costa, S; do Céu Sousa, M; Machado, M | 1 |
| Kiertiburanakul, S; Numthavej, P; Puangpetch, A; Sukasem, C; Thakkinstian, A; Wongprikorn, A | 1 |
| Carvalhal, A; Hall, E; Naccarato, M; Ostrowski, M; Wai, A | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TT; Yang, OO | 1 |
| Sungkanuparph, S; Wangpatharawanit, P | 1 |
| Bigoloni, A; Caramatti, G; Castagna, A; Cattaneo, D; Cinque, P; Ferretti, F; Fuchs, D; Galli, L; Gerevini, S; Gisslen, M; Lazzarin, A; Longo, V; Passeri, L; Spagnuolo, V; Zetterberg, H | 1 |
| Cedeño, S; Clotet, B; Estévez, JA; Miranda, C; Moltó, J; Valle, M | 1 |
| Domingo, P; Vidal, F | 1 |
| Apornpong, T; Avihingsanon, A; Banchongkit, S; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chaivooth, S; Chetchotisakd, P; Cooper, DA; Emery, S; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Kiertiburanakul, S; Klinbuayaem, V; Leerattanapetch, N; Mekviwattanawong, S; Munsakul, W; Nimitvilai, S; Phanuphak, P; Prasithsirikul, W; Ruxrungtham, K; Techapornroong, M | 1 |
| Belmonti, S; Borghetti, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Ambrose, P; Benson, CA; Devaraj, C; Ezhilarasi, C; Jenks, JD; Kumarasamy, N; Poongulali, S; Yepthomi, T | 1 |
| Bonet, J; Bonjoch, A; Clotet, B; Echeverría, P; Juega, J; Negredo, E; Pérez-Alvarez, N; Puig, J; Romero, R | 1 |
| Avihingsanon, A; Cao, H; Cheng, A; Hagins, D; Hodder, S; Jiang, S; Johnson, M; Kityo, C; Koenig, E; Squires, K; Szwarcberg, J; Voronin, E; White, K | 1 |
| Acosta, EP; Britto, P; Carey, VJ; Cressey, TR; Foca, M; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R | 1 |
| Badowski, ME; Biagi, M; Chiampas, T; Patel, M; Vaughn, P; Young, J | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| Farr, AM; Johnston, SS; Nelson, JK; Nkhoma, ET; Ritchings, C; Rosenblatt, L | 1 |
| Calvez, V; Castan, B; Hocqueloux, L; Landman, R; Meynard, JL; Muret, P; Peytavin, G; Tardy, JC | 1 |
| Brown, TT; Currier, JS; Dube, MP; Kelesidis, T; McComsey, GA; Moser, C; Ribaudo, HJ; Stein, JH; Tran, TTT; Yang, OO | 1 |
| Bernardino, JI; Martín-Carbonero, L; Montejano, R; Montes, ML; Moreno, V; Valencia, ME | 1 |
| Berenguer, J; Cao, H; Gallant, J; Liu, YP; Moyle, G; Myers, J; Rosenblatt, L; Shalit, P; Szwarcberg, J; Yang, L | 1 |
| Burger, DM; Colbers, EP; de Kanter, CT; Drenth, JP; Smolders, EJ; Velthoven-Graafland, K | 1 |
| Bani-Sadr, F; Gantner, P; Garraffo, R; Jovelin, T; Pugliese, P; Rey, D; Roger, PM; Treger, M | 1 |
| Post, FA | 1 |
| Luetkehoelter, J; Tseng, AL; Walmsley, SL | 1 |
| Claiborne, DT; Collier, DA; Deymier, MJ; Goldstein, RA; Gupta, RK; Hunter, E; Prince, JL; Sutherland, KA | 1 |
| Bonora, S; Bramato, C; Calcagno, A; Cenderello, G; D'Avolio, A; Di Perri, G; Marinaro, L; Orofino, G; Pirriatore, V; Ripamonti, D; Rizzi, M; Rusconi, S; Salassa, B; Trentini, L | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Kaleebu, P; Kapaata, AA; Kasamba, I; Kazooba, P; Lutaakome, J; Lyagoba, F; Mayanja, BN; Munderi, P; Namakoola, I | 1 |
| Ganase, B; Guillemi, SA; Harrigan, PR; Harris, M; Hull, MW; Saeedi, R; Watson, B; Zhang, W | 1 |
| Antinori, A; Borghetti, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Francisci, D; Grima, P; Latini, A; Madeddu, G; Mondi, A; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Chadwick, D; Hamzah, L; Jones, R; Jose, S; Nelson, M; Phillips, A; Post, FA; Sabin, CA; Trevelion, R; Williams, DI | 1 |
| Cattaneo, D; Gervasoni, C; Pezzani, D; Resnati, C; Riva, A | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Barreiro, P; García-Gascó, P; González-Pardo, G; Jiménez-Nácher, I; Maida, I; Morello, J; Parra, A; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Gallagher, DP; Kieran, J; Lambert, J; Mahon, N; Mallon, PW; Sheehan, G | 1 |
| Cruttenden, K; DiCenzo, R; Gelbard, H; Hochreiter, J; Mariuz, P; Peterson, DR; Rezk, NL; Schifitto, G | 1 |
| Deguchi, T; Ehara, H; Kikuchi, M; Minamidate, Y; Moriyama, Y; Tsuchiya, T; Tsurumi, H; Yasuda, M | 1 |
| Collins, C; Dickins, M; Hyland, R; Jones, B; Jones, H | 1 |
| Baumgartner, I; Cavassini, M; Evison, J; Flammer, AJ; Gämperli, A; Hayoz, D; Hermann, F; Hersberger, M; Huttner, A; Ledergerber, B; Lüscher, TF; Noll, G; Quitzau, K; Ruschitzka, F; Sudano, I; Vo, NT; Weber, R | 1 |
| Keiser, PH; Nassar, N | 1 |
| Bertz, R; Child, M; Lawrence, J; Mahnke, L; Persson, A; Satin, L | 1 |
| Frank, I; Torti, C | 1 |
| Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Thiry, A; Yang, R | 1 |
| Chin, BS; Choi, H; Choi, JY; Choi, SH; Han, SH; Jeong, SJ; Kim, CO; Kim, JM; Kim, MS; Lee, HS; Song, YG | 1 |
| Baroncelli, S; Bertolini, A; Bonora, S; Ciaffi, S; Cocchi, S; Codeluppi, M; D'Avolio, A; Di Benedetto, F; Esposito, R; Floridia, M; Guaraldi, G; Masetti, M; Motta, A; Pinetti, D | 1 |
| Drogoul, MP; Gagnieu, MC; Lacarelle, B; Lafeuillade, A; Mokhtari, S; Ravaux, I; Simon, N; Solas, C | 1 |
| Anunnatsiri, S; Chetchotisakd, P | 1 |
| Back, DJ; Baietto, L; Bonora, S; Colucci, D; D'Avolio, A; Di Perri, G; Gibbons, S; Khoo, S; Owen, A; Sciandra, M; Siccardi, M | 1 |
| Batterham, M; Chan, DJ; McNally, L; Ray, JE; Smith, DE | 1 |
| Fenstersheib, M; Fleischbein, E; Martelino, R; O'Brien, J | 1 |
| Cornely, OA; Fätkenheuer, G; Hartmann, P; Hofmann, A; Jung, N; Lehmann, C; Wyen, C | 1 |
| Barreiro, P; González, M; Gonzalez-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Wood, R | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Furrer, H; Glass, TR; Hirschel, B; Rickenbach, M; Tarr, PE; Vernazza, P; Young, J | 1 |
| Bierman, WF; Boucher, CA; Danner, SA; Nijhuis, M; van Agtmael, MA | 1 |
| Avihingsanon, A; Burger, DM; Chanmano, S; Cooper, DA; Gorowara, M; Kerr, SJ; Lange, J; Ohata, P; Phanuphak, P; Ruxrungtham, K; van der Lugt, J | 1 |
| Ameli, N; Anastos, K; Bacchetti, P; Cohen, M; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Hyman, CL; Levine, A; Young, M | 1 |
| Antinori, A; Barbarini, G; Bertoli, A; Bini, T; Caramello, P; Ceccherini-Silberstein, F; Di Perri, G; Gianotti, N; Lorenzini, P; Maserati, R; Melzi, S; Micheli, V; Mussini, C; Narciso, P; Perno, CF; Santoro, MM; Torti, C | 1 |
| Bastow, B; Coffin, JM; DiRienzo, AG; Fletcher, CV; Godfrey, C; Maldarelli, F; Margolis, DM; McKinnon, JE; Mellors, JW; Mollan, K; Palmer, S; Swindells, S; Thal, G; Wiegand, A; Wilkin, TJ; Woodward, W | 1 |
| Cain, P; Coakley, E; Farthing, C; Gallant, J; Grant, P; Short, W; Taylor, J; Thal, G; Zolopa, A | 1 |
| Dietz, B; Rajagopalan, R; Simpson, KN | 1 |
| Moreno, V; Valencia, ME | 1 |
| Sax, PE | 5 |
| Mathew, M; McComsey, G; McGrath, D; Rightmire, A; Wirtz, V; Yang, R | 1 |
| Aarons, L; Back, D; Boffito, M; Davies, G; Dickinson, L; Else, L; Khoo, S; Pozniak, A; Waters, L | 1 |
| Andrade Neto, JL; Donnelly, A; González-García, J; Grinsztejn, B; Ledesma, E; McGrath, D; Molina, JM; Phiri, P; Sension, M; Zavala, I | 1 |
| Boyle, BA; Cohen, CJ; DeJesus, E; Elion, R; Frank, I; Moyle, GJ; Sax, PE | 1 |
| Aranda, M; Arranz, JA; Blanco, JL; Clotet, B; Cosin, J; Cruceta, A; Dalmau, D; Domingo, P; Ferrer, E; García, I; Gatell, JM; Gutiérrez, F; Knobel, H; Lazzari, Ed; Llibre, JM; Mallolas, J; Martínez, E; Milinkovic, A; Murillas, J; Pedrol, E; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Vidal, F | 1 |
| Aboulker, JP; Bentata, M; Brun-Vézinet, F; Capitant, C; Chazallon, C; Descamps, D; Katlama, C; Landman, R; Peytavin, G; Pialoux, G; Yéni, P | 1 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LX | 1 |
| Cope, D; Iskander, E; Mikhail, N | 1 |
| Baroncelli, S; Bertolini, A; Bonora, S; Ciaffi, S; Cocchi, S; Codeluppi, M; Di Benedetto, F; Esposito, R; Floridia, M; Gerunda, GE; Guaraldi, G; Masetti, M; Motta, A; Pinetti, D | 1 |
| Antinori, A; Antonucci, F; Carosi, G; Castelnuovo, F; De Luca, A; Di Perri, G; Esposito, R; Lapadula, G; Lazzarin, A; Maggiolo, F; Maserati, R; Migliorino, G; Paraninfo, G; Quirino, T; Rizzardini, G; Torti, C | 1 |
| Chen, CY; Grinspoon, SK; Hadigan, CM; Joy, T; Liebau, JG; Makimura, H; Robbins, GK; Stanley, TL; Thomas, BJ; Weise, SB | 1 |
| Croom, KF; Dhillon, S; Keam, SJ | 1 |
| Barreiro, P; Fernández-Montero, JV; Soriano, V | 1 |
| Lötsch, J; von Hentig, N | 1 |
| Kongnyuy, EJ; Shang, J; Shey, M; Wiysonge, CS | 1 |
| Abeli, C; Bonfanti, P; Gianelli, E; Giuntini, R; Grosso, C; Madeddu, G; Marconi, P; Martinelli, C; Palvarini, L; Pellicano, G; Penco, G; Quirino, T; Ricci, E; Vichi, F | 1 |
| Chetchotisakd, P | 1 |
| Tozzi, V | 1 |
| Chang, SC; Chang, SY; Chen, MY; Hsieh, SM; Hung, CC; Sheng, WH | 1 |
| Sankawa, Y | 1 |
| Desai, M; Doyle, RJ; White, J | 1 |
| Cagliuso, M; Conti, V; Esposito, A; Mezzaroma, I; Pastori, D | 1 |
| Bonora, S; Calcagno, A; D'Avolio, A; Lanzafame, M; Penco, G; Perri, GD; Tettoni, MC | 1 |
| Arvieux, C; Bellissant, E; Bentué-Ferrer, D; Ruffault, A; Tribut, O | 1 |
| Backus, LI; Belperio, PS; Boothroyd, DB; Mole, LA | 1 |
| Ainsworth, J; Anderson, J; Back, D; Bansi, L; Dunn, D; Easterbrook, P; Fisher, M; Gazzard, B; Gibbons, S; Gilson, R; Hill, T; Johnson, M; Khoo, S; Leen, C; Orkin, C; Pillay, D; Sabin, C; Stöhr, W; Winston, A | 1 |
| Anwar, T; Back, DJ; Chiba, P; Janneh, O; Jungbauer, C; Khoo, SH; Kopp, S | 1 |
| Anceschi, MM; Ascenzi, P; Ivanovic, J; Mattia, E; Narciso, P; Nicastri, E; Notari, S; Pisani, G; Pucillo, LP; Signore, F; Tempestilli, M; Vallone, C | 1 |
| Belsey, E; Berzins, B; Dube, MP; Fichtenbaum, C; Guaraldi, G; Mitchell, C; Murphy, RL; Stein, JH; Torriani, F; Zala, C | 1 |
| Giguère, P; Jacques, AC; la Porte, CJ; Touchie, C; Zhang, G | 1 |
| Barrail-Tran, A; Chazallon, C; Cosson, C; Gérard, L; Girard, PM; Mentré, F; Piketty, C; Taburet, AM | 1 |
| Absalon, J; Andrade-Villanueva, J; Chetchotisakd, P; Corral, J; David, N; Echevarria, J; Lataillade, M; Mancini, M; McGrath, D; Molina, JM; Moyle, G; Percival, L; Wirtz, V; Yang, R | 1 |
| Cedeño, S; Clotet, B; Deig, E; Maria Llibre, J; Miranda, C; Moltó, J; Negredo, E; Valero, S; Valle, M | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Navarra, P; Prosperi, M; Ragazzoni, E | 1 |
| Rivero, A | 1 |
| López-Cortés, LF | 1 |
| Gatell, JM; Zamora, L | 1 |
| Dronda, F; Hernández, B; Moreno, S | 1 |
| Boix, V; Merino, E; Portilla, J; Reus, S | 1 |
| Anta, L; Garrido, C; Mendoza, CD; Poveda, E; Soriano, V; Treviño, A | 1 |
| Martínez Chamorro, E | 1 |
| González, M; Palacios, R; Ruiz, J; Santos, J | 1 |
| Camacho, A; Pérez-Camacho, I; Rivero, A; Torre-Cisneros, J | 1 |
| Curran, A; Ribera Pascuet, E | 1 |
| Antela López, A | 1 |
| Babiker, A; Fox, L; Gey, D; Lopardo, G; Markowitz, N; Paton, N; Tavel, JA; Wentworth, D; Wyman, N | 1 |
| Anderson, A; Gendelman, HE; McMillan, J; Miller, R; Nowacek, AS; Rabinow, B | 1 |
| Burger, DM; Faraj, D; Gelinck, L; Kroon, F; Kuks, PF; Richter, C; Van der Ende, ME; Van der Ven, A; van Luin, M; Van Schaik, RH; Visser, M; Wit, FW | 1 |
| Asensi, V; Carmena, J; Cartón, JA; de la Fuente, B; Echevarría, S; Esteban, H; Flores, J; González-García, J; Mahillo, B; Mariño, AI; Minguez, C; Moyano, B; Ocampo, A; Ribera, E; Rubio, R; Sepúlveda, MA; Serrano, L; Serrano, O; Vicent, R; Zarraga, M | 1 |
| DeJesus, E; Fischl, MA; Horton, JH; Lancaster, CT; Pakes, GE; Pappa, KA; Ross, LL; Smith, KY; Weinberg, WG | 1 |
| Lisovsky, I; Martinez-Cajas, JL; Moisi, D; Oliveira, M; Schader, SM; Wainberg, MA | 1 |
| Benalycherif, A; Bennai, Y; Diallo, MB; Fall, MB; Girard, PM; Gueye, NF; Kane, CT; Landman, R; Mboup, S; Ndiaye, B; Peytavin, G; Sow, PS | 1 |
| Andersson, LM; Andersson, O; Edén, A; Flamholc, L; Gisslén, M; Josephson, F; Nilsson, S; Ormaasen, V; Säll, C; Sönnerborg, A; Svedhem, V; Tunbäck, P | 1 |
| Agarwala, S; Bertz, R; Dragone, J; Eley, T; Li, T; Mahnke, L; Persson, A; Xu, X; Zhu, L | 1 |
| Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R | 1 |
| Calvez, V; Katlama, C; Lambert-Niclot, S; Machouf, N; Marcelin, AG; Murphy, RL; Peytavin, G; Simon, A; Soulie, C; Thomas, R; Wirden, M | 1 |
| Choe, KW; Choe, PG; Jeon, JH; Kim, HB; Kim, NJ; Oh, MD; Park, SW; Park, WB; Song, KH | 1 |
| Blanco, J; Bofill, M; Cabrera, C; Clotet, B; Cunyat, F; Marfil, S; Puig, T; Ruiz, L | 1 |
| Amiel, C; Bonnard, P; Girard, PM; Guiard-Schmid, JB; Lescure, FX; Meynard, JL; Pialoux, G; Poirier, JM; Slama, L; Zouai, O | 1 |
| Amin, J; Boyd, M; Carey, D; Emery, S; Petoumenos, K | 1 |
| Bellos, N; Dejesus, E; Murphy, D; Patel, LG; Ross, LL; Shaefer, MS; Squires, KE; Wannamaker, PG; Young, B; Zhao, HH | 1 |
| Bansi, L; Campbell, LJ; Cheserem, E; Hendry, BM; Ibrahim, F; Naftalin, C; Post, FA; Roe, J; Sabin, C | 1 |
| Brinkman, K; Claessen, FA; Mulder, JW; Prins, JM; Regez, RM; Sonder, GJ; van den Hoek, A; Veenstra, J | 1 |
| Avihingsanon, A; Belloso, WH; Boesecke, C; Cooper, DA; Duncombe, C; Emery, S; Gazzard, B; Li, L; Molina, JM; Petoumenos, K; Puls, RL; Srasuebkul, P | 1 |
| Choe, PG; Kim, HB; Kim, NH; Kim, NJ; Oh, MD; Park, SW; Park, WB; Song, JS; Song, KH | 1 |
| Back, DJ; Baietto, L; Bonora, S; Chierakul, N; Chuchuttaworn, C; Cuenca, L; D'Avolio, A; Davies, G; Di Perri, G; Dvorak, AM; Hoskins, JM; Khoo, S; McLeod, HL; Owen, A; Rodríguez Novoa, S; Saguenwong, N; Schipani, A; Siccardi, M; Simiele, M; Soriano, V | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Conti, F; Cozzi, V; Ripamonti, D | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Balogh, A; Biguenet, S; Carosi, G; Delfraissy, JF; Ghosn, J; Lazzarin, A; Leleu, G; Moreno, S; Pialoux, G; Pokrovsky, V; Sanz-Moreno, J; Vandeloise, E | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Hesse, K | 1 |
| Ansart, S; Bellein, V; Bressollette, L; de Saint-Martin, L; Pasquier, E; Perfezou, P; Vallet, S | 1 |
| Absalon, J; Johnson, M; McGrath, D; Sheppard, L; Squires, KE; Uy, J; Yang, R | 1 |
| de Béthune, MP; De Meyer, S; Dierynck, I; Lathouwers, E; Picchio, G; Spinosa-Guzman, S; Van De Casteele, T; Vanden Abeele, C | 1 |
| Curto, J; del Rio, L; Domingo, P; Ferrer, E; Gatell, JM; Martínez, E; Negredo, E; Ordóñez, J; Podzamczer, D; Ribera, E; Rosales, J; Saumoy, M | 1 |
| Bellón, JM; González, MI; José, MI; Larru, B; Mellado, MJ; Muñoz-Fernández, MÁ; Navarro, ML; Nso Roca, AP; Nso, AP; Ramos, JT | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Cozzi, V; Meraviglia, P; Milani, G | 1 |
| Cooper, RD; Tonelli, M | 1 |
| Alaeus, A; Heeg, B; Lescrauwaet, B; Neubauer, A; Sennfält, K; Thuresson, PO | 1 |
| Basar, M; Best, BM; Burchett, SK; Capparelli, EV; Hawkins, E; Hu, C; Mirochnick, M; Read, JS; Rossi, SS; Smith, E; Stek, AM | 1 |
| Bentley, TG; Broder, MS; Chang, EY; Juday, T; Uy, J | 1 |
| Daudon, M; De Castro, N; Glotz, D; Pillebout, E; Scemla, A; Verine, J; Viglietti, D | 1 |
| Altice, F; Botsko, M; Egan, JE; Fiellin, DA; Nandi, V; O'Connor, PG; Sullivan, LE; Tozzi, MJ; Vergara-Rodriguez, P | 1 |
| Benson, CA; Bolivar, H; Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Godfrey, C; Jahed, NC; Katzenstein, D; Mollan, K; Myers, L; Pappa, KA; Patterson, K; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| Alvarez, E; Cuenca, L; González-Lahoz, J; Morello, J; Rodríguez-Nóvoa, S; Soriano, V; Vispo, E | 1 |
| Casado, JL; Dronda, F; Hermida, JM; Hernandez-Novoa, B; Moreno, A; Moreno, S; Perez-Elias, MJ; Quereda, C; Rodriguez, JM; Rodriguez, MA | 1 |
| Gold, WL; Koblic, PM; la Porte, CJ; Lee, TC | 1 |
| Burger, DM; Hamers, RL; van den Berk, GE; Welzen, ME | 1 |
| Bogner, JR; Gyalrong-Steur, M; Seybold, U | 1 |
| Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
| Azria, E; Crenn-Hebert, C; Ferreira, C; Floch-Tudal, C; Herinomenzanahary, E; Mandelbrot, L; Mazy, F; Meier, F; Peytavin, G; Treluyer, JM | 1 |
| Casado, JL; Corral, I; Gonzalez-Rozas, M; Quereda, C; Tamarit, Mdel P | 1 |
| Ameli, N; Anastos, K; Bacchetti, P; Cohen, MH; Gandhi, M; Gange, SJ; Greenblatt, RM; Huang, Y; Milam, J; Minkoff, H; Sharp, GB; Young, M | 1 |
| Andrade-Villanueva, J; Cairns, V; Clotet, B; de Rossi, L; Domingo, P; Gellermann, HJ; Podzamczer, D; Reiss, P; Rockstroh, JK; Soriano, V; Taylor, S | 1 |
| Chen, MY; Ho, MW; Hsieh, SM; Hung, CC; Lin, HH; Lin, YH; Lu, CL; Sheng, WH; Wang, NC; Wong, WW | 1 |
| Barassi, A; Brandolini, M; Cusato, M; D'Arminio Monforte, A; Gulminetti, R; Maserati, R; Melzi D'Eril, GV; Regazzi, M; Sighinolfi, L; Tinelli, C; Villani, P | 1 |
| Bonnet, F; Cazanave, C; Dabis, F; Dauchy, FA; de La Faille, R; Dupon, M; Greib, C; Lawson-Ayayi, S; Mehsen, N; Miremont-Salamé, G; Rigothier, C | 1 |
| Andrade-Villanueva, J; Antunes, F; Arastéh, K; de Rossi, L; Di Perri, G; Domingo, P; Gellermann, H; Lutz, T; Migrone, H; Opravil, M; Podzamczer, D; Soriano, V; Taylor, S | 1 |
| Frankel, JK; Packer, CD | 1 |
| Bertz, R; Botes, M; Child, M; Conradie, F; Eley, T; Hu, W; Josipovic, D; McGrath, D; Osiyemi, O; Vandeloise, E; Wirtz, V; Zorrilla, C | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Aldrovandi, G; Brundage, RC; Fenton, T; Fletcher, CV; Graham, B; Kiser, JJ; Mofenson, LM; Rutstein, RM; Samson, P; Schnittman, S; Smith, E | 1 |
| Blanche, S; Dollfus, C; Firtion, G; Foissac, F; Hirt, D; Laurent, C; Treluyer, JM; Urien, S | 1 |
| Acosta, EP; Britto, P; Carey, V; Graham, B; Hazra, R; Jean-Philippe, P; King, JR; Wiznia, A; Yogev, R | 1 |
| Crutchley, RD; Hochreitter, J; Ma, Q; Morse, GD; Sulaiman, A | 1 |
| Arikan, D; Bertz, R; Coumbis, J; Farajallah, A; Stonier, M; Wu, Y; Xu, X; Zhang, J; Zhu, L | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Farajallah, A; McGrath, D; Sheppard, L; Uy, J; Wirtz, V; Yang, R | 1 |
| Alnouti, Y; Bathena, SP; Gautam, N; Gendelman, HE; Huang, J; McMillan, J; Roy, U | 1 |
| Bertz, R; Boffito, M; Child, M; Chung, E; Kashuba, A; Mahnke, L; Patterson, K; Tebas, P; Wang, X; Wu, Y; Zhang, J; Zhu, L | 1 |
| Chuck, SL; Cohen, C; Elion, R; Gathe, J; Hawkins, T; Kearney, BP; Liu, HC; Mathias, AA; Shalit, P; Warren, DR | 1 |
| Allavena, C; Dejesus, E; Fernandez Garcia, E; Fisher, M; Hardy, WD; Jackson, AG; Jayaweera, DT; Katlama, C; Mauss, S; Moyle, GJ; Raffi, F; Reiss, P; Slama, L; van Eeden, A; Vrouenraets, SM; Wit, FW | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Anu, R; Cauda, R; De Donatis, GM; Gillet, JP; Gottesman, MM; Handley, M; Lucia, MB; Wu, CP | 1 |
| Amole, CD; Brisebois, C; Brown Ripin, DH; Essajee, S; Koehler, E; Levin, AD; Moore, MC; Sickler, JJ; Singh, IR | 1 |
| Abelö, A; Ashton, M; Clewe, O; Flamholc, L; Gisslén, M; Ormaasen, V; Rekić, D; Röshammar, D; Sönnerborg, A | 1 |
| Alvarez Del Vayo Benito, C; Falcon-Neyra, L; León Leal, JA; Lopez-Cortes, LF; Neth, O; Obando, I; Ruiz-Valderas, R | 1 |
| Bertz, R; Hong, Y; Horga, M; Kowalski, KG; Pfister, M; Roy, A; Zhang, J; Zhu, L | 1 |
| Abraham, B; Bélec, L; Charpentier, C; Dandy, M; De Dieu Longo, J; Grésenguet, G; Matta, M; Mbelesso, P; Moussa, S; Péré, H | 1 |
| Ashton, M; Ekvall, H; Flamholc, L; Gisslén, M; Ormaasen, V; Röshammar, D; Simonsson, US; Vesterbacka, J; Wallmark, E | 1 |
| Albini, L; Bellagamba, R; Calabresi, A; Cesana, BM; Fezza, R; Focà, E; Gotti, D; Guaraldi, G; Izzo, I; Lapadula, G; Maggi, P; Manili, L; Motta, D; Narciso, P; Quiros-Roldan, E; Sighinolfi, L; Torti, C | 1 |
| Bhatti, L; Conner, C; Dejesus, E; Mills, A; Storfer, S | 1 |
| Andrade-Villanueva, J; Cheng, AK; Chuck, SL; Clotet, B; Clumeck, N; Lamarca, A; Liu, YP; Margot, N; Molina, JM; Zhong, L | 1 |
| Calvez, V; Courbon, E; Katlama, C; Laylavoix, F; Le Beller, C; Peytavin, G; Soulié, C | 1 |
| Baldelli, S; Cattaneo, D; Clementi, E; Cozzi, V; Fucile, S; Ripamonti, D | 1 |
| Caro-Vega, Y; Crabtree-Ramírez, B; López-Martínez, A; O'Brien, NM; Sierra-Madero, J | 1 |
| Bertz, R; Child, M; Eley, T; Farajallah, A; Krystal, M; Liao, S; McGrath, D; Molina, JM; Persson, A; Sevinsky, H; Xu, X; Zhang, J; Zhu, L | 1 |
| Blanton, LS; East, J | 1 |
| Cooper, DA; Duncombe, C; Emery, S; Gill, JM; Kerr, SJ; Li, PC; Puls, R; Taylor-Robinson, SD; Winston, A | 1 |
| Arnaiz, JA; Clotet, B; Cruceta, A; Dalmau, D; Diaz-Brito, V; Domingo, P; García, F; Gatell, JM; Knobel, H; León, A; Peraire, J | 1 |
| Asahchop, EL; Brenner, BG; Doualla-Bell, F; Grossman, Z; Lisovsky, I; Martinez-Cajas, JL; Mendelson, E; Moisi, D; Oliveira, M; Wainberg, MA | 1 |
| Chiarella, J; DeGrosky, M; Kozal, M; Lataillade, M; Moreno, E; Seekins, D; Simen, B; St John, E; Uy, J; Yang, R | 1 |
| Fernandez, VA; Reiser, IW; Spitalewitz, S; Thomas, DB | 1 |
| Andrade-Villanueva, J; Antinori, A; Astier, L; Balogh, A; Biguenet, S; Bogner, JR; Girard, PM; Hay, P; Moyle, GJ; Pans, M; Salvato, P; Santos, J | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Calmy, A; Cavassini, M; Furrer, H; Fux, CA; Schäfer, J; Vernazza, P; Weber, R; Young, J | 1 |
| Albano, J; Arikan, D; Esker, S; Jimenez-Exposito, MJ; Seekins, D; Tilson, H; Uy, J | 1 |
| Beileiter, K; Bloch, M; Boyd, MA; Carey, D; Cooper, DA; Emery, S; MacRae, K; Pett, SL; Ray, JE; Wand, H | 1 |
| Cenderello, G; Di Biagio, A; Loregian, A; Pagni, S; Palù, G; Rosso, R; Sormani, MP; Viscoli, C | 1 |
| Aguilar-Bernier, M; Del Boz, J; Fernández-Morano, T; Fúnez-Liébana, R | 1 |
| Chan, K; Kozai, T; Lima, VD; Montaner, JS; Nosyk, B; Wood, E; Zhang, W | 1 |
| Focà, E; Motta, D; Ripamonti, D; Torti, C | 1 |
| Adorni, F; Bonora, S; Clementi, E; Di Perri, G; Ferraris, L; Galli, M; Gervasoni, C; Milani, G; Peri, A; Riva, A; Tarkowski, M; Viganò, O | 1 |
| Alnouti, Y; Balkundi, S; Bronich, T; Gautam, N; Gendelman, HE; Gorantla, S; Kabanov, A; Kanmogne, GD; Liu, X; McMillan, J; Poluektova, L; Roy, U; Singh, S; Smith, N; Zhou, Y | 1 |
| Engsig, FN; Feldt-Rasmussen, B; Gerstoft, J; Kirk, O; Kronborg, G; Obel, N; Pedersen, C; Rasch, MG | 1 |
| Bossolasco, S; Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Hasson, H; Lazzarin, A; Nozza, S; Salpietro, S; Spagnuolo, V; Tambussi, G | 1 |
| Cheng, AK; DeJesus, E; Gathe, J; Henry, K; Kearney, BP; Molina, JM; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X; White, K; Yale, K | 1 |
| Arvieux, C; Borsa-Lebas, F; de la Blanchardière, A; Giroux, F; Hue, G; Jantzem, H; Kerspern, H; Massy, N; Meskar, A; Michau, C; Poinsignon, Y; Polard, E; Rakotondravelo, S; Tattevin, P; Tribut, O | 1 |
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| Adorni, F; Galli, M; Giacomet, V; Mameli, C; Rusconi, S; Viganò, A; Viganò, O; Zuccotti, GV | 1 |
| Pommer, P | 1 |
| Borghi, V; Capetti, A; Cicconi, P; Di Biagio, A; Di Giambenedetto, S; Francisci, D; Giacometti, A; Giannarelli, D; Maggiolo, F; Monno, L; Penco, G; Prinapori, R; Sterrantino, G; Zoncada, A | 1 |
| Carnevale, G; Cavallini, GM; Cossarizza, A; De Biasi, S; De Pol, A; Gibellini, L; Mussini, C; Nasi, M; O'Connor, JE; Pinti, M; Riccio, M; Sala de Oyanguren, FJ | 1 |
| Caruz, A; Girón-Gonzalez, JA; Lopez-Cortes, LF; Marquez, M; Merino, D; Mira, JA; Pineda, JA; Rivero, A; Rivero-Juarez, A; Santos-Gil, I; Tellez, F | 1 |
| Aleixo, MJ; Camacho, RJ; Cavaco-Silva, J; Cunha, C; Faria, D; Gomes, P; Gonçalves, Mde F; Valadas, E; Van Laethem, K; Vandamme, AM | 1 |
| Borderi, M; Calza, L; Colangeli, V; Di Bari, MA; Magistrelli, E; Manfredi, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D | 1 |
| Austin, R; Back, D; Boffito, M; Davies, G; Dickinson, L; Khoo, S; Owen, A; Schipani, A | 1 |
| Brockmeyer, N; Dupke, S; Eychenne, JL; Jansen, K; Jimenez-Exposito, MJ; Nakonz, T; Pugliese, P; Sönnerborg, A; Svedhem, V; Thalme, A | 1 |
| Cavassini, M; Cusini, A; Decosterd, LA; Fux, CA; Gaudenz, R; Günthard, HF; Gutmann, C; Hirschel, B; Klimkait, T; Ledergerber, B; Opravil, M; Rohrbach, J; Vernazza, PL; Widmer, N; Yerly, S; Zenger, F | 1 |
| Barrail-Tran, A; Descamps, D; Duval, X; Goujard, C; Mentré, F; Nembot, G; Panhard, X; Savic, RM; Taburet, AM; Verstuyft, C; Vrijens, B | 1 |
| Margolis, DA; Pakes, GE; Ross, LL; Santiago, L; Shaefer, MS; Sloan, LM; Squires, KE; Wine, BC; Young, B; Zhao, HH | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Stephan, C | 1 |
| Hayashi, T; Ikeda, H; Ishida, T; Kunimoto, Y; Miyamoto, A; Nakata, H; Noda, N; Okazaki, M; Shinomura, Y; Takahashi, S; Touda, N; Yasui, H | 1 |
| Baker, P; Bradbeer, C; George, M; Ngwenya, S | 1 |
| Bissio, E; Espinola, L; Gadano, A; Gallego, P; Lopardo, G; Stambullian, M | 1 |
| Katlama, C; Lê, MP; Peytavin, G; Soulie, C; Stitou, H | 1 |
| Bissio, E; Lopardo, GD | 1 |
| Baudry, T; Boibieux, A; Chidiac, C; Ferry, T; Gagnieu, MC; Goutelle, S; Livrozet, JM; Peyramond, D; Tod, M | 1 |
| Balamane, M; Bosch, RJ; Collier, AC; Daar, ES; Fischl, MA; Katzenstein, D; Lalama, CM; Mollan, K; Sax, PE; Tierney, C | 1 |
| Collier, AC; Daar, ES; Fischl, MA; Haas, DW; Mollan, K; Morse, GD; Ribaudo, HJ; Sax, PE; Tierney, C | 1 |
| Borsa-Lebas, F; Choisy, P; de la Tribonnière, X; Hocqueloux, L; Le Moal, G; Legac, E; Parienti, JJ; Plainchamp, D; Prazuck, T; Yazdanpanah, Y | 1 |
| Craig, C; Fätkenheuer, G; Heera, J; Leal, M; McFadyen, L; Mildvan, D; Mills, A; Podzamczer, D; Portsmouth, S; Rinehart, AR; Than, S; Valdez, H; Valluri, SR; Vourvahis, M | 1 |
| Aragones, AM; Cano, SM; Castello, A; Gomez-Arbones, X; Porcel, JM; Puig, T; Schoenenberger, JA | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Äbelö, A; Ashton, M; Barrail-Tran, A; Bergstrand, M; Calcagno, A; D'Avolio, A; Gisslén, M; Ormaasen, V; Rekić, D; Röshammar, D; Tarning, J; Vigan, M | 1 |
| Cau, P; Cremer, J; Dellamonica, P; Faucher, O; Kaspi, E; Lacarelle, B; Lévy, N; Micallef, J; Nicolino-Brunet, C; Perrin, S; Poizot-Martin, I; Reynes, J; Robaglia-Schlupp, A; Roll, P; Solas, C; Stretti, C; Tamalet, C; Tamalet, CN | 1 |
| Dabis, F; De Wit, S; El-Sadr, W; Kirk, O; Law, MG; Lundgren, JD; Monforte, Ad; Phillips, AN; Pradier, C; Reiss, P; Ryom, L; Sabin, CA; Weber, R; Worm, SW | 1 |
| Cannizzaro, MV; Chimenti, S; Chiricozzi, A; Giunta, A; Nisticò, SP; Saraceno, R | 1 |
| Concia, E; Corsini, F; Lanzafame, M; Lattuada, E; Vento, S | 1 |
| Abram, M; Cheng, AK; DeJesus, E; Fordyce, MW; Gathe, J; Henry, K; Molina, JM; Plummer, A; Ramanathan, S; Rockstroh, JK; Szwarcberg, J; Wei, X | 1 |
| Cauda, R; Ciccarelli, N; Cingolani, A; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Farina, S; Mondi, A; Murri, R; Navarra, P; Sidella, L; Tamburrini, E | 1 |
| Bigliano, P; Bonora, S; Bramato, C; Calcagno, A; D'Avolio, A; Di Perri, G; Gonzalez de Requena, D; Libanore, V; Motta, I; Orofino, G; Orsucci, E; Salassa, B; Simiele, M; Tettoni, MC | 1 |
| Best, BM; Burchett, SK; Byroads, M; Caparelli, E; Cressey, TR; Hawkins, E; Kreitchmann, R; Mirochnick, M; Rossi, S; Shapiro, DE; Smith, E; Stek, A; Wang, J; Watts, DH | 1 |
| Feinberg, J | 2 |
| Piliero, PJ | 2 |
| Gaylord, G | 1 |
| Piliero, P; Sanne, I; Schnittman, S; Squires, K; Thiry, A | 1 |
| Haas, DW; Jaeger, H; Nunes, D; Piliero, P; Schnittman, S; Schrader, S; Sension, M; Thiry, A; Zala, C | 1 |
| Goldsmith, DR; Perry, CM | 1 |
| Huff, B | 1 |
| Murphy, RL | 1 |
| Bierl, H | 1 |
| Moyle, GJ | 1 |
| Raffi, F | 1 |
| Cahn, P; Giordano, M; Kelleher, T; Murphy, RL; Percival, L; Phanuphak, P; Sanne, I | 1 |
| Bartlett, JG | 1 |
| Pham, PA | 1 |
| Kirkpatrick, P; Lebbos, J; Raja, A | 1 |
| Boyle, BA | 1 |
| Sulkowski, MS | 1 |
| Beijnen, JH; Crommentuyn, KM; Hillebrand, MJ; Huitema, AD; Rosing, H | 1 |
| Kakuda, T; Sargent, S; Schutz, M | 1 |
| Colonno, R; Friborg, J; McLaren, C; Parkin, N; Rose, R; Thiry, A | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Piketty, C; Taburet, AM; Vincent, I | 1 |
| Havlir, DV; O'Marro, SD | 1 |
| Cahn, P; Giordano, M; Kelleher, T; Mancini, M; Murphy, R; Pantaleo, G; Phanuphak, P; Pokrovskiy, V; Rozenbaum, W; Sension, M; Wood, R | 1 |
| Wehr, A | 1 |
| DeGoey, DA; Randolph, JT | 1 |
| Eholié, SP; Girard, PM; Lacombe, K; Serfaty, L; Wendum, D | 1 |
| Gazzard, BG; Moyle, G | 1 |
| Delfraissy, JF; Gatell, JM; Giordano, M; Jemsek, J; Lazzarin, A; Pokrovskiy, V; Powderly, WG; Rivero, A; Rozenbaum, W; Schrader, S; Sension, M; Squires, K; Thiry, A; Vibhagool, A | 1 |
| Chojnacki, JK; Coleman, CI; Musial, BL | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; Codemo, R; Gervasoni, C; Gornati, R; Ortu, M; Piolini, R; Pisacreta, M; Porretta, T; Tordato, F; Trovati, S | 1 |
| Orrick, JJ; Steinhart, CR | 1 |
| Benzie, AA; Boffito, M; Gazzard, BG; Hill, A; Kruse, G; Kurowski, M; Moyle, GJ; Nelson, MR; Pozniak, AL | 1 |
| Rockstroh, J | 1 |
| Becker, S | 1 |
| Busti, AJ; Hall, RG; Margolis, DM | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; Rightmire, A; Rodriguez, C; Sankoh, S; Wilber, R | 2 |
| Coupal, L; Gilmore, N; Grover, SA; Mukherjee, J | 1 |
| Feldt, T; Göbels, K; Häussinger, D; Kroidl, A; Kuschak, D; Leidel, R; Oette, M; Sagir, A | 1 |
| Deray, G; Izzedine, H; Launay-Vacher, V; Peytavin, G; Valantin, MA | 1 |
| Jaillon, P; Poirier, JM; Robidou, P | 1 |
| Collier, AC; Kosel, BW; Storey, SS | 1 |
| Behrens, GM; Castro-Frenzel, B; Christensen, S; Esser, S; Fätkenheuer, G; Lubach-Ruitman, M; Möbius, U; Rump, JA; Schmidt, RE; Stoll, M; Voigt, E | 1 |
| Beijnen, JH; Crommentuyn, KM; Dost, F; Huitema, AD; Schellens, JH; Sparidans, RW | 1 |
| Amin, J; Bloch, M; Carr, A; Cooper, DA; Emery, S; Mallon, PW; Marriott, D; Ray, J; Winston, A | 1 |
| Farthing, C; Khanlou, H | 1 |
| Bigoloni, A; Boeri, E; Castagna, A; Fusetti, G; Gianotti, N; Guffanti, M; Lazzarin, A; Regazzi, M; Schira, G; Seminari, E; Tiberi, S; Villani, P | 1 |
| Castagna, A; Cusato, M; Fusetti, G; Galli, A; Gianotti, N; Guffanti, M; Lazzarin, A; Regazzi, M; Seminari, E; Villani, P | 1 |
| Clotet, B; Fuster, D | 1 |
| Harris, M; Montaner, JS | 1 |
| Bernal, E; Gutiérrez, F; Masiá, M; Padilla, S | 1 |
| Bloch, MT; Marriott, D; McLachlan, AJ; Ray, JE | 1 |
| Colonno, R; Discotto, L; Friborg, J; Weinheimer, S; Yang, H | 1 |
| Barrail, A; Goujard, C; Le Tiec, C; Taburet, AM | 1 |
| Agarwala, S; Andrews, L; Child, M; Daley, L; Friedland, G; O'Mara, E; Schreibman, T; Shi, J; Wang, Y | 1 |
| Christensen, AR; Furtek, KJ; Hale, BR; Jones, LE; Petersen, K; Riddle, MS; Tasker, SA | 1 |
| Bonnard, P; Guiard-Schmid, JB; Jaillon, P; Lukiana, T; Meynard, JL; Pialoux, G; Poirier, JM; Slama, L | 1 |
| Adler, E; Cohen, C; Fessel, WJ; Gladysz, A; Gonzalez-Garcia, J; McGovern, R; McLaren, C; Nieto-Cisneros, L; Zala, C | 1 |
| Dellamonica, P | 1 |
| Hill, A | 1 |
| Scott, LJ; Swainston Harrison, T | 1 |
| Herzmann, C; Johnson, M; Kinloch, S | 1 |
| Calvez, V; Flandre, P; Günthard, HF; Hirsch, HH; Marcelin, AG; Masquelier, B; Perrin, L; Peytavin, G; Vora, S; Yerly, S; Zinkernagel, A | 1 |
| Barlow, G; Thaker, H; Trower, K; Wilmot, R | 1 |
| Bhatti, L; Farthing, C; Khanlou, H | 1 |
| Barreiro, P; Barrios, A; Corral, A; González-Lahoz, J; Jiménez-Nacher, I; Rendón, A; Rodríguez Nóvoa, S; Soriano, V | 1 |
| Luber, AD | 1 |
| Clarke, A; de Ruiter, A; Issa, R; Lechelt, M; Lyons, F; Magaya, V | 1 |
| Coco, J; DeJesus, E; Grinsztejn, B; Johnson, M; Lazzarin, A; Lichtenstein, K; McLaren, C; Odeshoo, L; Rightmire, A; Rodriguez, C; Wirtz, V | 1 |
| Altice, FL; Bruce, RD | 1 |
| Biollaz, J; Buclin, T; Cavassini, M; Colombo, S; Decosterd, LA; Franc, C; Guignard, N; Khonkarly, M; Rochat, B; Tarr, PE; Telenti, A | 1 |
| Bonnard, P; Guiard-Schmid, JB; Meynard, JL; Poirier, JM | 1 |
| Crum, NF; Furtek, KJ; Olson, PE; Wallace, MR | 1 |
| Naeger, LK; Struble, KA | 1 |
| Anderson, PL; Fletcher, CV; Kiser, JJ; Lichtenstein, KA | 1 |
| Chan-Tack, KM; Edozien, A | 1 |
| Bonnard, P; Girard, PM; Guiard-Schmid, JB; Jaillon, P; Lukiana, T; Meynard, JL; Pialoux, G; Poirier, JM; Zouai, O | 1 |
| Colonno, RJ; Giordano, M; Kelleher, T; Lazzarin, A; Squires, K | 1 |
| Gold, J; Jeganathan, S; Smith, D | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Gérard, L; Girard, PM; Marcelin, AG; Piketty, C; Saïdi, Y | 1 |
| Aboulker, JP; Calvez, V; Chazallon, C; Clavel, F; Gérard, L; Girard, PM; Madelaine-Chambrin, I; Marcelin, AG; Molina, JM; Piketty, C; Taburet, AM | 1 |
| Antela, A; Casado, JL; Dronda, F; Moreno, A; Moreno, S; Pérez-Elías, MJ | 1 |
| Bower, M; Gazzard, B; Holmes, P; Nelson, M; Stebbing, J | 1 |
| Azuaje, C; Crespo, M; Curran, A; Diaz, M; Feijoo, M; Lopez, RM; Ocaña, I; Pahissa, A; Pou, L; Ribera, E | 1 |
| Arvieux, C; Dailly, E; Jolliet, P; Perré, P; Raffi, F; Tattevin, P; Tribut, O | 1 |
| Keusch, G; Möddel, M; Pfammatter, R; Varga, Z | 1 |
| Mentré, F; Panhard, X; Piketti, C; Taburet, AM | 1 |
| Boucher, S; Breilh, D; Fleury, H; Lazaro, E; Neau, D; Pellegrin, I; Pellegrin, JL; Ragnaud, JM; Saux, MC; Schrive, MH; Vray, M | 1 |
| Piacenti, FJ | 1 |
| Bastow, B; Coombs, RW; DiRienzo, AG; Fletcher, CV; Godfrey, C; Margolis, DM; McKinnon, J; Mellors, JW; Ray, MG; Swindells, S; Thal, GD; Wang, H; Wilkin, T | 1 |
| Back, D; Boffito, M; Dickinson, L; Fletcher, C; Gazzard, B; Hill, A; Maitland, D; Moyle, G; Nelson, M; Pozniak, A | 1 |
| Biollaz, J; Buclin, T; Cavassini, M; Colombo, S; Csajka, C; Décosterd, LA; Telenti, A | 1 |
| Blanche, S; Delaugerre, C; Jullien, V; Macassa, E; Rouzioux, C; Teglas, JP; Tréluyer, JM; Veber, F | 1 |
| Abdullah, SM; Busti, AJ; Canham, RM; Das, SR; Margolis, DM; Peeters, MJ; Tsikouris, JP | 1 |
| Duggan, JM; Sahloff, EG | 1 |
| Chen, JM; Chen, X; Cihlar, T; Hatada, M; He, GX; Leavitt, SA; Lee, WA; Liu, X; McDermott, MJ; Mulato, AS; Stray, KM; Swaminathan, S; Yang, ZY | 1 |
| Back, D; Boffito, M; Ford, J; Gazzard, B; Hill, A; Khoo, S; Maitland, D; Moyle, G; Nelson, M; Pozniak, A | 1 |
| Johnson, M | 1 |
| Ballard, C; Best, B; Caperna, J; Capparelli, E; Goicoechea, M; Haubrich, R | 1 |
| Girard, PM; Meynard, JL; Pacanowski, J; Petit, I; Poirier, JM | 1 |
| Behrens, G; Lankisch, TO; Manns, MP; Moebius, U; Schmidt, RE; Strassburg, CP; Wehmeier, M | 1 |
| Beijnen, JH; Prins, JM; Repping, S; Ter Heine, R; van der Veen, F; van Leeuwen, E | 1 |
| Dekhtyar, T; Kempf, DJ; Lu, L; Mo, H; Molla, A; Parkin, N; Stewart, KD | 1 |
| Chang, HR; Pella, PM | 1 |
| Baker, RK; Brooks, JT; Buchacz, K; Chmiel, JS; Moorman, A; Wood, KC; Young, B | 1 |
| Chan-Tack, KM; Fantry, LE; Gilliam, BL; Qaqish, RB; Redfield, RR; Rode, RA | 1 |
| Barreiro, P; González-Lahoz, J; González-Pardo, G; Jiménez-Nácher, I; Martín-Carbonero, L; Rodríguez-Nóvoa, S; Soriano, V | 1 |
| Josephson, F; Karlström, O; Sönnerborg, A | 1 |
| Brun, S; Chumney, EC; King, MS; Luo, MP; Simpson, KN | 1 |
| Dauer, B; Harder, S; Klauke, S; Kurowski, M; Lutz, T; Müller, A; Oertel, B; Rottmann, C; Staszewski, S; von Hentig, N; Wolf, T | 1 |
| DiFrancesco, R; Fischl, MA; Gripshover, B; Hochreitter, J; Keil, K; Morse, GD; Reichman, RC; Zingman, BS | 1 |
| Ly, T; Ruiz, ME | 1 |
| Brazeau, D; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, BM; Ma, Q; Morse, GD; Reichman, RC; Slish, JC; Venuto, CS; Zingman, BS | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Jiménez-Nácher, I; Labarga, P; Martín-Carbonero, L; Rodríguez-Novoa, S; Ruiz, A; Soriano, V | 1 |
| Pérez-Elías, MJ | 1 |
| Bigoloni, A; Castagna, A; Caumo, A; Dagba, G; Danise, A; Galli, A; Galli, L; Guffanti, M; Lazzarin, A; Luzi, L | 1 |
| DiFrancesco, R; Donnelly, J; Fischl, MA; Gripshover, B; McCance-Katz, EF; Moody, DE; Morse, GD; Reichman, RC; Zingman, BS | 1 |
| Fukushima, K; Haraya, K; Ito, Y; Kodera, S; Seki, Y; Shibata, N; Sugioka, N; Takada, K; Terasaka, S; Wada, A | 1 |
| Attema-de Jonge, ME; Brinkman, K; Burger, DM; Franssen, EJ | 1 |
| Chen, J; Gatell, JM; Gonzalez, CJ; Grinsztejn, B; Harvey, CM; Isaacs, RD; Katlama, C; Lazzarin, A; Nguyen, BY; Vittecoq, D | 1 |
| Anderson, PL; Bushman, LR; Gerig, NE; Kiser, JJ; Lichtenstein, KA | 1 |
| Ambuhl, P; Huber, M; Keusch, G; Moch, H; Moddel, M; Opravil, M; Pfammatter, R; Schmid, S; Varga, Z; Wuthrich, RP | 1 |
| Cooper, DA; Emery, S; Law, M; MacRae, K; Mallon, PW; Satchell, C; Schutz, M; Williams, KM; Winston, A | 1 |
| Antunes, F; Gatell, J; Gruber, C; Horban, A; Lazzarin, A; Ledesma, E; Leen, C; Odeshoo, L; Salmon-Ceron, D; Van den Dungen, M; Van Wijngaerden, E; Wirtz, V | 1 |
| Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM | 1 |
| Aboulker, JP; Chazallon, C; Gérard, L; Girard, PM; Piketty, C; Taburet, AM | 1 |
| Daneel, S; Decosterd, L; Fierz, W; Hirschel, B; Hoffmann, M; Klimkait, T; Schiffer, V; Vernazza, P | 1 |
| Arduino, RC; Barnett, BJ; Torres, HA | 1 |
| Acosta, EP; Agarwala, S; Alston-Smith, B; Bertz, R; Child, M; Gerber, JG; Haas, DW; Hosey, L; Kendall, MA; Koletar, SL; Zolopa, AR | 1 |
| Giratto, JE; Girotto, JE; Salazar, JC; St Germain, RM; Wells, L; Yigit, S | 1 |
| Gianotti, N; Lazzarin, A; Soria, A | 1 |
| Bigoloni, A; Castagna, A; Chiaravalli, G; Galli, L; Gianotti, N; Guffanti, M; Lazzarin, A; Margonato, A | 1 |
| DiFrancesco, R; Friedland, G; Ma, Q; McCance-Katz, EF; Moody, DE; Morse, GD; Pade, P; Rainey, PM | 1 |
| Dauer, B; Haberl, A; Harder, S; Klauke, S; Lutz, T; Staszewski, S; von Hentig, N | 1 |
| Bernal, E; Gutiérrez, F; Martín-Hidalgo, A; Masiá, M; Padilla, S; Ramos, JM | 1 |
| Bower, M; Gazzard, B; Holmes, P; Jones, R; McKenna, A; Nathan, B; Nelson, M; Powles, T; Stebbing, J | 1 |
| Burger, DM; Cleijsen, RM; de Wolf, F; Gras, L; Koopmans, PP; Kroon, FP; Lunel, FV; van de Ende, ME | 1 |
| Back, D; Boffito, M; Bonora, S; D'Avolio, A; Else, L; Gazzard, B; Mandalia, S; Moyle, G; Nelson, M; Pozniak, A; Waters, LJ | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Brower, R; Frank, I; Kim, D; Luber, AD; Peloquin, CA; Silverman, R | 1 |
| Botsi, C; Katsambas, AD; Kourkounti, S; Kyriakis, KP; Leuow, K; Paparizos, VA | 1 |
| Battegay, M; Bodmer, M; Elzi, L; Haschke, M; Krähenbühl, S; Kummer, O; Mossdorf, E | 1 |
| Asselah, K; Borsa-Lebas, F; Couzigou, C; Daudon, M; Escaut, L; Higueret, D; Liotier, JY; May, T; Meynard, JL; Neau, D; Quencez, JL; Vittecoq, D; Zucman, D | 1 |
| Boston, NS; Brazeau, D; Catanzaro, L; DiFrancesco, R; Fischl, MA; Forrest, A; Gripshover, B; Ma, Q; Morse, GD; Reichman, RC; Slish, J; Zingman, BS | 1 |
| Blanco, A; Clotet, B; Miranda, C; Miranda, J; Moltó, J; Negredo, E; Santos, JR; Valle, M | 1 |
| Arribas, JR; Pulido, F | 1 |
| David, N; Hammond, J; Krantz, E; Malan, DR; McGrath, D; Wirtz, V | 1 |
| Barreiro, P; Blanco, F; de Mendoza, C; García-Gasco, P; González-Lahoz, J; Martín-Carbonero, L; Morello, J; Rivas, P; Rodríguez-Novoa, S; Ruiz-Sancho, A; Soriano, V; Vispo, E | 1 |
| Dietz, B; Jones, WJ; Rajagopalan, R; Simpson, KN | 1 |
| Cicero, ML; Di Vincenzo, P; Ferramosca, S; Galli, M; Pia De Pasquale, M; Rusconi, S; Sirianni, F; Vergani, B; Vigano', O; Vitiello, P | 1 |
| Cunningham, CK; Fletcher, CV; Flynn, PM; Harris, DR; Havens, PL; Kapogiannis, BG; Kiser, JJ; Liu, NX; Major-Wilson, H; Muenz, LR; Viani, RM; Wilson, CM | 1 |
| Airoldi, M; Bertuletti, P; Cattaneo, D; Frigerio, L; Maggiolo, F; Ripamonti, D; Ruggeri, M; Suter, F | 1 |
| Bardier, A; Daudon, M; Izzedine, H; M'rad, MB; Salmon, D | 1 |
| Antinori, A; Bertoli, A; Caramello, P; Cargnel, A; Carosi, G; Di Perri, G; Esposito, R; Filice, G; Lazzarin, A; Lorenzini, P; Maserati, R; Moroni, M; Narciso, P; Perno, CF; Rizzardini, G; Santoro, MM | 1 |
| Athichathanabadi, C; Bowonwatanuwong, C; Chaovavanich, A; Chumpathat, N; Manosuthi, W; Prasithsirikul, W; Ruxrungtham, K; Sungkanuparph, S; Tantisiriwat, W | 1 |
| Bracciale, L; Cauda, R; Colafigli, M; De Luca, A; Di Giambenedetto, S; Tamburrini, E | 1 |
| Abdel-Kader, L; Camacho, A; Lozano, F; Macías, J; Palacios, R; Pineda, JA; Rivero, A; Santos, J | 1 |
| Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Herrington, JD; Maclayton, DO; Nguyen, ST; Payne, KD; Rahman, AP; Rodriguez-Barradas, MC | 1 |
| Bedimo, R; Busti, AJ; Hardin, DS; Margolis, DM | 1 |
| Goshima, C; Jinno, S | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Taylor-Worth, RJ | 1 |
| Ceccarelli, G; D'Ettorre, G; Massetti, AP; Mastroianni, CM; Vullo, V; Zaffiri, L | 1 |
| Bacarelli, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Navarra, P; Ragazzoni, E; Regazzi, M; Villani, P | 1 |
| von Hentig, N | 1 |
| Babacan, E; Kaykhin, P; Lötsch, J; Staszewski, S; Stephan, C; Stürmer, M; von Hentig, N | 1 |
| Calabresi, A; Carosi, G; Costarelli, S; Izzo, I; Lapadula, G; Quiros-Roldan, E; Torti, C | 1 |
| Bertilsson, L; Böttiger, Y; Diczfalusy, U; Flamholc, L; Gisslén, M; Josephson, F; Ormaasen, V; Sönnerborg, A | 1 |
| Babacan, E; Carlebach, A; Haberl, A; Harder, S; Knecht, G; Lennemann, T; Staszewski, S; von Hentig, N | 1 |
| González-Mena, A; Guelar-Grimberg, A; Knobel-Freud, H; Vallecillo-Sánchez, G | 1 |
| Bilello, JA; Drusano, GL; Echols, R; Kaul, S; O'Mara, E; Preston, SL; Schnittman, S | 1 |
67 review(s) available for atazanavir sulfate and HIV Coinfection
| Article | Year |
|---|---|
Azapeptides -A History of Synthetic Milestones and Key Examples.
Topics: Amino Acids; Atazanavir Sulfate; Aza Compounds; Carbon; Goserelin; HIV Infections; Humans; Nitrogen; Peptides; Peptidomimetics | 2022 |
A Combination of Novel HIV-1 Protease Inhibitor and Cytochrome P450 (CYP) Enzyme Inhibitor to Explore the Future Prospective of Antiviral Agents: Evotaz.
Topics: Anti-HIV Agents; Anti-Infective Agents; Antiviral Agents; Atazanavir Sulfate; Child; Cobicistat; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Protease Inhibitors; United States | 2023 |
HIV-related nephropathy: new aspects of an old paradigm.
Topics: Acute Kidney Injury; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chronic Disease; HIV Infections; Humans; Kidney; Risk Factors; Tenofovir | 2020 |
A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Astrocytes; Atazanavir Sulfate; Benzoxazines; Central Nervous System; Cognitive Dysfunction; Cyclopropanes; Dideoxynucleosides; Endothelial Cells; HIV Infections; Humans; Neurons; Nevirapine; Nitriles; Oligodendroglia; Pyrimidines | 2020 |
Atazanavir / ritonavir versus Lopinavir / ritonavir-based combined antiretroviral therapy (cART) for HIV-1 infection: a systematic review and meta-analysis.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lopinavir; Ritonavir; Treatment Outcome; Viral Load | 2020 |
Cardiovascular risks associated with protease inhibitors for the treatment of HIV.
Topics: Animals; Atazanavir Sulfate; Atherosclerosis; Cardiovascular Diseases; Darunavir; Dyslipidemias; Heart Disease Risk Factors; HIV Infections; HIV Protease Inhibitors; Humans; Randomized Controlled Trials as Topic | 2021 |
Efficacy and safety of atazanavir/ritonavir-based antiretroviral therapy for HIV-1 infected subjects: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Second- and Third-line Antiretroviral Therapy for Children and Adolescents: A Scoping Review.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Cohort Studies; Darunavir; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Nitriles; Practice Guidelines as Topic; Pyridazines; Pyrimidines; Raltegravir Potassium; Viral Load | 2017 |
Atazanavir sulfate + cobicistat for the treatment of HIV infection.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Cobicistat; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Patient Safety; Solubility; Treatment Outcome | 2017 |
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; Quinolones; Ritonavir | 2017 |
Contemporary protease inhibitors and cardiovascular risk.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Risk Assessment; Ritonavir | 2018 |
Clinical pharmacokinetics of antiretroviral drugs in older persons.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; Guidelines as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lamivudine; Liver; Lopinavir; Middle Aged; Oligopeptides; Pyridines; Young Adult | 2013 |
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
Topics: Alleles; Anti-HIV Agents; Atazanavir Sulfate; Glucuronosyltransferase; HIV Infections; Homozygote; Humans; Hyperbilirubinemia; Oligopeptides; Polymorphism, Genetic; Prospective Studies; Pyridines; Retrospective Studies | 2013 |
HIV-associated lipodystrophy: impact of antiretroviral therapy.
Topics: Adiposity; Aging; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; Drug Combinations; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Nucleosides; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sulfonamides | 2013 |
A meta-analysis of the efficacy and safety of unboosted atazanavir compared with ritonavir-boosted protease inhibitor maintenance therapy in HIV-infected adults with established virological suppression after induction.
Topics: Atazanavir Sulfate; Drug Substitution; Drug Therapy, Combination; HIV Infections; Humans; Maintenance Chemotherapy; Oligopeptides; Protease Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Ritonavir | 2014 |
Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.
Topics: Atazanavir Sulfate; Carbamates; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Synergism; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Thiazoles | 2014 |
A systematic review of the use of atazanavir in women infected with HIV-1.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Pregnancy; Pyridines; Ritonavir; Sex Factors; Treatment Outcome; Viral Load | 2014 |
Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Demography; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Function Tests; Male; Renal Insufficiency, Chronic; Risk Factors | 2015 |
Efficacy of protease inhibitor monotherapy vs. triple therapy: meta-analysis of data from 2303 patients in 13 randomized trials.
Topics: Atazanavir Sulfate; Cerebrospinal Fluid; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Treatment Outcome | 2016 |
Renal effects of novel antiretroviral drugs.
Topics: Adenine; Alanine; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Creatinine; Disease Progression; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Oxazines; Piperazines; Proteinuria; Pyridones; Quinolones; Raltegravir Potassium; Renal Insufficiency, Chronic; Tenofovir | 2017 |
Less-drug regimen including atazanavir in maintenance treatment of HIV infection: how, who, when, why?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; Humans; Maintenance Chemotherapy; Sustained Virologic Response; Treatment Outcome | 2017 |
Managing chronic kidney disease in the older adults living with HIV.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chronic Disease; Darunavir; Drug Substitution; HIV Infections; Humans; Kidney; Kidney Diseases; Lopinavir; Middle Aged; Tenofovir | 2017 |
Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient.
Topics: Alkaline Phosphatase; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium | 2008 |
Atazanavir: its role in HIV treatment.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pregnancy; Pyridines | 2008 |
HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2009 |
Atazanavir: a review of its use in the management of HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2009 |
HIV protease inhibitors: recent clinical trials and recommendations on use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Atazanavir Sulfate; Clinical Trials as Topic; Darunavir; Drug Interactions; Drug Resistance, Viral; HIV Fusion Inhibitors; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Metabolome; Oligopeptides; Pyridines; Pyrones; Sulfonamides; Treatment Outcome | 2009 |
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2009 |
The CASTLE study: atazanavir/r versus lopinavir/r in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Clinical Trials, Phase III as Topic; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Pharmacogenetics of antiretrovirals.
Topics: Alkynes; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Dideoxynucleosides; Glucuronosyltransferase; HIV Infections; HLA-A Antigens; HLA-B Antigens; HLA-DRB1 Chains; Humans; Nevirapine; Oligopeptides; Oxidoreductases, N-Demethylating; Pharmacogenetics; Pyridines | 2010 |
Clinical pharmacology, efficacy and safety of atazanavir: a review.
Topics: Adult; Animals; Atazanavir Sulfate; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2009 |
[Pharmacology, pharmacokinetic features and interactions of atazanavir].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; Biotransformation; Blood Proteins; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; Fetal Blood; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Infant, Newborn; Kidney Diseases; Liver Diseases; Maternal-Fetal Exchange; Metabolic Clearance Rate; Molecular Structure; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pyridines | 2008 |
[Efficacy of atazanavir in simplification regimens].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Administration Schedule; Drug Therapy, Combination; Dyslipidemias; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Multicenter Studies as Topic; Oligopeptides; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome | 2008 |
[Efficacy of atazanavir in treatment-naive patients].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Resistance, Viral; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome | 2008 |
[Efficacy of atazanavir in rescue therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Resistance, Viral; Drug Synergism; Dyslipidemias; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Insulin Resistance; Oligopeptides; Patient Compliance; Point Mutation; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome; Viral Load | 2008 |
[Lipid profile of atazanavir].
Topics: Adipocytes; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Cells, Cultured; Cholesterol; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Glucose; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Multicenter Studies as Topic; Oligopeptides; Pyridines; Risk Factors; Salvage Therapy; Triglycerides | 2008 |
[Adverse effects of atazanavir].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbohydrate Metabolism; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Gastrointestinal Diseases; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Hyperinsulinism; Insulin Resistance; Oligopeptides; Pyridines; Urolithiasis | 2008 |
[Safety of atazanavir in patients with HIV and hepatitis B and/or C virus coinfection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Cohort Studies; Disease Progression; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Insulin Resistance; Liver; Liver Cirrhosis; Multicenter Studies as Topic; Oligopeptides; Pyridines | 2008 |
[Clinical utility of atazanavir].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cohort Studies; Comorbidity; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Insulin Resistance; Oligopeptides; Patient Acceptance of Health Care; Pyridines; Ritonavir; Salvage Therapy; Treatment Outcome; Viral Load | 2008 |
[Utility of atazanavir in special populations].
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Child; Child, Preschool; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Emigrants and Immigrants; Female; Heroin Dependence; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperbilirubinemia, Neonatal; Infant; Infant, Newborn; Insulin Resistance; Kidney Diseases; Liver Diseases; Male; Methadone; Multicenter Studies as Topic; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyridines; Young Adult | 2008 |
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; HIV Infections; Humans; Lipids; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Ritonavir | 2010 |
Renal disease associated with antiretroviral therapy in the treatment of HIV.
Topics: Adenine; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Indinavir; Kidney Diseases; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2011 |
Virological efficacy and safety of antiretroviral therapy-switch to atazanavir-based regimen: a review of the literature.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Treatment Outcome | 2012 |
Complete resolution of erythrodermic psoriasis in an HIV and HCV patient unresponsive to antipsoriatic treatments after highly active antiretroviral therapy (Ritonavir, Atazanavir, Emtricitabine, Tenofovir).
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Humans; Immunocompromised Host; Male; Middle Aged; Oligopeptides; Organophosphonates; Psoriasis; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Atazanavir: a novel HIV-1 protease inhibitor.
Topics: Animals; Atazanavir Sulfate; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines | 2002 |
Atazanavir.
Topics: Administration, Oral; Anti-HIV Agents; Atazanavir Sulfate; Capsules; Clinical Trials as Topic; Drug Administration Schedule; HIV Infections; HIV Protease; Oligopeptides; Pyridines | 2003 |
Reviving protease inhibitors: new data and more options.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Furans; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Organophosphates; Pyridines; Pyrones; Sulfonamides | 2003 |
Boosted PIs: competition hots up.
Topics: Atazanavir Sulfate; Drug Administration Schedule; HIV Infections; Humans; Indinavir; Lopinavir; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Saquinavir | 2003 |
Releasing the true power of protease inhibitors.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines; Randomized Controlled Trials as Topic | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Atazanavir: new option for treatment of HIV infection.
Topics: Atazanavir Sulfate; Drug Resistance; HIV Infections; Humans; Oligopeptides; Pyridines | 2004 |
Peptidomimetic inhibitors of HIV protease.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Dipeptides; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Models, Molecular; Molecular Mimicry; Molecular Structure; Nelfinavir; Oligopeptides; Organophosphates; Peptides; Phenylbutyrates; Pyridines; Pyrimidinones; Ritonavir; Saquinavir; Sulfonamides; Urethane | 2004 |
Does atazanavir cause lipodystrophy?
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Pyridines | 2004 |
Atazanavir: a new protease inhibitor to treat HIV infection.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Saquinavir | 2004 |
Atazanavir.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; In Vitro Techniques; Oligopeptides; Pyridines | 2004 |
Atazanavir: improving the HIV protease inhibitor class.
Topics: Animals; Atazanavir Sulfate; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2003 |
Atazanavir for the treatment of human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Resistance, Viral; HIV Infections; Humans; Oligopeptides; Pyridines | 2004 |
Atazanavir: A novel once-daily protease inhibitor.
Topics: Area Under Curve; Atazanavir Sulfate; Biological Availability; Drug Therapy, Combination; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Intestinal Absorption; Male; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic | 2004 |
Review of atazanavir: a novel HIV protease inhibitor.
Topics: Administration, Oral; Animals; Atazanavir Sulfate; Contraindications; Drug Approval; Drug Interactions; Drug Resistance, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Patient Compliance; Pyridines; Randomized Controlled Trials as Topic; Ritonavir | 2005 |
Management of HIV-infected patients with multidrug-resistant virus.
Topics: Adenine; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; HIV-1; Humans; Oligopeptides; Organophosphonates; Peptide Fragments; Pyridines; Pyrones; Randomized Controlled Trials as Topic; Sulfonamides; Tenofovir; Treatment Failure; Viral Load | 2004 |
Clinical pharmacokinetics and summary of efficacy and tolerability of atazanavir.
Topics: Adenine; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir | 2005 |
Atazanavir: a review of its use in the management of HIV infection.
Topics: Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperlipidemias; In Vitro Techniques; Insulin Resistance; Oligopeptides; Protease Inhibitors; Pyridines | 2005 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
Atazanavir: simplicity and convenience in different scenarios.
Topics: Area Under Curve; Atazanavir Sulfate; Drug Interactions; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Multicenter Studies as Topic; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Treatment Outcome | 2007 |
Antiviral activity and clinical efficacy of atazanavir in HIV-1-infected patients: a review.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir | 2007 |
Atazanavir/ritonavir: a review of its use in HIV therapy.
Topics: Animals; Atazanavir Sulfate; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir | 2008 |
183 trial(s) available for atazanavir sulfate and HIV Coinfection
| Article | Year |
|---|---|
First Pharmacokinetic Data of Tenofovir Alafenamide Fumarate and Tenofovir With Dolutegravir or Boosted Protease Inhibitors in African Children: A Substudy of the CHAPAS-4 Trial.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Child; Darunavir; Emtricitabine; Fumarates; HIV Infections; Humans; Lopinavir; Protease Inhibitors; Ritonavir; Tenofovir | 2023 |
Pharmacogenetic interactions between antiretroviral drugs and vaginally administered hormonal contraceptives.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Contraceptive Agents, Female; Contraceptive Agents, Hormonal; Contraceptive Devices, Female; Cyclopropanes; Cytochrome P-450 CYP2B6; Desogestrel; Drug Interactions; Ethinyl Estradiol; Female; Genetic Association Studies; Genotype; HIV Infections; Humans; Middle Aged; Pharmacogenetics; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Ritonavir; Vagina | 2020 |
A population pharmacokinetic model is beneficial in quantifying hair concentrations of ritonavir-boosted atazanavir: a study of HIV-infected Zimbabwean adolescents.
Topics: Adolescent; Atazanavir Sulfate; Black People; Female; Hair; HIV Infections; HIV Protease Inhibitors; Humans; Male; Models, Biological; Ritonavir; Zimbabwe | 2020 |
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Topics: Adolescent; Anti-Retroviral Agents; Atazanavir Sulfate; Caregivers; Female; Hair; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Models, Biological; Overweight; Ritonavir; Tenofovir; Thinness; Viral Load; Zimbabwe | 2021 |
Brief Report: Ritonavir Concentrations in Hair Predict Virologic Outcomes in HIV-Infected Adolescents With Virologic Failure on Atazanavir-Based or Ritonavir-Based Second-Line Treatment.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Female; Hair; HIV Infections; Humans; Male; Ritonavir; Treatment Failure; Treatment Outcome; Viral Load; Zimbabwe | 2021 |
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2017 |
Antiviral Activity, Safety, and Exposure-Response Relationships of GSK3532795, a Second-Generation Human Immunodeficiency Virus Type 1 Maturation Inhibitor, Administered as Monotherapy or in Combination With Atazanavir With or Without Ritonavir in a Phase
Topics: Adult; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Ritonavir; RNA, Viral; Young Adult | 2017 |
Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Darunavir; Female; Half-Life; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Saliva; Young Adult | 2017 |
Defining a Cutoff for Atazanavir in Hair Samples Associated With Virological Failure Among Adolescents Failing Second-Line Antiretroviral Treatment.
Topics: Adolescent; Adolescent Behavior; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Child; Female; Hair; HIV Infections; Humans; Male; Medication Adherence; Ritonavir; Self Report; Treatment Failure; Viral Load; Zimbabwe | 2017 |
Conflicting effects of atazanavir therapy on atherosclerotic risk factors in stable HIV patients: A randomized trial of regimen switch to atazanavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Biomarkers; Cross-Sectional Studies; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oxidative Stress; Risk Factors; Viral Load | 2017 |
Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s.
Topics: Acquired Immunodeficiency Syndrome; Adult; Atazanavir Sulfate; Biomarkers; Female; HIV Infections; HIV Protease Inhibitors; Humans; Inflammation; Male; Treatment Outcome | 2018 |
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Mutation, Missense; Organophosphates; Piperazines; Prodrugs; Ritonavir; Sustained Virologic Response; Treatment Outcome; Viral Load | 2018 |
Safety and Efficacy of Atazanavir Powder and Ritonavir in HIV-1-Infected Infants and Children From 3 Months to <11 Years of Age: The PRINCE-2 Study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Infant; Male; Powders; Ritonavir; RNA, Viral | 2018 |
Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and -2 Studies.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Male; Ritonavir; Viral Load | 2018 |
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2018 |
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Inflammation; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2018 |
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Neurocognitive Disorders; Ritonavir | 2018 |
Short-term cost analysis of raltegravir versus atazanavir + ritonavir or darunavir + ritonavir for treatment-naive adults with HIV-1 infection in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; Darunavir; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV-1; Humans; Male; Models, Economic; Raltegravir Potassium; Ritonavir; United States | 2018 |
No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Disease-Free Survival; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA, Viral; Survival Rate | 2018 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers.
Topics: Adult; Amides; Antiviral Agents; Atazanavir Sulfate; Benzofurans; Carbamates; Cyclopropanes; Darunavir; Drug Interactions; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Lopinavir; Male; Middle Aged; Quinoxalines; Ritonavir; Sulfonamides; Viral Nonstructural Proteins; Young Adult | 2019 |
Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; Humans; Logistic Models; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Viral Load | 2013 |
Adherence profiles and therapeutic responses of treatment-naive HIV-infected patients starting boosted atazanavir-based therapy in the ANRS 134-COPHAR 3 trial.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Surveys and Questionnaires; Tenofovir; Viral Load | 2013 |
Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Viral Load; Young Adult | 2013 |
Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles; Treatment Outcome; Viral Load | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Bilirubin; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Young Adult; Zinc Sulfate | 2013 |
Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Oligopeptides; Plasma; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyridines; Ritonavir | 2013 |
Assessment of pharmacokinetic interactions of the HCV NS5A replication complex inhibitor daclatasvir with antiretroviral agents: ritonavir-boosted atazanavir, efavirenz and tenofovir.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepatitis C; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrrolidines; Ritonavir; Tenofovir; Valine; Viral Nonstructural Proteins; Young Adult | 2013 |
Role of ritonavir in the drug interactions between telaprevir and ritonavir-boosted atazanavir.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Chromatography, Liquid; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Plasma; Pyridines; Ribavirin; Ritonavir | 2014 |
Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Darunavir; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lipids; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Spain; Sulfonamides | 2014 |
Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tomography, X-Ray Computed; Young Adult | 2014 |
Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Proteins; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Neopterin; Oligopeptides; Protein Binding; Pyridines; Ritonavir; RNA, Viral; Sulfonamides | 2014 |
Baseline natural killer and T cell populations correlation with virologic outcome after regimen simplification to atazanavir/ritonavir alone (ACTG 5201).
Topics: Atazanavir Sulfate; CD4-CD8 Ratio; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Killer Cells, Natural; Oligopeptides; Pyridines; Ritonavir; RNA, Viral | 2014 |
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Oligopeptides; Pyridines; Treatment Outcome; Viral Load; Young Adult | 2014 |
Atazanavir exposure is effective during pregnancy regardless of tenofovir use.
Topics: Adolescent; Adult; Area Under Curve; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Gestational Age; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Pregnancy; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2015 |
[Initial HIV therapy. ACTG 5257: convincing results for raltegravir compared with protease inhibitors].
Topics: Acquired Immunodeficiency Syndrome; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2014 |
Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression: 48-week efficacy and safety results.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load | 2014 |
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Male; Metabolic Clearance Rate; Middle Aged; Oligopeptides; Plasma; Pyridines; Ritonavir; Sex Characteristics; Time Factors; Treatment Failure; Treatment Outcome | 2014 |
Long-term safety and efficacy of atazanavir-based therapy in HIV-infected infants, children and adolescents: the Pediatric AIDS Clinical Trials Group Protocol 1020A.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Child; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Infant; Oligopeptides; Pyridines; South Africa; Treatment Outcome; United States; Viral Load | 2015 |
Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.
Topics: Adenine; Adult; Atazanavir Sulfate; Darunavir; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Tenofovir; Therapeutic Equivalency; Viral Load | 2014 |
A randomized trial in healthy subjects to assess the bioequivalence of an atazanavir/cobicistat fixed-dose combination tablet versus administration as separate agents.
Topics: Administration, Oral; Adolescent; Adult; Atazanavir Sulfate; Biological Availability; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Therapy, Combination; Female; Healthy Volunteers; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Therapeutic Equivalency; Young Adult | 2015 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
Simultaneous plasma and genital pharmacokinetics and pharmacodynamics of atazanavir and efavirenz in HIV-infected women starting therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Middle Aged; RNA, Viral; Viral Load; Young Adult | 2015 |
[Results of a comparative study of the efficacy of once daily darunavir/atazanavir in treatment-naïve patients with HIV infection].
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Viral Load | 2014 |
Comparison of the metabolic effects of ritonavir-boosted darunavir or atazanavir versus raltegravir, and the impact of ritonavir plasma exposure: ACTG 5257.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Blood Glucose; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Raltegravir Potassium; Ritonavir | 2015 |
Changes in Inflammation and Immune Activation With Atazanavir-, Raltegravir-, Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Darunavir; Female; HIV Infections; Humans; Inflammation; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Raltegravir Potassium; Treatment Outcome | 2015 |
Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Density; Darunavir; Drug Therapy, Combination; Emtricitabine; Female; HIV; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Male; Middle Aged; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load; Young Adult | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
PRINCE-1: safety and efficacy of atazanavir powder and ritonavir liquid in HIV-1-infected antiretroviral-naïve and -experienced infants and children aged ≥3 months to <6 years.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Male; Prospective Studies; Ritonavir | 2015 |
Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study).
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Female; Genetic Markers; Genotype; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Peroxisome-Targeting Signal 1 Receptor; Pharmacogenetics; Pilot Projects; Plasma; Receptors, Cytoplasmic and Nuclear | 2015 |
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Bone Density; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Kidney; Lamivudine; Lipids; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Brief Report: Cobicistat Compared With Ritonavir as a Pharmacoenhancer for Atazanavir in Combination With Emtricitabine/Tenofovir Disoproxil Fumarate: Week 144 Results.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Viral Load | 2015 |
Brief Report: Switch to Ritonavir-Boosted Atazanavir Plus Raltegravir in Virologically Suppressed Patients With HIV-1 Infection: A Randomized Pilot Study.
Topics: Adult; Atazanavir Sulfate; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Pilot Projects; Prospective Studies; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Young Adult | 2016 |
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Australia; Europe; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Tenofovir; United States; Young Adult | 2016 |
Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.
Topics: Administration, Oral; Adolescent; Adult; Aged; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Anti-Infective Agents; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Encephalitis; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Pneumonia, Pneumocystis; Reverse Transcriptase Inhibitors; Ritonavir; Toxoplasmosis, Cerebral; Young Adult | 2016 |
Long-Term Efficacy, Tolerability, and Renal Safety of Atazanavir/Ritonavir-based Antiretroviral Therapy in a Cohort of Treatment-Naïve Patients with HIV-1 Infection: the REMAIN Study.
Topics: Adolescent; Adult; Atazanavir Sulfate; Cohort Studies; Drug Administration Schedule; Europe; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Male; Middle Aged; Ritonavir; Treatment Outcome; Young Adult | 2016 |
Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Male; Middle Aged; Ritonavir; Viral Load; Young Adult | 2016 |
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bone Density; Coinfection; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Prospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2016 |
Nucleoside-Sparing Regimens With Raltegravir and a Boosted Protease Inhibitor: An Unsettled Issue.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Raltegravir Potassium; Ritonavir; RNA, Viral; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2016 |
Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomiz
Topics: Adult; Africa; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nucleosides; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Evolution of changes in cognitive function after the initiation of antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cognition; Cognition Disorders; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Male; Middle Aged; Neuropsychological Tests; Nevirapine; Ritonavir; Young Adult | 2016 |
Effects of Pitavastatin on Lipid Profiles in HIV-Infected Patients with Dyslipidemia and Receiving Atazanavir/Ritonavir: A Randomized, Double-Blind, Crossover Study.
Topics: Adult; Atazanavir Sulfate; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lipoproteins, LDL; Male; Middle Aged; Quinolines; Ritonavir; Treatment Outcome; Triglycerides | 2016 |
Switching Lopinavir/Ritonavir to Atazanavir/Ritonavir vs Adding Atorvastatin in HIV-Infected Patients Receiving Second-Line Antiretroviral Therapy With Hypercholesterolemia: A Randomized Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atorvastatin; Cholesterol; Female; HIV Infections; Humans; Hypercholesterolemia; Lipoproteins, LDL; Lopinavir; Male; Middle Aged; Ritonavir | 2016 |
Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients.
Topics: Adult; Atazanavir Sulfate; Biomarkers; Drug-Related Side Effects and Adverse Reactions; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Neuropsychological Tests; Pilot Projects; Real-Time Polymerase Chain Reaction; Ritonavir; Spinal Puncture; Viral Load | 2016 |
Low-dose versus standard-dose ritonavir-boosted atazanavir in virologically suppressed Thai adults with HIV (LASA): a randomised, open-label, non-inferiority trial.
Topics: Adolescent; Adult; Atazanavir Sulfate; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Pregnancy; Ritonavir; Thailand; Viral Load; Young Adult | 2016 |
Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cobicistat; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; International Cooperation; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2016 |
Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carotid Intima-Media Thickness; Darunavir; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Linear Models; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Oxidation-Reduction; Prospective Studies; Raltegravir Potassium; Ritonavir; RNA, Viral; Tenofovir | 2017 |
Atazanavir Plus Cobicistat: Week 48 and Week 144 Subgroup Analyses of a Phase 3, Randomized, Double-Blind, Active-Controlled Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cobicistat; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Male; RNA, Viral; Sustained Virologic Response; Treatment Outcome; Withholding Treatment | 2017 |
Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Cross-Over Studies; Cytochrome P-450 CYP3A Inhibitors; Female; HIV Infections; Humans; Imidazoles; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ritonavir; Valine; Young Adult | 2017 |
Efficacy and safety of "unboosting" atazanavir in a randomized controlled trial among HIV-infected patients receiving tenofovir DF.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; CD4 Lymphocyte Count; Drug Substitution; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2017 |
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Viral Load; Young Adult | 2017 |
Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Liver; Male; Middle Aged; Oligopeptides; Oxidative Stress; Prospective Studies; Pyridines; Young Adult | 2009 |
Anti-HIV agents. The Castle study: lopinavir vs. atazanavir.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Viral Load | 2008 |
A king in the CASTLE? Optimum initial HIV protease inhibitor.
Topics: Atazanavir Sulfate; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Tablets; Viral Load | 2008 |
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2008 |
A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Female; HIV Infections; Humans; Liver Diseases; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Serum | 2008 |
CASTLE data show no gender differences.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Sex Factors; Viral Load | 2008 |
Nucleoside-free boosted double PI regimen: significant CD4+ T-cell recovery in patients with poor immunologic response despite virologic suppression.
Topics: ADP-ribosyl Cyclase 1; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Flow Cytometry; HIV Infections; HIV Protease Inhibitors; HLA-DR Antigens; Humans; Longitudinal Studies; Male; Membrane Glycoproteins; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Saquinavir; T-Lymphocyte Subsets; Viral Load | 2008 |
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; Treatment Outcome; Viremia; Young Adult | 2009 |
Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia receiving a boosted protease inhibitor.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Viremia; Virus Replication | 2009 |
Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Pyridines; Ritonavir; Stavudine | 2009 |
Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cholesterol, LDL; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Hyperlipidemias; Male; Middle Aged; Oligopeptides; Pyridines | 2009 |
Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV/r-containing HAART: the ATAZIP study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Atazanavir Sulfate; Drug Resistance, Viral; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lipids; Liver; Lopinavir; Male; Middle Aged; Mutation; Oligopeptides; Pyridines; Pyrimidinones; Safety | 2009 |
Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asparagine; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Quinolines; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Viral Load | 2009 |
Effects of switching from lopinavir/ritonavir to atazanavir/ritonavir on muscle glucose uptake and visceral fat in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Glucose; HIV Infections; HIV Protease Inhibitors; Humans; Intra-Abdominal Fat; Lipid Metabolism; Lopinavir; Male; Middle Aged; Muscle, Skeletal; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2009 |
Change to atazanavir/ritonavir treatment improves lipids but not endothelial function in patients on stable antiretroviral therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir | 2010 |
Influence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trial.
Topics: Adult; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Orosomucoid; Pyridines; Serum Albumin | 2010 |
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Topics: Adenine; Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Effect of nevirapine on the steady-state trough concentrations of atazanavir in HIV-infected patients receiving atazanavir/ritonavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Pilot Projects; Pyridines; Ritonavir | 2010 |
Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: the STALWART study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Fever; Furans; HIV Infections; Humans; Interleukin-2; Lopinavir; Male; Nausea; Oligopeptides; Opportunistic Infections; Organophosphates; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Treatment Outcome | 2010 |
Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Topics: Adenine; Adolescent; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; Carbamates; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Emtricitabine; Furans; Genetic Variation; HIV Infections; HIV-1; Humans; Middle Aged; Oligopeptides; Organophosphates; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Sequence Analysis, RNA; Sulfonamides; Tenofovir; Treatment Failure | 2010 |
Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Senegal; Treatment Outcome | 2010 |
Differential effects of efavirenz, lopinavir/r, and atazanavir/r on the initial viral decay rate in treatment naïve HIV-1-infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2010 |
Effect of low-dose omeprazole (20 mg daily) on the pharmacokinetics of multiple-dose atazanavir with ritonavir in healthy subjects.
Topics: Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Ritonavir | 2011 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Gastrointestinal Diseases; HIV Infections; HIV-1; Humans; Irritable Bowel Syndrome; Lopinavir; Male; Medication Adherence; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Pyrimidinones; Quality of Life; Ritonavir; Surveys and Questionnaires; Tenofovir; Young Adult | 2010 |
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Efavirenz versus boosted atazanavir or zidovudine and abacavir in antiretroviral treatment-naive, HIV-infected subjects: week 48 data from the Altair study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Female; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2010 |
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance.
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Circadian Rhythm; Cytochrome P-450 CYP3A; Female; Gene Frequency; Genotype; HIV Infections; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Oligopeptides; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pregnane X Receptor; Pyridines; Receptors, Steroid; Young Adult | 2010 |
Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavir-boosted regimen.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Random Allocation; Ritonavir; RNA, Viral; Viral Load; Virus Replication; Young Adult | 2010 |
Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Sex Factors | 2011 |
In vitro susceptibility and virological outcome to darunavir and lopinavir are independent of HIV type-1 subtype in treatment-naive patients.
Topics: Adamantane; Adult; Analysis of Variance; Atazanavir Sulfate; Carbamates; Darunavir; Drug Resistance, Viral; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lopinavir; Microbial Sensitivity Tests; Molecular Typing; Nelfinavir; Neuraminidase; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Saquinavir; Sulfonamides; Viral Load | 2010 |
Atazanavir pharmacokinetics with and without tenofovir during pregnancy.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.
Topics: Adolescent; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Viral Load; Young Adult | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Dyslipidemias; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Chi-Square Distribution; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Male; Oligopeptides; Prospective Studies; Pyridines; Treatment Outcome; Triglycerides | 2011 |
Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cardiovascular Diseases; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2011 |
Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Puerto Rico; Pyridines; Ritonavir; South Africa; United States; Viral Load | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Atazanavir and atazanavir/ritonavir pharmacokinetics in HIV-infected infants, children, and adolescents.
Topics: Adolescent; Atazanavir Sulfate; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Male; Oligopeptides; Pyridines; Ritonavir; South Africa; Treatment Outcome; United States; Young Adult | 2011 |
Steady-state pharmacokinetics of tenofovir-based regimens in HIV-infected pediatric patients.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Child; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2011 |
Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Atazanavir Sulfate; Biotransformation; Drug Therapy, Combination; Female; HIV Infections; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Oligopeptides; Pyridines; Rifabutin; Ritonavir; Tuberculosis; Young Adult | 2011 |
Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
Topics: Adenine; Adult; Aged; Antiviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2011 |
Effects of the H2-receptor antagonist famotidine on the pharmacokinetics of atazanavir-ritonavir with or without tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Viral Load | 2011 |
Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Treatment Outcome | 2011 |
Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.
Topics: Adenine; Adult; Atazanavir Sulfate; Deoxycytidine; Drug Administration Schedule; Dyslipidemias; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Male; Oligopeptides; Organophosphonates; Pyridines; Saquinavir; Tenofovir; Treatment Outcome | 2011 |
Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.
Topics: Atazanavir Sulfate; Bilirubin; Biomarkers; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2011 |
Virological response and resistance profiles after 24 months of first-line antiretroviral treatment in adults living in Bangui, Central African Republic.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Central African Republic; DNA Fingerprinting; Drug Resistance, Viral; Female; Genetic Variation; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load; Young Adult; Zidovudine | 2012 |
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Limit of Detection; Lopinavir; Male; Middle Aged; Nonlinear Dynamics; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Viral Load | 2011 |
A randomized, pilot trial to evaluate glomerular filtration rate by creatinine or cystatin C in naive HIV-infected patients after tenofovir/emtricitabine in combination with atazanavir/ritonavir or efavirenz.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Creatinine; Cyclopropanes; Cystatin C; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir | 2012 |
A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphorus Compounds; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2011 |
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Aspartate Aminotransferases; Atazanavir Sulfate; CD4 Lymphocyte Count; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Quinolones; Raltegravir Potassium; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2012 |
Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir versus lopinavir/ritonavir in HIV-infected, treatment-naive patients who participated in the CASTLE Study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Emtricitabine; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cognition; Cognition Disorders; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Zidovudine | 2012 |
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Oligopeptides; Post-Exposure Prophylaxis; Pyridines; Ritonavir; Zidovudine | 2012 |
A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposity.
Topics: Abdominal Fat; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Protease Inhibitors; Pyridines; Young Adult | 2012 |
A randomized study of pharmacokinetics, efficacy, and safety of 2 raltegravir plus atazanavir strategies in ART-treated adults.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome | 2012 |
Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Female; Glucuronosyltransferase; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Prospective Studies; Pyridines; Treatment Outcome; Triglycerides | 2012 |
Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; Tenofovir; Thiazoles | 2012 |
Effect of adherence as measured by MEMS, ritonavir boosting, and CYP3A5 genotype on atazanavir pharmacokinetics in treatment-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Alleles; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Deoxycytidine; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Models, Biological; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pharmacogenetics; Pyridines; Ritonavir; Tenofovir; Young Adult | 2012 |
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; C-Reactive Protein; Coronary Disease; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Inflammation; Interleukin-6; Lamivudine; Lipids; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Pyridines; Risk Assessment; Ritonavir; Treatment Outcome; Young Adult | 2013 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Fasting; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Serum | 2013 |
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Mutation, Missense; Oligopeptides; Pyridines; Ritonavir; Treatment Failure | 2012 |
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Genetic Variation; Genotype; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Jaundice; Oligopeptides; Pyridines; Ritonavir | 2013 |
Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Male; Maraviroc; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Tenofovir; Triazoles; Viral Load; Young Adult | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
Topics: Aging; Atazanavir Sulfate; Carbamates; Cross-Sectional Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamin Type A; Leukocytes, Mononuclear; Longitudinal Studies; Lopinavir; Male; Nuclear Proteins; Oligopeptides; Protein Precursors; Pyridines; Ritonavir; Sulfonamides; Viral Load | 2012 |
A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Bilirubin; Bone Density; Carbamates; Cobicistat; Confidence Intervals; Creatinine; Deoxycytidine; Double-Blind Method; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Ritonavir; RNA, Viral; Tenofovir; Thiazoles; Triglycerides | 2013 |
Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Organophosphonates; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2013 |
Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects.
Topics: Adult; Atazanavir Sulfate; Didanosine; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Stavudine; Time Factors; Viral Load | 2003 |
Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Male; Oligopeptides; Pilot Projects; Protease Inhibitors; Pyridines; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Treatment Failure | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Atazanavir in treatment-experienced patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2003 |
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol, LDL; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Stavudine; Treatment Outcome; Triglycerides | 2003 |
Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Area Under Curve; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Ritonavir; Spectrophotometry, Ultraviolet; Tenofovir | 2004 |
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cholesterol; Cholesterol, LDL; Female; HIV Infections; Humans; Hyperlipidemias; Lamivudine; Lipids; Male; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Safety; Stavudine; Time Factors; Triglycerides | 2004 |
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Oxazines; Pyridines; RNA, Viral; Zidovudine | 2004 |
Boosted Reyataz comparable to Kaletra.
Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Maximum Tolerated Dose; Oligopeptides; Probability; Pyridines; Pyrimidinones; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2005 |
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Female; HIV Infections; Humans; Hyperlipidemias; Lamivudine; Life Expectancy; Male; Markov Chains; Middle Aged; Nelfinavir; Oligopeptides; Pyridines; Risk Factors; Stavudine | 2005 |
Atazanavir for treatment of HIV infection in clinical routine: efficacy, pharmacokinetics and safety.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Clinical Chemistry Tests; Drug Monitoring; Drug Therapy, Combination; Hematologic Tests; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome | 2005 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Drug Administration Schedule; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Viral Load | 2005 |
Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cholesterol; Cohort Studies; Female; HIV Infections; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Male; Middle Aged; Oligopeptides; Pyridines; Triglycerides | 2005 |
Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Oligopeptides; Predictive Value of Tests; Pyridines; RNA, Viral | 2005 |
PI monotherapy effective as maintenance.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Comparison of atazanavir with lopinavir/ritonavir in patients with prior protease inhibitor failure: a randomized multinational trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol; Cholesterol, LDL; Female; HIV; HIV Infections; Humans; Lopinavir; Male; Oligopeptides; Protease Inhibitors; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Triglycerides | 2005 |
96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lipids; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Time Factors; Treatment Outcome | 2006 |
Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures.
Topics: Adult; Atazanavir Sulfate; Blood Proteins; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Protein Binding; Pyridines; Pyrimidinones; Ritonavir; Treatment Outcome | 2006 |
Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ritonavir in treatment-experienced patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Approval; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Mutation; Oligopeptides; Phenotype; Pyridines; Ritonavir; Treatment Outcome; Viral Load | 2006 |
Early clinical experience with atazanavir in treatment-experienced patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; New South Wales; Oligopeptides; Pyridines; Treatment Outcome; Viral Load | 2006 |
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Salvage Therapy; Tenofovir; Treatment Failure | 2006 |
Rescue therapy with once-daily atazanavir-based regimens for antiretroviral-experienced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Salvage Therapy; Spain | 2006 |
Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Topics: Adult; Algorithms; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Patient Compliance; Pilot Projects; Pyridines; Ritonavir; RNA, Messenger; Viral Load | 2006 |
Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Pyridines; RNA, Viral; Semen; Time Factors; Treatment Outcome | 2007 |
Renal function in patients receiving tenofovir with ritonavir/lopinavir or ritonavir/atazanavir in the HIV Outpatient Study (HOPS) cohort.
Topics: Adenine; Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; Humans; Kidney; Lopinavir; Male; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Ritonavir; Tenofovir | 2006 |
Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy.
Topics: Adult; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Time Factors; Treatment Outcome; Viral Load | 2007 |
Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial.
Topics: Adolescent; Adult; Aged; Atazanavir Sulfate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Resistance, Multiple; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Logistic Models; Male; Middle Aged; Oligopeptides; Organic Chemicals; Pyridines; Pyrrolidinones; Raltegravir Potassium; Treatment Outcome; Viral Load | 2007 |
The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Treatment Outcome | 2007 |
Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Treatment Outcome; Viral Load | 2007 |
Renal function in antiretroviral-experienced patients treated with tenofovir disoproxil fumarate associated with atazanavir/ritonavir.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Creatinine; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Male; Middle Aged; Models, Biological; Oligopeptides; Organophosphonates; Prognosis; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2007 |
Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Area Under Curve; Atazanavir Sulfate; Chromatography, Liquid; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Matched-Pair Analysis; Metabolic Clearance Rate; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Time Factors; Treatment Outcome | 2007 |
Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir | 2007 |
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Topics: Adult; Aged; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Microbial Sensitivity Tests; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Stavudine; Viral Load; Withholding Treatment | 2008 |
Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; CD4 Lymphocyte Count; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Pyrimidinones; RNA, Viral; Treatment Outcome | 2008 |
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Monitoring; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Male; Maternal-Fetal Exchange; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridines; Ritonavir | 2007 |
Viro-immunologic response to ritonavir-boosted or unboosted atazanavir in a large cohort of multiply treated patients: the CARe Study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Italy; Male; Middle Aged; Oligopeptides; Proportional Hazards Models; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Viremia | 2008 |
Improvement in insulin sensitivity and dyslipidemia in protease inhibitor-treated adult male patients after switch to atazanavir/ritonavir.
Topics: Adult; Aged; Atazanavir Sulfate; Body Composition; Dyslipidemias; HIV Infections; HIV Protease Inhibitors; Humans; Insulin Resistance; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Treatment Outcome; Triglycerides | 2008 |
Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Topics: Adolescent; Anti-HIV Agents; Antifungal Agents; Atazanavir Sulfate; CCR5 Receptor Antagonists; Cyclohexanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Maraviroc; Middle Aged; Oligopeptides; Pyridines; Saquinavir; Statistics as Topic; Triazoles | 2008 |
Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4beta-hydroxycholesterol levels.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Enzyme Induction; Enzyme Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxycholesterols; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2008 |
Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable.
Topics: Adult; Atazanavir Sulfate; Dose-Response Relationship, Drug; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Monte Carlo Method; Oligopeptides; Pyridines; Viral Load; Virus Replication | 2001 |
476 other study(ies) available for atazanavir sulfate and HIV Coinfection
| Article | Year |
|---|---|
Predicting Drug-Drug Interactions between Rifampicin and Ritonavir-Boosted Atazanavir Using PBPK Modelling.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Rifampin; Ritonavir | 2022 |
Pharmacokinetics of Atazanavir Boosted With Cobicistat in Pregnant and Postpartum Women With HIV.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Child; Cobicistat; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Placenta; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies | 2022 |
Prevalence and predictors of glucose metabolism disorders among People Living with HIV on combination antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Blood Glucose; Cross-Sectional Studies; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Ethiopia; Female; Glucose; Glucose Metabolism Disorders; HIV; HIV Infections; Humans; Insulin; Male; Prevalence; Ritonavir | 2022 |
Lipid profile levels in HIV-AIDS patients on treatment with efavirenz and atazanavir. Cohort study.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cholesterol, LDL; Cohort Studies; Cyclopropanes; HIV Infections; Humans; Retrospective Studies | 2021 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
Durability of switched therapy after failure of WHO-recommended antiretroviral therapy regimens in a resource-limited setting.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Retrospective Studies; Ritonavir; Viral Load; World Health Organization; Young Adult | 2022 |
Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cohort Studies; Darunavir; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Oxazines; Piperazines; Pregnancy; Premature Birth; Pyridones; Quinolones; Raltegravir Potassium; Rilpivirine; Ritonavir; United States | 2022 |
Atazanavir-Concentrate Loaded Soft Gelatin Capsule for Enhanced Concentration in Plasma, Brain, Spleen, and Lymphatics.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Brain; Corn Oil; Gelatin; HIV Infections; Molecular Docking Simulation; Oleic Acid; Polyethylene Glycols; Polysorbates; Polyvinyls; Propylene Glycols; Rats; Spleen | 2022 |
Antiretroviral protease inhibitors induce features of cellular senescence that are reversible upon drug removal.
Topics: Aging, Premature; Animals; Anti-HIV Agents; Atazanavir Sulfate; Cellular Senescence; Darunavir; HIV Infections; HIV Protease Inhibitors; Mice; Ritonavir | 2023 |
Potential association between chia seeds use and low atazanavir trough concentrations in an HIV-infected patient.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Pyridines; Ritonavir | 2023 |
Atazanavir urolithiasis without recent intake of atazanavir.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Administration Schedule; Drug Substitution; Hepatitis C; HIV Infections; Humans; Inactivation, Metabolic; Late Onset Disorders; Liver; Male; Time Factors; Urolithiasis | 2019 |
Anti-HIV and Anti-Hepatitis C Virus Drugs Inhibit P-Glycoprotein Efflux Activity in Caco-2 Cells and Precision-Cut Rat and Human Intestinal Slices.
Topics: Aged; Animals; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzimidazoles; Caco-2 Cells; Carbamates; Drug Interactions; Female; Fluorenes; Hepatitis C; HIV Infections; Humans; Imidazoles; Intestines; Lopinavir; Male; Maraviroc; Middle Aged; Pyrrolidines; Rats; Rats, Wistar; Ritonavir; Saquinavir; Valine; Zidovudine | 2019 |
Antiretroviral therapy and vaginally administered contraceptive hormones: a three-arm, pharmacokinetic study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Contraceptive Agents; Contraceptive Devices, Female; Cyclopropanes; Desogestrel; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Lynestrenol; Middle Aged; Progesterone; Ritonavir; Viral Load; Young Adult | 2019 |
Life-threatening rhabdomyolysis and Fanconi syndrome related to tenofovir disoproxil fumarate administration in an HIV-infected patient.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Fanconi Syndrome; Fluid Therapy; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Nevirapine; Rhabdomyolysis; Tenofovir | 2020 |
Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women.
Topics: Area Under Curve; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Chromatography, High Pressure Liquid; Citrus sinensis; Cytochrome P-450 CYP3A Inhibitors; Diarrhea; Dose-Response Relationship, Drug; Female; Genotype; Hair; Heroin Dependence; HIV Infections; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Longitudinal Studies; MicroRNAs; Polymorphism, Single Nucleotide; Racial Groups; Receptors, Cell Surface; Tandem Mass Spectrometry | 2020 |
Antiretroviral Penetration across Three Preclinical Animal Models and Humans in Eight Putative HIV Viral Reservoirs.
Topics: Animals; Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Emtricitabine; Female; HIV Infections; Humans; In Vitro Techniques; Maraviroc; Mice; Raltegravir Potassium; Tenofovir | 2019 |
The impact of integrase inhibitor-based regimens on markers of inflammation among HIV naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytokines; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Inflammation; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Raltegravir Potassium | 2020 |
Response to letter to the editor: switch to dolutegravir and unboosted atazanavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Viral Load | 2019 |
Two-drug regimens with dolutegravir for maintaining viral suppression: looking at the right companion.
Topics: Atazanavir Sulfate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Viral Load | 2019 |
Drug-Drug Interactions Between Antiretrovirals and Carbamazepine/Oxcarbazepine: A Real-Life Investigation.
Topics: Adult; Anti-Retroviral Agents; Anticonvulsants; Atazanavir Sulfate; Carbamazepine; Darunavir; Drug Interactions; Drug Monitoring; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Male; Middle Aged; Oxazines; Oxcarbazepine; Piperazines; Pyridones | 2020 |
Live Attenuated Vaccine With a Stabilized Mutation and Gene Deletion for Prevention of Respiratory Syncytial Virus Disease in Young Children.
Topics: Atazanavir Sulfate; Case-Control Studies; Child; Child, Preschool; Darunavir; Gene Deletion; HIV; HIV Infections; Humans; Myocardial Infarction; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses | 2020 |
Long-term safety and efficacy of dolutegravir and unboosted atazanavir among experienced HIV-infected adults.
Topics: Adult; Atazanavir Sulfate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oxazines; Piperazines; Pyridones; Viral Load | 2019 |
Is the Risk of Myocardial Infarction in People With Human Immunodeficiency Virus (HIV) Associated With Atazanavir or Darunavir? A Nested Case-Control Study Within the French Hospital Database on HIV.
Topics: Adult; Atazanavir Sulfate; Case-Control Studies; Cohort Studies; Darunavir; Databases, Factual; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Myocardial Infarction; Risk Factors; Treatment Outcome | 2020 |
Darunavir and Cardiovascular Risk: Evaluating the Data to Inform Clinical Care.
Topics: Atazanavir Sulfate; Cardiovascular Diseases; Case-Control Studies; Darunavir; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Myocardial Infarction; Risk Factors | 2020 |
Cotrimoxazole Prophylaxis is Not Associated with a Higher Occurrence of Atazanavir Treatment Failure: Analysis of Worldwide Pharmacovigilance Data.
Topics: Africa; Anti-HIV Agents; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Pharmacovigilance; Ritonavir; Treatment Failure; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Comorbidity; Coronary Vessels; Endothelial Cells; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Male; Maraviroc; NF-kappa B; Oxazines; Piperazines; Pyridones; Ritonavir; Signal Transduction; Sirtuin 1; Ubiquitin Thiolesterase | 2020 |
Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.
Topics: Atazanavir Sulfate; Blood-Brain Barrier; Curcumin; Drug Carriers; Drug Compounding; HIV Infections; HIV-1; Humans; Laser Therapy; Nanoparticles; Precision Medicine; Ritonavir; Theranostic Nanomedicine | 2020 |
Antiretroviral Therapy Concentrations Differ in Gut vs. Lymph Node Tissues and Are Associated With HIV Viral Transcription by a Novel RT-ddPCR Assay.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biopsy; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Darunavir; Female; Gastrointestinal Tract; HIV Infections; HIV-1; Humans; Ileum; Lymph Nodes; Male; Raltegravir Potassium; Real-Time Polymerase Chain Reaction; San Francisco; Virus Replication | 2020 |
Sleeve Gastrectomy Compared With Roux-en-Y Gastric Bypass in Individuals Living With HIV.
Topics: Adult; Atazanavir Sulfate; Body Mass Index; Gastrectomy; Gastric Bypass; HIV Infections; Humans; Middle Aged; Obesity; Retrospective Studies; Tenofovir; Treatment Outcome | 2020 |
Impact of antiretroviral regimen on viral suppression among pregnant women living with HIV in Brazil.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Brazil; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Treatment Outcome; Viral Load | 2020 |
Effects of atazanavir, darunavir, and raltegravir on fat and muscle among persons living with HIV.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Italy; Male; Middle Aged; Muscles; Raltegravir Potassium; Retrospective Studies; Viral Load | 2020 |
Association Between Atazanavir-Induced Hyperbilirubinemia and Cardiovascular Disease in Patients Infected with HIV.
Topics: Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Ischemic Stroke; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Proportional Hazards Models; Retrospective Studies; Time Factors | 2020 |
Unveiling the basis of antiretroviral therapy-induced osteopenia: the effects of Dolutegravir, Darunavir and Atazanavir on osteogenesis.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Darunavir; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Osteogenesis; Oxazines; Piperazines; Pyridones | 2021 |
Higher plasma drug levels in elderly people living with HIV treated with darunavir.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Case-Control Studies; Cross-Sectional Studies; Cyclopropanes; Darunavir; Drug Interactions; HIV Infections; Humans; Male; Middle Aged; Plasma; Sweden | 2021 |
Evaluation of the effects of atazanavir-ritonavir on the pharmacokinetics of lumefantrine in patients living with HIV in Lagos University Teaching Hospital, South-Western Nigeria.
Topics: Adult; Anti-Retroviral Agents; Antimalarials; Artemether, Lumefantrine Drug Combination; Atazanavir Sulfate; Case-Control Studies; Chromatography, High Pressure Liquid; Drug Combinations; Female; HIV Infections; Hospitals, Teaching; Humans; Malaria; Male; Middle Aged; Nigeria; Plasmodium falciparum; Racemases and Epimerases; Ritonavir | 2021 |
Outcome of a HIV Positive Patient Infected with COVID-19 After an Autologous Bone Marrow Transplantation: A Case Report.
Topics: Atazanavir Sulfate; Bone Marrow Transplantation; Comorbidity; COVID-19 Drug Treatment; HIV Infections; HIV Protease Inhibitors; Hodgkin Disease; Humans; Iran; Male; Middle Aged; SARS-CoV-2; Treatment Outcome | 2021 |
Changes in lipidomic profile by anti-retroviral treatment regimen: An ACTG 5257 ancillary study.
Topics: Adult; Anti-Retroviral Agents; Atazanavir Sulfate; Chi-Square Distribution; Darunavir; Female; HIV Infections; Humans; Lipidomics; Lipids; Male; Mass Spectrometry; Middle Aged; Plasma; Raltegravir Potassium; Tenofovir | 2021 |
Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Contraceptive Agents; Desogestrel; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2022 |
Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.
Topics: Adult; Atazanavir Sulfate; Darunavir; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medication Adherence; Middle Aged; Registries; Regression Analysis; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2017 |
Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; British Columbia; Canada; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2017 |
Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome | 2017 |
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Biomarkers; Brachial Artery; Cardiovascular Diseases; Carotid Intima-Media Thickness; CD4 Lymphocyte Count; Chi-Square Distribution; Cyclopropanes; Darunavir; Endothelium, Vascular; Female; HIV Infections; Humans; Inflammation Mediators; Italy; Lipids; Longitudinal Studies; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Predictive Value of Tests; Risk Factors; Ritonavir; Time Factors; Treatment Outcome; Vasodilation | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?
Topics: Atazanavir Sulfate; Blood Proteins; Darunavir; Dose-Response Relationship, Drug; Female; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Pregnancy; Protein Binding | 2017 |
A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Biomarkers, Pharmacological; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV Infections; Humans; Malawi; Male; Medication Adherence; Middle Aged; Ritonavir; Treatment Failure; Urban Health; Viral Load | 2017 |
Cardiovascular outcomes among HIV-infected veterans receiving atazanavir.
Topics: Adult; Aged; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Risk Assessment; Stroke; Treatment Outcome; United States; Veterans | 2017 |
Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Cell Line; Cognitive Dysfunction; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Methamphetamine; Multidrug Resistance-Associated Proteins; Rhodamines; tat Gene Products, Human Immunodeficiency Virus; Transendothelial and Transepithelial Migration; Zonula Occludens-1 Protein | 2017 |
Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Leukocytes, Mononuclear; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimesters; Prospective Studies; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
No impact of HIV-1 protease minority resistant variants on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; pol Gene Products, Human Immunodeficiency Virus; Ritonavir; Viral Load | 2018 |
Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Black or African American; Female; Genetic Association Studies; Genotype; Glucuronosyltransferase; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; Humans; Jaundice; Male; Middle Aged; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; White People | 2018 |
Improvement in lipids after switch to boosted atazanavir or darunavir in children/adolescents with perinatally acquired HIV on older protease inhibitors: results from the Pediatric HIV/AIDS Cohort Study.
Topics: Adolescent; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Drug Therapy, Combination; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Longitudinal Studies; Male; Ritonavir; Viral Load; Young Adult | 2018 |
Atazanavir and darunavir in pregnant women with HIV: evaluation of laboratory and clinical outcomes from an observational national study.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Cholesterol; Darunavir; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Treatment Outcome; Triglycerides; Viral Load | 2018 |
The relevance of drug-drug interactions in clinical practice: the case of concomitant boosted protease inhibitors plus alpha-1 blocker administration.
Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Atazanavir Sulfate; Cobicistat; Darunavir; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir | 2018 |
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Treatment Failure | 2018 |
PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.
Topics: Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Synergism; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Liver-Specific Organic Anion Transporter 1; Pharmacogenetics; Pregnane X Receptor; Ritonavir | 2018 |
Prevalence and correlates of persistent intracellular HIV transcription in individuals on efavirenz versus atazanavir-based regimens: A prospective cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Prospective Studies; Reverse Transcription; RNA, Messenger; RNA, Viral; Viral Load; Virus Latency; Virus Replication | 2018 |
Incidence of symptomatic CSF viral escape in HIV infected patients receiving atazanavir/ritonavir (ATV/r)-containing ART: a tertiary care cohort in western India.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atazanavir Sulfate; Child; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; India; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Young Adult | 2018 |
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Tenofovir; Treatment Failure; Viral Load | 2018 |
Long-term treatment with atazanavir (ATV) in real life in Belgium: a retrospective observational cohort of 2264 HIV patients
Topics: Adult; Atazanavir Sulfate; Belgium; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies | 2019 |
Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.
Topics: Adult; Atazanavir Sulfate; Australia; Cardiovascular Diseases; Darunavir; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Prospective Studies; Treatment Outcome; United States | 2018 |
Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir.
Topics: Adult; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver-Specific Organic Anion Transporter 1; Polymorphism, Single Nucleotide; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Pregnane X Receptor; Prospective Studies; Ritonavir | 2018 |
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Biomarkers; Carotid Intima-Media Thickness; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Adhesion Molecules; Endothelial Cells; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Lymphocyte Activation; Male; Prospective Studies; Pulse Wave Analysis; Random Allocation; Ritonavir | 2018 |
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: a multicenter retrospective cohort study from 2007 to 2015.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4-CD8 Ratio; Cohort Studies; Darunavir; Dideoxynucleosides; Female; HIV Infections; Humans; Inflammation; Italy; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2018 |
Chronic granulomatous interstitial nephritis and urothelial metaplasia associated with ritonavir-boosted atazanavir: a case study and literature review.
Topics: Atazanavir Sulfate; HIV Infections; Humans; Male; Metaplasia; Middle Aged; Nephritis, Interstitial; Ritonavir; Urothelium | 2018 |
Three HIV Drugs, Atazanavir, Ritonavir, and Tenofovir, Coformulated in Drug-Combination Nanoparticles Exhibit Long-Acting and Lymphocyte-Targeting Properties in Nonhuman Primates.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Delayed-Action Preparations; Drug Combinations; Drug Delivery Systems; HIV Infections; Humans; Leukocytes, Mononuclear; Lipids; Lymphocytes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Risk factors for kidney disease among HIV-1 positive persons in the methadone program.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Indinavir; Kidney Diseases; Male; Methadone; Narcotics; Opiate Substitution Treatment; Opioid-Related Disorders; Poland; Risk Factors; Sex Factors; Tenofovir; Time Factors | 2019 |
Pharmacokinetics and 48-week safety and efficacy of generic ritonavir tablet-boosted atazanavir in HIV-1-infected Thai adults.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Monitoring; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Ritonavir; Tablets; Time Factors; Treatment Outcome | 2018 |
Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; Darunavir; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Inflammation; Male; Middle Aged; Prospective Studies; Ritonavir | 2018 |
A Clinical Prediction Rule for Protease Inhibitor Resistance in Patients Failing Second-Line Antiretroviral Therapy.
Topics: Adult; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Lopinavir; Male; Middle Aged; Multivariate Analysis; Mutation | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Mg-supplementation attenuated lipogenic and oxidative/nitrosative gene expression caused by Combination Antiretroviral Therapy (cART) in HIV-1-transgenic rats.
Topics: Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Dietary Supplements; Disease Models, Animal; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lipogenesis; Liver; Magnesium; Male; NF-E2-Related Factor 2; Nitric Oxide; Nitric Oxide Synthase Type II; Oxidation-Reduction; Oxidative Stress; Rats; Rats, Inbred F344; Rats, Transgenic; Ritonavir | 2019 |
Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Substitution; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Outcome; Viral Load | 2019 |
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Ritonavir; Uganda; Viral Load | 2019 |
Concomitant Use of Cotrimoxazole and Atazanavir in HIV-infected Patients: A Therapeutic Drug Monitoring and Pharmacovigilance Based Dual Approach.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Pharmacovigilance; Trimethoprim, Sulfamethoxazole Drug Combination | 2019 |
A Profile of Adverse Drug Reactions of Atazanavir- and Lopinavir-Based Antiretroviral Regimens in Namibia.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Namibia; Pharmacovigilance; Young Adult | 2019 |
Influence of
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Polymorphism, Genetic; Ritonavir; Thailand | 2019 |
Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Myocardial Infarction; United States | 2019 |
Pharmacokinetics of two common antiretroviral regimens in older HIV-infected patients: a pilot study.
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Black or African American; Cyclopropanes; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; Female; Frail Elderly; HIV; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; White People | 2013 |
Association between atazanavir plasma levels and renal function in HIV-positive individuals on antiretroviral therapy with undetectable viral load.
Topics: Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Glomerular Filtration Rate; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Viral Load; Young Adult | 2013 |
Cost-utility analysis of lopinavir/ritonavir versus atazanavir + ritonavir administered as first-line therapy for the treatment of HIV infection in Italy: from randomised trial to real world.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cost-Benefit Analysis; HIV Infections; Humans; Italy; Lopinavir; Oligopeptides; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Ritonavir | 2013 |
Boosting HIV treatment options: good news, new challenges.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Cobicistat; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Thiazoles | 2013 |
Long-term gender-based outcomes for atazanavir/ritonavir (ATV/r)- containing regimens in treatment-experienced patients with HIV.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Sex Factors; Treatment Outcome; Viral Load; Young Adult | 2013 |
High levels of atazanavir and darunavir in urine and crystalluria in asymptomatic patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Crystallization; Darunavir; Female; HIV Infections; Humans; Male; Microscopy, Polarization; Middle Aged; Oligopeptides; Plasma; Pyridines; Sulfonamides; Urine; Young Adult | 2013 |
Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapy.
Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Macaca mulatta; Macrophages; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Pyridines; Ritonavir; Tissue Distribution | 2013 |
Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Electrocardiography; Female; Heart Rate; HIV Infections; Humans; Hyperlipidemias; Long QT Syndrome; Male; Middle Aged; Oligopeptides; Prevalence; Pyridines; Risk Factors; Surveys and Questionnaires; Viral Load | 2013 |
Macrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Drug Delivery Systems; Folate Receptors, GPI-Anchored; Folic Acid; HIV Infections; HIV-1; Humans; Macrophages; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Pyridines; Tissue Distribution | 2013 |
Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Mutation Rate; Mutation, Missense; Oligopeptides; Pyridines; Treatment Failure; United States | 2013 |
Factors affecting antiretroviral pharmacokinetics in HIV-infected women with virologic suppression on combination antiretroviral therapy: a cross-sectional study.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Linear Models; Middle Aged; Nevirapine; Oligopeptides; Pyridines; Risk Factors; Viral Load | 2013 |
Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Carbazoles; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Half-Life; HIV Infections; HIV-1; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Nootropic Agents; Oligopeptides; Protein Kinase Inhibitors; Pyridines; Ritonavir | 2013 |
Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfected patients.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Darunavir; Female; Follow-Up Studies; Hepatitis C; HIV Infections; Humans; Liver; Male; Nevirapine; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides | 2013 |
Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Follow-Up Studies; HIV Infections; Humans; Hyperbilirubinemia; Incidence; Kaplan-Meier Estimate; Male; Middle Aged; Oligopeptides; Proportional Hazards Models; Prospective Studies; Pyridines; Treatment Outcome | 2013 |
Is ritonavir-boosted atazanavir a risk for cholelithiasis compared to other protease inhibitors?
Topics: Adult; Atazanavir Sulfate; Cholelithiasis; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2013 |
Boosted or unboosted atazanavir as a simplification of lopinavir/ritonavir-containing regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2013 |
An unusual case of HIV virologic failure during treatment with boosted atazanavir.
Topics: Absorption; Adult; Atazanavir Sulfate; Biological Availability; Garlic; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Treatment Failure; Viral Load | 2013 |
Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Hyperbilirubinemia; Infant, Newborn; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Prevalence; Pyridines; Risk Assessment | 2013 |
Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Comorbidity; Denmark; Female; HIV Infections; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Dialysis; Renal Replacement Therapy; Risk Factors; Tenofovir | 2014 |
Evaluation of renal adverse effects of combination anti-retroviral therapy including tenofovir in HIV-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Combinations; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir | 2013 |
Revealing the metabolic sites of atazanavir in human by parallel administrations of D-atazanavir analogs.
Topics: Atazanavir Sulfate; Chromatography, High Pressure Liquid; Deuterium; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Hydrolysis; Metabolic Networks and Pathways; Oligopeptides; Oxidation-Reduction; Pyridines; Tandem Mass Spectrometry | 2013 |
Short communication: Aging not gender is associated with high atazanavir plasma concentrations in Asian HIV-infected patients.
Topics: Adult; Age Factors; Asia; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Sex Factors | 2013 |
Atazanavir and chest pain.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chest Pain; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Treatment Outcome | 2014 |
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Proportional Hazards Models; Pyridines; Retrospective Studies; Ritonavir; Sulfonamides | 2013 |
Pharmacokinetics of rifabutin during atazanavir/ritonavir co-administration in HIV-infected TB patients in India.
Topics: Adult; Antibiotics, Antitubercular; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; India; Male; Microbial Sensitivity Tests; Oligopeptides; Polypharmacy; Pyridines; Rifabutin; Ritonavir; Tuberculosis | 2013 |
Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Drug Resistance, Viral; Female; Genes, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Mutation; Oligopeptides; Pyridines; Retrospective Studies; Risk Factors; Ritonavir; Viral Load | 2014 |
Extended mathematical model for "in vivo" quantification of the interaction betweeen atazanavir and bilirubin.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Biomarkers, Pharmacological; Drug Therapy, Combination; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Male; Models, Theoretical; Oligopeptides; Polymorphism, Genetic; Pyridines; Young Adult | 2014 |
Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lipids; Liver Function Tests; Lopinavir; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Pyridines; RNA, Viral; Viral Load | 2014 |
Cumulative exposure to ritonavir-boosted atazanavir is associated with cholelithiasis in patients with HIV-1 infection.
Topics: Abdomen; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cholelithiasis; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Prevalence; Pyridines; Ritonavir; Time Factors; Ultrasonography | 2014 |
Recurrent nephrolithiasis associated with atazanavir use.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Calcium Oxalate; HIV Infections; Humans; Lithotripsy, Laser; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Pyridines; Recurrence; Stents; Tomography, X-Ray Computed; Ureteral Calculi; Ureteroscopy | 2014 |
High prevalence of the UGT1A1*28 variant in HIV-infected individuals in Greece.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cross-Sectional Studies; Glucuronosyltransferase; Greece; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pharmacogenetics; Polymorphism, Genetic; Prevalence; Pyridines; Ritonavir | 2014 |
Evaluation of boosted and unboosted atazanavir plasma concentration in HIV infected patients.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Atazanavir Sulfate; Creatinine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Middle Aged; Oligopeptides; Pyridines; Regression Analysis; Retrospective Studies; Sex Factors | 2013 |
Metronidazole or Cotrimoxazole therapy is associated with a decrease in intestinal bioavailability of common antiretroviral drugs.
Topics: Administration, Oral; Analysis of Variance; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Biological Availability; Colon; Electric Conductivity; HIV Infections; Intestinal Absorption; Male; Metronidazole; Oligopeptides; Pyridines; Rats; Rats, Sprague-Dawley; Ritonavir; Trimethoprim, Sulfamethoxazole Drug Combination | 2014 |
Comparative impact of antiretroviral drugs on markers of inflammation and immune activation during the first two years of effective therapy for HIV-1 infection: an observational study.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; C-Reactive Protein; CD4 Lymphocyte Count; Chemokine CXCL10; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Immune System; Inflammation; Interferon-gamma; Interleukin-6; Lipopolysaccharide Receptors; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2014 |
In Vitro and In Situ evaluation of pH-dependence of atazanavir intestinal permeability and interactions with acid-reducing agents.
Topics: Acids; Animals; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Caco-2 Cells; Drug Interactions; Eating; HIV Infections; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Intestinal Mucosa; Intestines; Male; Oligopeptides; Omeprazole; Permeability; Proton Pump Inhibitors; Pyridines; Rats, Sprague-Dawley; Reducing Agents | 2014 |
Natural polymorphisms and unusual mutations in HIV-1 protease with potential antiretroviral resistance: a bioinformatic analysis.
Topics: Atazanavir Sulfate; Base Sequence; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Molecular Docking Simulation; Molecular Sequence Data; Mutation; Oligopeptides; Phenotype; Polymorphism, Genetic; Pyridines; Pyrones; Sulfonamides | 2014 |
Therapeutic drug monitoring of atazanavir/ritonavir in pregnancy.
Topics: Adult; Analysis of Variance; Anti-HIV Agents; Atazanavir Sulfate; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Ritonavir; Young Adult | 2014 |
Managing drug-drug interactions in an HIV-infected patient receiving antiretrovirals, anti-HCV therapy and carbamazepine: a 'tour de force' for clinical pharmacologists.
Topics: Anticonvulsants; Antiviral Agents; Atazanavir Sulfate; Carbamazepine; Cytochrome P-450 CYP3A; Drug Dosage Calculations; Drug Interactions; Drug Monitoring; Enzyme Activation; Epilepsy; Hepatitis C; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2014 |
Acute renal failure and liver toxicity in an HIV/hepatitis C coinfected patient receiving telaprevir and boosted atazanavir.
Topics: Acute Kidney Injury; Anti-HIV Agents; Atazanavir Sulfate; Hepatitis C, Chronic; HIV Infections; Humans; Middle Aged; Oligopeptides; Pyridines | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Calculi; Male; Oligopeptides; Pyridines | 2014 |
[HIV infection. Compatibility of recent protease inhibitors in direct comparison - the advantage of DRV].
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Darunavir; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Sulfonamides; Viral Load | 2014 |
Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Substitution; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2014 |
Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
Topics: 3' Untranslated Regions; Adolescent; Adult; Aged; Atazanavir Sulfate; Case-Control Studies; Female; Genotype; Genotyping Techniques; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Polymorphism, Single Nucleotide; Pyridines; Young Adult | 2014 |
Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction.
Topics: Adult; Aged; Atazanavir Sulfate; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pulmonary Aspergillosis; Pyridines; Ritonavir; Voriconazole | 2014 |
Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2014 |
Potential association between rosuvastatin use and high atazanavir trough concentrations in ritonavir-treated HIV-infected patients.
Topics: Adult; Age Factors; Atazanavir Sulfate; Body Weight; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Ritonavir; Rosuvastatin Calcium; Sex Factors; Viral Load | 2015 |
Changes in bone mineral density after 96 weeks of treatment with atazanavir/ritonavir or lopinavir/ritonavir plus tenofovir DF/emtricitabine in treatment-naive patients with HIV-1 infection: the CASTLE body composition substudy.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Atazanavir Sulfate; Body Composition; Bone Density; HIV Infections; HIV-1; Humans; Lopinavir; Multivariate Analysis; Oligopeptides; Pyridines; Ritonavir | 2015 |
Antenatal atazanavir: a retrospective analysis of pregnancies exposed to atazanavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; London; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prenatal Care; Pyridines; Retrospective Studies; Viral Load | 2014 |
Improved serum cholesterol in paediatric patients switched from suppressive lopinavir-based therapy to boosted darunavir or atazanavir: an 18-month retrospective study.
Topics: Adolescent; Analysis of Variance; Anti-HIV Agents; Atazanavir Sulfate; Child; Cholesterol; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Retrospective Studies; Sulfonamides | 2014 |
Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Monitoring; HIV Infections; Humans; Lopinavir; Nevirapine; Oligopeptides; Plasma; Pyridines; Retrospective Studies | 2014 |
Clinical features and risk factors for atazanavir (ATV)-associated urolithiasis: a case-control study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Case-Control Studies; Female; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Risk Factors; Urolithiasis | 2014 |
Muscle symptoms and creatine phosphokinase elevations in patients receiving raltegravir in clinical practice: Results from the SCOLTA project long-term surveillance.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Creatine Kinase; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Muscle Weakness; Myalgia; Oligopeptides; Prospective Studies; Pyridines; Pyrrolidinones; Raltegravir Potassium | 2015 |
Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Cooperative Behavior; Developed Countries; Europe; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Prospective Studies; Treatment Outcome; United States; Viral Load; Young Adult | 2015 |
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.
Topics: Adult; Anti-Retroviral Agents; Asia; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Follow-Up Studies; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Survival Analysis; Treatment Failure; Viral Load; Young Adult | 2015 |
Use of efavirenz or atazanavir/ritonavir is associated with better clinical outcomes of HAART compared to other protease inhibitors: routine evidence from the Italian MASTER Cohort.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Italy; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
Herb-drug interaction between an anti-HIV Chinese herbal SH formula and atazanavir in vitro and in vivo.
Topics: Animals; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Drug Combinations; Drugs, Chinese Herbal; Gene Expression Regulation, Enzymologic; Herb-Drug Interactions; HIV Infections; HIV Protease; Humans; Male; Rats; Rats, Sprague-Dawley; Thailand | 2015 |
Changes in kidney function in patients with suppressed HIV RNA who substitute their protease inhibitor with atazanavir/ritonavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir | 2015 |
Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A; Emtricitabine; Female; Glucuronosyltransferase; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant, Newborn; Male; Oxazines; Piperazines; Pregnancy; Pyridones; Ritonavir; Tenofovir | 2015 |
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Nephrolithiasis; Ritonavir; Viral Load | 2015 |
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Immunological and Virological Outcomes of Patients Switched from LPV/r to ATV/r-Containing Second- Line Regimens.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; HIV Infections; Hospitals, Teaching; Humans; Lopinavir; Male; Middle Aged; Nigeria; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Meconium Atazanavir Concentrations and Early Language Outcomes in HIV-Exposed Uninfected Infants With Prenatal Atazanavir Exposure.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; Female; HIV Infections; Humans; Infant; Infant, Newborn; Language Development; Male; Maternal-Fetal Exchange; Meconium; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Pyridines; Tandem Mass Spectrometry | 2015 |
Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.
Topics: Animals; Anti-Retroviral Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Delayed-Action Preparations; Drug Carriers; Folate Receptors, GPI-Anchored; Folic Acid; HIV Infections; Humans; Injections, Intramuscular; Mice, SCID; Nanomedicine; Nanoparticles; Poloxamer; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2015 |
[In Process Citation].
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Drug Administration Schedule; HIV Infections; Humans; Medication Adherence; Physician-Patient Relations | 2015 |
Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood; CD4 Lymphocyte Count; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Middle Aged; Raltegravir Potassium; T-Lymphocyte Subsets; Treatment Outcome; Viral Load | 2015 |
Infant peripheral blood repetitive element hypomethylation associated with antiretroviral therapy in utero.
Topics: Adult; Alu Elements; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; DNA Methylation; Epigenesis, Genetic; Female; HIV; HIV Infections; Humans; Infant, Newborn; Long Interspersed Nucleotide Elements; Mother-Child Relations; Pregnancy | 2015 |
Impact of switching from lopinavir/ritonavir to boosted and un-boosted atazanavir on glucose metabolism: the ATAzanavir & GLUcose metabolism (ATAGLU) study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Blood Glucose; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Lopinavir; Middle Aged; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2016 |
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Dideoxynucleosides; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir | 2015 |
Lopinavir and atazanavir in pregnancy: comparable infant outcomes, virological efficacies and preterm delivery rates.
Topics: Adolescent; Adult; Atazanavir Sulfate; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Lopinavir; Middle Aged; Pregnancy; Pregnancy Outcome; Premature Birth; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2016 |
A simple, efficient, and sensitive method for simultaneous detection of anti-HIV drugs atazanavir, ritonavir, and tenofovir by use of liquid chromatography-tandem mass spectrometry.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; HIV Infections; Humans; Ritonavir; Tandem Mass Spectrometry; Tenofovir | 2015 |
Effect of hepatitis B and C clearance on atazanavir exposure.
Topics: Antiviral Agents; Atazanavir Sulfate; Hepatitis B; Hepatitis C; HIV Infections; Humans; Male; Oligopeptides | 2015 |
Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Coinfection; Cross-Sectional Studies; Drug Interactions; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Models, Biological; Nonlinear Dynamics; Renal Elimination; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Thailand; Treatment Outcome | 2015 |
Choice of effect measure in HIV randomized trials.
Topics: Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Endpoint Determination; HIV Infections; HIV-1; Humans; Randomized Controlled Trials as Topic; Ritonavir; RNA, Viral; Time; Treatment Outcome; Viral Load | 2015 |
The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy.
Topics: Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; MAP Kinase Kinase Kinases; Mice; Mice, SCID; Mitogen-Activated Protein Kinase Kinase Kinase 11; Nanocapsules; Protein Kinase Inhibitors; Pyridines; Pyrroles; Treatment Outcome | 2016 |
Safety of darunavir and atazanavir in HIV-infected children in Europe and Thailand.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Cohort Studies; Darunavir; Europe; Female; HIV Infections; Humans; Male; Thailand | 2016 |
HIV and the kidney in the acute medical unit.
Topics: Acute Kidney Injury; Anti-Retroviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Tenofovir | 2015 |
Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Drug Therapy, Combination; Female; Health Expenditures; Health Services; HIV Infections; Humans; Male; Medicaid; Medication Adherence; Middle Aged; Models, Econometric; Propensity Score; Retrospective Studies; Ritonavir; Socioeconomic Factors; United States | 2016 |
Cellular Responses and Tissue Depots for Nanoformulated Antiretroviral Therapy.
Topics: Animals; Atazanavir Sulfate; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; HIV Infections; HIV Protease Inhibitors; Humans; Immunity, Innate; Macrophages, Peritoneal; Male; Mice; Mice, Inbred BALB C; Microscopy, Confocal; Nanoparticles; Tissue Distribution | 2015 |
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Topics: Atazanavir Sulfate; Darunavir; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; HIV Infections; HIV-1; Humans; Lopinavir; Mutation; Point-of-Care Systems; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2015 |
Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.
Topics: Adult; Aged; Aging; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclin-Dependent Kinase Inhibitor p16; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Gene Expression; HIV Infections; Humans; Male; Middle Aged; Nucleotides; Ritonavir; Tenofovir; Young Adult | 2016 |
Effect of Methamphetamine on Spectral Binding, Ligand Docking and Metabolism of Anti-HIV Drugs with CYP3A4.
Topics: Amphetamine-Related Disorders; Atazanavir Sulfate; Catalytic Domain; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Inactivation, Metabolic; Lopinavir; Methamphetamine; Microsomes, Liver; Molecular Docking Simulation; Nelfinavir; Protein Binding; Pyridines; Pyrones; Sulfonamides | 2016 |
Strategies for price reduction of HIV medicines under a monopoly situation in Brazil.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Brazil; Commerce; Cost Control; Drug Costs; Health Services Accessibility; HIV Infections; Humans | 2015 |
Atazanavir use and carotid intima media thickness progression in HIV: potential influence of bilirubin.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Atherosclerosis; Bilirubin; Carotid Intima-Media Thickness; Female; HIV Infections; Humans; Male; Retrospective Studies | 2016 |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic st
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Combinations; Drug Monitoring; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lamivudine; Male; Middle Aged; Peroxisome-Targeting Signal 1 Receptor; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2017 |
Atazanavir exposure in utero and neurodevelopment in infants: a comparative safety study.
Topics: Adult; Atazanavir Sulfate; Female; Fetal Development; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infant, Newborn; Male; Nervous System; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Prospective Studies; Young Adult | 2016 |
Acute intermittent porphyria precipitated by atazanavir/ritonavir.
Topics: Abdominal Pain; Atazanavir Sulfate; Female; HIV Infections; Humans; Middle Aged; Porphyria, Acute Intermittent; Protease Inhibitors; Ritonavir; Treatment Outcome | 2016 |
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Peru; Pharmacogenetics; Polymorphism, Genetic; Retrospective Studies; South Africa; United States; Young Adult | 2016 |
Factors involved in continuance of atazanavir-based regimens: Results from a cohort of HIV1-positive patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load | 2016 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir- vs. efavirenz-based antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Biomarkers; Cyclopropanes; Female; HIV Infections; Humans; Lipoproteins, LDL; Male; Oxidative Stress; Peroxidase; Phospholipases A2; Plasma; Prospective Studies | 2016 |
Comparison of Population Pharmacokinetics Based on Steady-State Assumption Versus Electronically Monitored Adherence to Lopinavir, Atazanavir, Efavirenz, and Etravirine: A Retrospective Study.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Medication Adherence; Nitriles; Pyridazines; Pyrimidines; Retrospective Studies; Reverse Transcriptase Inhibitors | 2016 |
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cobicistat; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ritonavir | 2016 |
Heme oxygenase-1-derived bilirubin counteracts HIV protease inhibitor-mediated endothelial cell dysfunction.
Topics: Acetylcysteine; Atazanavir Sulfate; Bilirubin; Cardiovascular Diseases; Cell Proliferation; Endothelial Cells; Gene Expression Regulation; Heme Oxygenase-1; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; NF-E2-Related Factor 2; Promoter Regions, Genetic; Reactive Oxygen Species; Ritonavir; Rotenone | 2016 |
Comparative Impact of Suppressive Antiretroviral Regimens on the CD4/CD8 T-Cell Ratio: A Cohort Study.
Topics: Adult; Age Factors; Alkynes; Atazanavir Sulfate; Benzoxazines; CD4-CD8 Ratio; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Interferon Type I; Male; Middle Aged; Oligopeptides; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ribavirin; Ritonavir | 2016 |
Symptomatic Bradycardia and Heart Failure Triggered by Ivabradine in a Patient Receiving Antiretroviral Therapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Benzazepines; Bradycardia; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Emtricitabine; Female; Heart Failure; HIV Infections; Humans; Ivabradine; Middle Aged; Ritonavir; Tenofovir | 2016 |
Frequency of atazanavir-associated leukocyturia development and renal function decline.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines | 2016 |
Antileishmanial activity of antiretroviral drugs combined with miltefosine.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Antiprotozoal Agents; Atazanavir Sulfate; Benzoxazines; Coinfection; Cyclopropanes; Darunavir; Delavirdine; Drug Therapy, Combination; HIV Infections; Humans; Leishmania infantum; Leishmaniasis, Visceral; Macrophages; Male; Mice, Inbred BALB C; Nevirapine; Phosphorylcholine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
[HIV infection and pregnancy. Improved therapy management for HIV infected pregnant patients].
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Germany; Guideline Adherence; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Middle Aged; Pregnancy; Pregnancy Complications, Infectious | 2016 |
A case of a probable drug interaction between lurasidone and atazanavir-based antiretroviral therapy.
Topics: Antipsychotic Agents; Atazanavir Sulfate; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Lurasidone Hydrochloride; Male; Middle Aged | 2016 |
Changes in Markers of T-Cell Senescence and Exhaustion With Atazanavir-, Raltegravir-, and Darunavir-Based Initial Antiviral Therapy: ACTG 5260s.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Atazanavir Sulfate; Darunavir; Female; HIV Infections; Humans; Immunophenotyping; Male; Prospective Studies; Raltegravir Potassium; T-Lymphocyte Subsets | 2016 |
Population pharmacokinetic modelling of the changes in atazanavir plasma clearance caused by ritonavir plasma concentrations in HIV-1 infected patients.
Topics: Adult; Aged; Atazanavir Sulfate; Computer Simulation; Cross-Sectional Studies; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Predictive Value of Tests | 2016 |
Atazanavir dose reduction: one size does not fit all.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Ritonavir | 2016 |
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; DNA, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocytes, Mononuclear; Pilot Projects; Polymerase Chain Reaction; Ritonavir | 2016 |
Improved tuberculosis outcomes with daily vs. intermittent rifabutin in HIV-TB coinfected patients in India.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antibiotics, Antitubercular; Atazanavir Sulfate; Child; Child, Preschool; Coinfection; Dose-Response Relationship, Drug; Electronic Health Records; Female; HIV Infections; Humans; India; Infant; Male; Middle Aged; Retrospective Studies; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis; Young Adult | 2016 |
Impact of protease inhibitors on the evolution of urinary markers: Subanalyses from an observational cross-sectional study.
Topics: Acute Kidney Injury; Adult; Albuminuria; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Cross-Sectional Studies; Darunavir; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Proteinuria; Ritonavir | 2016 |
Pharmacokinetics of Unboosted Atazanavir in Treatment-experienced HIV-infected Children, Adolescents and Young Adults.
Topics: Adolescent; Adult; Atazanavir Sulfate; Child; HIV Infections; Humans; Prospective Studies; Young Adult | 2016 |
Co-administration of elvitegravir/cobicistat/tenofovir disoproxil fumarate/emtricitabine and atazanavir in treatment-experienced HIV patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Drug Therapy, Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Treatment Outcome | 2017 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
Risk of cardiovascular events among patients with HIV treated with atazanavir-containing regimens: a retrospective cohort study.
Topics: Adolescent; Adult; Atazanavir Sulfate; Cardiovascular Diseases; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Young Adult | 2016 |
Abacavir/lamivudine + unboosted atazanavir in routine clinical practice: Twelve years experience.
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Time Factors | 2018 |
Dolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patient.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2017 |
Switch to Ritonavir-Boosted versus Unboosted Atazanavir plus Raltegravir Dual-Drug Therapy Leads to Similar Efficacy and Safety Outcomes in Clinical Practice.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Coinfection; Drug Resistance, Viral; Drug Substitution; Female; Genotype; HIV Infections; HIV-1; Humans; Male; Middle Aged; Retreatment; Retrospective Studies; Ritonavir; Time-to-Treatment; Treatment Outcome; Viral Load | 2016 |
Increase in international normalized ratio after switching from atazanavir/ritonavir to darunavir/cobicistat in a patient on warfarin: boosters are not always equal.
Topics: Aged; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Blood Chemical Analysis; Cobicistat; Darunavir; Drug Interactions; HIV Infections; Humans; International Normalized Ratio; Male; Ritonavir; Warfarin | 2017 |
Wide variation in susceptibility of transmitted/founder HIV-1 subtype C Isolates to protease inhibitors and association with in vitro replication efficiency.
Topics: Atazanavir Sulfate; Darunavir; DNA Replication; Drug Resistance, Viral; gag Gene Products, Human Immunodeficiency Virus; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Microbial Sensitivity Tests; Virus Replication; Zambia | 2016 |
Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Mutation, Missense; Plasma; Raltegravir Potassium; Retrospective Studies; Selection, Genetic; Treatment Outcome; Viral Load | 2017 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
From antiretroviral therapy access to provision of third line regimens: evidence of HIV Drug resistance mutations to first and second line regimens among Ugandan adults.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Cross-Sectional Studies; Darunavir; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Uganda; Young Adult | 2016 |
Improved kidney function in patients who switch their protease inhibitor from atazanavir or lopinavir to darunavir.
Topics: Adult; Atazanavir Sulfate; Cohort Studies; Cytochrome P-450 CYP3A Inhibitors; Darunavir; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Treatment Outcome; United Kingdom | 2017 |
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Gastrectomy; HIV Infections; Humans; Male; Middle Aged; Tenofovir | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2008 |
Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports.
Topics: Adult; Atazanavir Sulfate; Drug Therapy, Combination; Electrocardiography; HIV Infections; HIV Protease Inhibitors; Humans; Male; Methadone; Middle Aged; Narcotics; Oligopeptides; Pyridines; Ritonavir; Tachycardia, Ventricular | 2008 |
Effects of minocycline and valproic acid coadministration on atazanavir plasma concentrations in human immunodeficiency virus-infected adults receiving atazanavir-ritonavir.
Topics: Adult; Anticonvulsants; Atazanavir Sulfate; Cognition Disorders; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Minocycline; Oligopeptides; Pyridines; Ritonavir; Valproic Acid | 2008 |
Acute renal failure due to bilateral ureteral stone impaction in an HIV-positive patient.
Topics: Acute Kidney Injury; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Tomography, X-Ray Computed; Ureteral Calculi; Ureteral Obstruction | 2008 |
FDA notifications. Atazanavir capsule label is updated for pediatric patients.
Topics: Adolescent; Atazanavir Sulfate; Child; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pediatrics; Pyridines; United States; United States Food and Drug Administration | 2008 |
Maraviroc: in vitro assessment of drug-drug interaction potential.
Topics: Area Under Curve; Atazanavir Sulfate; Cyclohexanes; Cytochrome P-450 CYP3A; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ketoconazole; Liver; Male; Maraviroc; Microsomes, Liver; Oligopeptides; Predictive Value of Tests; Pyridines; Ritonavir; Saquinavir; Triazoles | 2008 |
FDA notifications. Revised atazanavir package insert.
Topics: Atazanavir Sulfate; Drug Approval; Drug Interactions; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Oligopeptides; Pyridines; United States; United States Food and Drug Administration | 2008 |
Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Databases, Factual; Drug Interactions; Drug Therapy, Combination; Female; Histamine H2 Antagonists; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Medical Audit; Multivariate Analysis; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Time Factors; Treatment Failure; Treatment Outcome; Viral Load | 2008 |
Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir.
Topics: Atazanavir Sulfate; Electrocardiography; Heart Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Signal Processing, Computer-Assisted | 2008 |
Two cases of multidrug-resistant human immunodeficiency virus infection treated with atazanavir and lopinavir/ritonavir combination therapy.
Topics: Adult; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies | 2008 |
Low-dose, once-daily atazanavir/ritonavir (200/100): an effective treatment for HIV-infected patients in Thailand.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Thailand; Treatment Outcome | 2008 |
Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C-->T) with reduced concentrations of unboosted atazanavir.
Topics: Adult; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pregnane X Receptor; Pyridines; Receptors, Steroid | 2008 |
Correlation between HIV-1 RNA load in blood and seminal plasma depending on antiretroviral treatment status, regimen and penetration of semen by antiretroviral drugs.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Blood; Chromatography, High Pressure Liquid; Cohort Studies; Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Longitudinal Studies; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Plasma; Pyridines; Pyrimidinones; RNA, Viral; Semen; Statistics as Topic; Viral Load | 2008 |
FDA notifications. Updates made to Reyataz package insert.
Topics: Atazanavir Sulfate; Drug Labeling; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; United States; United States Food and Drug Administration | 2008 |
Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.
Topics: Adult; Antiviral Agents; Atazanavir Sulfate; Bilirubin; Drug Interactions; Female; Glucuronosyltransferase; Hepacivirus; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pyridines; Ribavirin | 2008 |
96-week CASTLE data show similar efficacy results.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Lopinavir; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2008 |
FDA notifications. Alternative dosing regimen for atazanavir is approved.
Topics: Atazanavir Sulfate; Drug Administration Schedule; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; United States; United States Food and Drug Administration | 2008 |
Hierarchical modeling gave plausible estimates of associations between metabolic syndrome and components of antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Metabolic Syndrome; Models, Statistical; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Switzerland | 2009 |
A low dose of ritonavir-boosted atazanavir provides adequate pharmacokinetic parameters in HIV-1-infected Thai adults.
Topics: Adult; Asian People; Atazanavir Sulfate; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Thailand | 2009 |
Protease inhibitor levels in hair strongly predict virologic response to treatment.
Topics: Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Monitoring; Epidemiologic Methods; Female; Hair; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Pyrimidinones; Ritonavir; Specimen Handling; Treatment Outcome; Viral Load | 2009 |
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Topics: Amino Acid Sequence; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Chi-Square Distribution; Codon; Drug Resistance, Multiple, Viral; Drug Resistance, Viral; Drug Synergism; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Logistic Models; Longitudinal Studies; Male; Multivariate Analysis; Mutation; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Viremia | 2009 |
Cost-effectiveness analysis of lopinavir/ritonavir and atazanavir+ritonavir regimens in the CASTLE study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Budgets; CD4 Lymphocyte Count; Coronary Disease; Cost Savings; Cost-Benefit Analysis; Decision Support Techniques; Drug Costs; Drug Therapy, Combination; HIV Infections; Humans; Life Expectancy; Lopinavir; Markov Chains; Models, Econometric; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Smoking; United States | 2009 |
CASTLE analysis finds no benefit for once daily dosing.
Topics: Atazanavir Sulfate; Drug Administration Schedule; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Patient Compliance; Pyridines | 2008 |
96-week data from CASTLE study presented.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2008 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. Darunavir and atazanavir: 96-week data from ARTEMIS and CASTLE.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Darunavir; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Sulfonamides; Viral Load | 2008 |
Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Female; Healthy Volunteers; HIV Infections; Humans; Middle Aged; Models, Statistical; Oligopeptides; Plasma; Pyridines; Ritonavir; Young Adult | 2009 |
Select updates from the 16th CROI: treatment-related cardiovascular risk, pharmacokinetic issues, and interleukin-2 use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Dideoxynucleosides; Drug Interactions; HIV Infections; Humans; Interleukin-2; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium | 2009 |
Provider prescribing of 4 antiretroviral agents after implementation of drug use guidelines in the Department of Veterans Affairs.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Darunavir; Enfuvirtide; Guideline Adherence; Guidelines as Topic; Health Plan Implementation; HIV Envelope Protein gp41; HIV Infections; Humans; Oligopeptides; Peptide Fragments; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Department of Veterans Affairs | 2009 |
Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Dyslipidemias; Emtricitabine; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Oligopeptides; Organophosphonates; Pravastatin; Pyridines; Rhabdomyolysis; Ritonavir; Tenofovir | 2009 |
Efficacy and safety of atazanavir in patients with end-stage liver disease.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; Humans; Liver Failure; Liver Function Tests; Liver Transplantation; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Treatment Outcome; Viral Load | 2009 |
Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.
Topics: Adult; Alanine Transaminase; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Hepatitis C; HIV Infections; Humans; Hyperbilirubinemia; Liver; Male; Multivariate Analysis; Oligopeptides; Prevalence; Proportional Hazards Models; Pyridines; Risk Factors; Ritonavir; Severity of Illness Index | 2009 |
Cytochrome P450 3A inhibition by atazanavir and ritonavir, but not demography or drug formulation, influences saquinavir population pharmacokinetics in human immunodeficiency virus type 1-infected adults.
Topics: Adult; Age Factors; Aged; Atazanavir Sulfate; Cytochrome P-450 CYP3A Inhibitors; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pregnancy; Pyridines; Ritonavir; Saquinavir; Sex Factors; Young Adult | 2009 |
Atazanavir: new indication. First-line treatment: fewer gastrointestinal disorders but more cases of jaundice and a risk of torsades de pointes.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Atazanavir Sulfate; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Jaundice; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Randomized Controlled Trials as Topic; Ritonavir; Torsades de Pointes; Viral Load | 2009 |
Efficacy and safety of boosted and unboosted atazanavir-containing antiretroviral regimens in real life: results from a multicentre cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Kaplan-Meier Estimate; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Impact of first-line protease inhibitors on predicted resistance to tipranavir in HIV-1-infected patients with virological failure.
Topics: Adult; Atazanavir Sulfate; DNA Mutational Analysis; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Pyrones; Ritonavir; RNA, Viral; Sulfonamides; Treatment Failure; Young Adult | 2009 |
[Medication change due to side effects or possible long-term complications. Side effect management with vision].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Deoxycytidine; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Long-Term Care; Lopinavir; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Pyrimidinones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic | 2009 |
Response to Crum-Cianflone et al., syphilitic hepatitis among HIV-infected patients.
Topics: Agglutination Tests; Antibodies, Bacterial; Atazanavir Sulfate; Hepatitis; HIV Infections; HIV Protease Inhibitors; Homosexuality; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Syphilis; Treatment Outcome; Treponema pallidum | 2009 |
Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals.
Topics: Aged; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Labyrinth Diseases; Lithiasis; Male; Middle Aged; Oligopeptides; Parotid Diseases; Pyridines; Radiography; Semicircular Canals; Treatment Outcome | 2009 |
Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; History, 17th Century; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2009 |
Trends in uptake of recently approved antiretrovirals within a national healthcare system.
Topics: Ambulatory Care Facilities; Anti-Retroviral Agents; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Approval; Drug Prescriptions; Electronic Health Records; Female; Health Facility Size; HIV Infections; Humans; Male; Oligopeptides; Practice Patterns, Physicians'; Pyridines; Pyrones; Retrospective Studies; Sulfonamides; Time Factors; United States; United States Food and Drug Administration; Veterans | 2010 |
Factors influencing lopinavir and atazanavir plasma concentration.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Weight; Cyclopropanes; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; Pyrimidinones; Rifabutin; United Kingdom | 2010 |
P-glycoprotein, multidrug resistance-associated proteins and human organic anion transporting polypeptide influence the intracellular accumulation of atazanavir.
Topics: Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; CD4-Positive T-Lymphocytes; Cell Line; Digitonin; HIV Infections; Humans; Indicators and Reagents; Intracellular Space; Leukocytes, Mononuclear; Membrane Transport Modulators; Multidrug Resistance-Associated Proteins; Oligopeptides; Organic Anion Transporters; Pyridines | 2009 |
Transplacental transfer of antiretroviral drugs and newborn birth weight in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apgar Score; Atazanavir Sulfate; Birth Weight; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Lopinavir; Maternal-Fetal Exchange; Nelfinavir; Nevirapine; Oligopeptides; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyridines; Pyrimidinones | 2009 |
Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult.
Topics: Acute Disease; Atazanavir Sulfate; Choledocholithiasis; Female; Gallstones; Hepatitis; HIV Infections; HIV Protease Inhibitors; Humans; Liver; Middle Aged; Oligopeptides; Pyridines | 2010 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Administration Schedule; Drug Interactions; Drug Monitoring; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2010 |
[Introduction. Usefulness of atazanavir in the treatment of patients infected by human immunodeficiency virus].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2008 |
[Viral resistance and genetic barrier of atazanavir].
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Resistance, Viral; Drug Synergism; Genes, pol; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Models, Molecular; Multicenter Studies as Topic; Mutation; Mutation, Missense; Oligopeptides; Point Mutation; Protein Conformation; Pyridines; Ritonavir; Structure-Activity Relationship | 2008 |
Single-tablet Quad regimen achieves high rate of virologic suppression.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Cytochrome P-450 CYP3A Inhibitors; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Treatment Outcome; Viral Load | 2010 |
Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cells, Cultured; Cyclopropanes; Delayed-Action Preparations; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunohistochemistry; Macrophages; Microscopy, Confocal; Microscopy, Electron, Transmission; Nanoconjugates; Nanotechnology; Oligopeptides; Pyridines; Ritonavir | 2010 |
Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir.
Topics: Adolescent; Adult; Aged; Alkynes; Atazanavir Sulfate; Atovaquone; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proguanil; Pyridines; Pyrimidinones; Ritonavir; Young Adult | 2010 |
Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol, HDL; Cholesterol, LDL; Fasting; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Male; Medication Adherence; Middle Aged; Oligopeptides; Patient Satisfaction; Prospective Studies; Pyridines; Ritonavir; Transaminases; Treatment Outcome; Triglycerides; Viral Load | 2010 |
HIV-1 protease codon 36 polymorphisms and differential development of resistance to nelfinavir, lopinavir, and atazanavir in different HIV-1 subtypes.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Cell Line; Cells, Cultured; Codon; Genotype; HIV Infections; HIV Protease; HIV-1; Humans; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones | 2010 |
Report from the 5th IAS Conference on HIV Pathogenesis Treatment and Prevention. Nevirapine vs. boosted atazanavir--the ARTEN Study.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Nevirapine; Oligopeptides; Pyridines; Reverse Transcriptase Inhibitors | 2009 |
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.
Topics: Adult; Aged; Atazanavir Sulfate; Blood Proteins; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Oligopeptides; Protein Binding; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bilirubin; Female; Gene Frequency; Genes, MDR; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Korea; Logistic Models; Male; Middle Aged; Multivariate Analysis; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; Sequence Analysis, DNA; Severity of Illness Index | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
Genotypic and phenotypic evolution of HIV type-1 protease during in vitro sequential or concomitant combination of atazanavir and amprenavir.
Topics: Atazanavir Sulfate; Carbamates; Cell Line; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; Furans; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Phenotype; Pyridines; Recombination, Genetic; Sulfonamides; Treatment Failure | 2010 |
Factors predictive of virological failure on atazanavir in 310 HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; ROC Curve; Viral Load; Young Adult | 2010 |
Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; London; Male; Oligopeptides; Organophosphonates; Pyridines; Risk Factors; Tenofovir | 2010 |
Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chemoprevention; Drug Therapy, Combination; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Netherlands; Oligopeptides; Patient Compliance; Pyridines; Reverse Transcriptase Inhibitors; Sexual Behavior; Young Adult | 2010 |
Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.
Topics: Adult; Alleles; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Female; Follow-Up Studies; Gene Frequency; Glucuronosyltransferase; HIV Infections; Humans; Hyperbilirubinemia; Incidence; Male; Middle Aged; Oligopeptides; Promoter Regions, Genetic; Pyridines; Republic of Korea | 2010 |
Exposure-related effects of atazanavir on the pharmacokinetics of raltegravir in HIV-1-infected patients.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium | 2010 |
Recent FDA approvals and changes.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Capsules; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Pyridines; Reverse Transcriptase Inhibitors; Stavudine; Tablets; United States; United States Food and Drug Administration | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2010 |
Impact of atazanavir-based HAART regimen on the carotid intima-media thickness of HIV-infected persons: a comparative prospective cohort.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Atherosclerosis; Cohort Studies; Female; France; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Tunica Intima; Tunica Media | 2010 |
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adults.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Body Fat Distribution; Body Mass Index; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Young Adult | 2011 |
HIV-infected adolescents: relationship between atazanavir plasma levels and bilirubin concentrations.
Topics: Adolescent; Adolescent Health Services; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Child; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Hyperbilirubinemia; Male; Oligopeptides; Pyridines; Spain | 2011 |
Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Monitoring; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pharmacogenetics; Pyridines | 2012 |
Cost-effectiveness of atazanavir/ritonavir compared with lopinavir/ritonavir in treatment-naïve human immunodeficiency virus-1 patients in Sweden.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Cost-Benefit Analysis; HIV Infections; HIV-1; Humans; Lopinavir; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Sweden | 2011 |
Cost effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in treatment-naïve human immunodeficiency virus-infected patients in the United States.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Cost-Benefit Analysis; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Markov Chains; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Reverse Transcriptase Inhibitors; Risk Assessment; Ritonavir; Tenofovir; United States | 2011 |
Chronic interstitial nephritis in an HIV type-1-infected patient receiving ritonavir-boosted atazanavir.
Topics: Africa, Northern; Atazanavir Sulfate; Crystallization; Drug Therapy, Combination; France; Granulomatous Disease, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Nephritis, Interstitial; Oligopeptides; Pyridines; Ritonavir | 2011 |
Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Buprenorphine; Buprenorphine, Naloxone Drug Combination; Chemical and Drug Induced Liver Injury; Cohort Studies; Dose-Response Relationship, Drug; Drug Interactions; HIV Infections; Humans; Naloxone; Oligopeptides; Opioid-Related Disorders; Pyridines | 2011 |
Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.
Topics: Adult; Alleles; Atazanavir Sulfate; Bilirubin; Biomarkers; CD4 Lymphocyte Count; Coinfection; Female; Follow-Up Studies; Glucuronosyltransferase; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Odds Ratio; Oligopeptides; Pyridines; Regression Analysis; Retrospective Studies; RNA, Viral; ROC Curve; Viral Load | 2011 |
The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; End Stage Liver Disease; Female; HIV Infections; HIV-1; Humans; Liver Cirrhosis; Male; Oligopeptides; Pyridines | 2011 |
Medication-based urolithiasis and atazanavir.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Uric Acid; Urinary Calculi; Urolithiasis | 2011 |
Interaction between antiretroviral drugs and acenocoumarol.
Topics: Acenocoumarol; Alkynes; Anti-HIV Agents; Anticoagulants; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Venous Thrombosis | 2011 |
Changes in lipid profiles after switching to a protease inhibitor-containing cART--unfavourable effect of fosamprenavir in obese patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Cholesterol; Cohort Studies; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipid Metabolism; Male; Middle Aged; Oligopeptides; Organophosphates; Pyridines; Retrospective Studies; Saquinavir; Sulfonamides | 2011 |
Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bilirubin; Cohort Studies; Female; Fetal Blood; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia, Neonatal; Infant, Newborn; Jaundice, Neonatal; Male; Maternal-Fetal Exchange; Medical Records; Oligopeptides; Phototherapy; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Pyridines; Retrospective Studies; Ritonavir | 2011 |
HIV type 1 viral encephalitis after development of viral resistance to plasma suppressive antiretroviral therapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Encephalitis, Viral; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Treatment Outcome; Viral Load | 2012 |
Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Monitoring; Female; Hair; HIV Infections; Humans; Longitudinal Studies; Medication Adherence; Middle Aged; Models, Statistical; Oligopeptides; Pyridines; Treatment Outcome | 2011 |
Therapeutic monitoring and variability of atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Monitoring; Female; Fibrosis; Hepacivirus; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2011 |
Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cross-Sectional Studies; Fanconi Syndrome; Female; France; HIV Infections; HIV-1; Humans; Kidney Tubules, Proximal; Logistic Models; Male; Middle Aged; Odds Ratio; Oligopeptides; Organophosphonates; Prevalence; Pyridines; Risk Assessment; Risk Factors; Tenofovir; Time Factors | 2011 |
Cushing's syndrome due to antiretroviral-budesonide interaction.
Topics: Aged; Atazanavir Sulfate; Budesonide; Cushing Syndrome; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Glucocorticoids; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2011 |
[Persistence in focus. Atazanavir proves itself anew in long-term therapy].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; Humans; Long-Term Care; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic | 2011 |
Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents.
Topics: Adenine; Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Combinations; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; HIV Infections; Humans; Male; Models, Biological; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Tissue Distribution | 2011 |
Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Middle Aged; Monitoring, Physiologic; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Statistics as Topic; Treatment Outcome | 2011 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues.
Topics: Alkynes; Animal Structures; Animals; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; HIV Infections; Humans; Indinavir; Male; Mice; Mice, Inbred BALB C; Oligopeptides; Pyridines; Ritonavir; Tandem Mass Spectrometry | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells.
Topics: Antibiotics, Antineoplastic; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Flow Cytometry; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Oligopeptides; Pyridines; Pyrimidinones; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; Sarcoma, Kaposi; Treatment Outcome | 2011 |
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Developing Countries; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Health Planning; Health Services; HIV Infections; Humans; Lamivudine; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2011 |
Simplified human immunodeficiency virus maintenance therapy in virologically suppressed children with Ritonavir-boosted protease inhibitor monotherapy.
Topics: Adolescent; Anti-HIV Agents; Atazanavir Sulfate; Child; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Oligopeptides; Pyridines; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2011 |
Model-based approach for optimization of atazanavir dose recommendations for HIV-infected pediatric patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Body Weight; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Models, Biological; Oligopeptides; Pediatrics; Practice Guidelines as Topic; Pyridines; Treatment Outcome | 2011 |
Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biliary Tract Diseases; HIV Infections; Humans; Lithiasis; Male; Middle Aged; Oligopeptides; Pyridines | 2012 |
Limited sampling strategies for the estimation of atazanavir daily exposure in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Biological Availability; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Young Adult | 2013 |
Different baseline characteristics and different outcomes of HIV-infected patients receiving HAART through clinical trials compared with routine care in Mexico.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; Epidemiologic Methods; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Mexico; Nevirapine; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2012 |
Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
Topics: Adult; AIDS-Related Opportunistic Infections; Anemia, Hemolytic; Anti-HIV Agents; Anti-Infective Agents; Atazanavir Sulfate; Dapsone; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Pneumocystis carinii; Pneumonia, Pneumocystis; Pyridines | 2012 |
The role of polymorphisms at position 89 in the HIV-1 protease gene in the development of drug resistance to HIV-1 protease inhibitors.
Topics: Amino Acid Substitution; Anti-HIV Agents; Atazanavir Sulfate; Cells, Cultured; Drug Resistance, Viral; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Leukocytes, Mononuclear; Lopinavir; Nelfinavir; Oligopeptides; Polymorphism, Genetic; Pyridines; Virus Cultivation | 2012 |
Virologic failures on initial boosted-PI regimen infrequently possess low-level variants with major PI resistance mutations by ultra-deep sequencing.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genotype; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Mutation; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2012 |
Immune reconstitution renal-limited sarcoidosis presenting as acute kidney injury.
Topics: Acute Kidney Injury; Adenine; Adult; AIDS-Associated Nephropathy; Anti-Retroviral Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Oligopeptides; Organophosphonates; Prednisone; Pyridines; Ritonavir; Sarcoidosis; Tenofovir; Young Adult | 2012 |
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2012 |
Monitoring the risk of birth defects associated with atazanavir exposure in pregnancy.
Topics: Abnormalities, Drug-Induced; Adult; Anti-HIV Agents; Atazanavir Sulfate; Data Collection; Female; HIV Infections; Humans; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Pyridines; Registries; Retrospective Studies; Young Adult | 2012 |
Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Coinfection; Drug Interactions; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Viral Load | 2012 |
Cutaneous CD8+ T-cell infiltrates associated with human immunodeficiency virus.
Topics: Adenine; Alopecia; Anti-HIV Agents; Antigens, Differentiation, T-Lymphocyte; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD8-Positive T-Lymphocytes; Deoxycytidine; Diagnosis, Differential; Emtricitabine; HIV Infections; Humans; Lymphoma, T-Cell, Cutaneous; Male; Middle Aged; Oligopeptides; Organophosphonates; Prednisone; Pseudolymphoma; Pyridines; Ritonavir; Skin; Tenofovir | 2012 |
Assessing the effectiveness of antiretroviral regimens in cohort studies involving HIV-positive injection drug users.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Substance Abuse, Intravenous; Treatment Outcome; Viral Load | 2012 |
Unboosted atazanavir for treatment of HIV infection: rationale and recommendations for use.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Patient Selection; Practice Guidelines as Topic; Pregnancy; Pyridines; Randomized Controlled Trials as Topic; Risk Factors | 2012 |
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.
Topics: Adult; Animals; Anti-Retroviral Agents; Atazanavir Sulfate; Blood-Brain Barrier; Brain; Cells, Cultured; Coculture Techniques; Drug Carriers; Drug Delivery Systems; Endothelial Cells; Folic Acid; HIV Infections; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Fluorescence; Mononuclear Phagocyte System; Nanoparticles; Oligopeptides; Pyridines; Ritonavir; Spleen; Tissue Distribution; Viral Load | 2012 |
Renal function and incidence of chronic kidney disease in HIV patients: a Danish cohort study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Denmark; Female; Glomerular Filtration Rate; HIV Infections; Humans; Incidence; Kidney; Linear Models; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Renal Insufficiency, Chronic; Tenofovir | 2012 |
Monotherapy with atazanavir as a simplification strategy: results from an observational study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-CD8 Ratio; Female; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; RNA, Viral; Treatment Failure | 2012 |
Complicated atazanavir-associated cholelithiasis: a report of 14 cases.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Atazanavir Sulfate; Calculi; Cholelithiasis; Female; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Spectrophotometry, Infrared | 2012 |
High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Kidney Calculi; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2012 |
Efficacy and safety of a dual boosted protease inhibitor-based regimen, atazanavir and fosamprenavir/ritonavir, against HIV: experience in a pediatric population.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Child; Female; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Oligopeptides; Organophosphates; Pyridines; Ritonavir; RNA, Viral; Salvage Therapy; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
[A single tablet against HIV: new combination preparation improves therapy].
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Cobicistat; Cyclopropanes; Deoxycytidine; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Glomerular Filtration Rate; HIV Infections; Humans; Oligopeptides; Organophosphonates; Pyridines; Quinolones; Randomized Controlled Trials as Topic; Ritonavir; Tenofovir; Thiazoles; Viral Load | 2012 |
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort.
Topics: Adenine; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV-1; Humans; Italy; Longitudinal Studies; Lopinavir; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Retrospective Studies; Ritonavir; Tenofovir; Time Factors | 2013 |
The protease inhibitor atazanavir triggers autophagy and mitophagy in human preadipocytes.
Topics: Adipocytes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Autophagy; Blotting, Western; Cells, Cultured; Dose-Response Relationship, Drug; Female; Flow Cytometry; Green Fluorescent Proteins; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Male; Microscopy, Electron; Mitophagy; Oligopeptides; Pyridines | 2012 |
Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coinfection; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Interleukins; Male; Middle Aged; Oligopeptides; Pyridines; RNA, Viral; Viral Load | 2013 |
Mutations selected in HIV-2-infected patients failing a regimen including atazanavir.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV-2; Humans; Mutation; Oligopeptides; Pyridines; Ritonavir; Treatment Failure | 2013 |
Incidence of renal toxicity in HIV-infected, antiretroviral-naïve patients starting tenofovir/emtricitabine associated with efavirenz, atazanavir/ritonavir, or lopinavir/ritonavir.
Topics: Adenine; Adult; Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Diseases; Lopinavir; Male; Middle Aged; Oligopeptides; Organophosphonates; Proteinuria; Pyridines; Retrospective Studies; Ritonavir; Tenofovir | 2013 |
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Furans; HIV Infections; Humans; Italy; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Oxazines; Pyridines; Self Report; Sulfonamides; Surveys and Questionnaires; Viral Load | 2013 |
Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Male; Middle Aged; Models, Statistical; Oligopeptides; Plasma; Pyridines; Ritonavir; Young Adult | 2013 |
Long-term efficacy and safety of atazanavir/ritonavir treatment in a real-life cohort of treatment-experienced patients with HIV type 1 infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Data Collection; Databases, Factual; Europe; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Young Adult | 2013 |
Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cerebrospinal Fluid; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Plasma; Pyridines; RNA, Viral; Treatment Outcome; Viral Load | 2013 |
Coadministration of tenofovir decreased atazanavir plasma concentration after unilateral nephrectomy.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Interactions; HIV Infections; Humans; Liver Function Tests; Male; Nephrectomy; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2013 |
Atazanavir-related hyperbilirubinaemia is not highlighted in the British National Formulary.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Delivery of Health Care; Female; Germany; HIV Infections; Humans; Hyperbilirubinemia; Jaundice; Oligopeptides; Pharmacopoeias as Topic; Practice Guidelines as Topic; Pyridines; Referral and Consultation; United Kingdom | 2012 |
Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Ritonavir; Salivary Gland Calculi | 2013 |
Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Hispanic or Latino; HIV Infections; Humans; Hyperbilirubinemia; Incidence; Jaundice; Male; Middle Aged; Oligopeptides; Pyridines | 2013 |
Pharmacokinetic-pharmacodynamic modeling of unboosted Atazanavir in a cohort of stable HIV-infected patients.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Biological Availability; Drug Administration Schedule; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Models, Biological; Oligopeptides; Pyridines; Treatment Failure | 2013 |
Pharmacologic boosting of atazanavir in maintenance HIV-1 therapy: the COREYA propensity-score adjusted study.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Endpoint Determination; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Oligopeptides; Pyridines; Time Factors; Treatment Outcome | 2012 |
The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Monitoring; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nevirapine; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors | 2013 |
External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Biomarkers; Computer Simulation; Drug Monitoring; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Medication Adherence; Middle Aged; Nomograms; Oligopeptides; Pyridines; Reproducibility of Results; Ritonavir | 2013 |
Atazanavir is not associated with an increased risk of cardio- or cerebrovascular disease events.
Topics: Adult; Aged; Atazanavir Sulfate; Australia; Comorbidity; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Incidence; Male; Middle Aged; Myocardial Infarction; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Ritonavir; Stroke; Time Factors; Treatment Outcome; United States; Viral Load | 2013 |
Pharmacokinetic exposure and virological efficacy of a reduced atazanavir dose.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Viral Load | 2012 |
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
Topics: Adiposity; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Bone and Bones; Cognition; Drug Resistance, Viral; Endpoint Determination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Oligopeptides; Patient Compliance; Pilot Projects; Pregnancy; Pyridines; Quality of Life; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure | 2013 |
Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Chromatography, Liquid; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Mass Spectrometry; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2013 |
Promising new agents on the horizon.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Nitriles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridazines; Pyridines; Pyrimidines; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2002 |
BMS-232632, a new protease inhibitor, is taken once daily.
Topics: Atazanavir Sulfate; Drug Administration Schedule; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2000 |
[Simple, safe and effective. New protease inhibitor means progress].
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines | 2002 |
[Highly effective and tolerable protease inhibitor. New trump card against HIV].
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines; Treatment Outcome; Viral Load | 2003 |
Anti-HIV drug updates--three drugs on the near horizon.
Topics: Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Deoxycytidine; Drug Approval; Drug Design; Emtricitabine; Enfuvirtide; HIV Envelope Protein gp41; HIV Infections; Humans; Oligopeptides; Peptide Fragments; Pyridines; United States; United States Food and Drug Administration; Viral Load | 2003 |
Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; United States; United States Food and Drug Administration; Viral Load | 2003 |
Atazanavir gets FDA Advisory Committee's thumbs-up.
Topics: Advisory Committees; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Food-Drug Interactions; HIV Infections; Humans; Oligopeptides; Pyridines; United States; United States Food and Drug Administration | 2003 |
[New protease inhibitor against HIV. Viral load decreases--without lipid increase].
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Oligopeptides; Pyridines; Viral Load | 2003 |
[Atazanavir--first protease inhibitor for one dose administration].
Topics: Atazanavir Sulfate; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Viral Load | 2003 |
Atazanavir (Reyataz) and emtricitabine (Emtriva) for HIV infection.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance; Emtricitabine; HIV Infections; HIV-1; Humans; Jaundice; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic | 2003 |
BMS issues PK notice regarding ATV + TDF.
Topics: Adenine; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Clinical Trials as Topic; Drug Industry; HIV Infections; Humans; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Pyridines; Tenofovir; United States; United States Food and Drug Administration | 2003 |
FDA notifications. Reyataz is approved for HIV treatment.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Approval; HIV Infections; Humans; Oligopeptides; Pyridines; United States; United States Food and Drug Administration | 2003 |
Atazanavir: clinical use.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Viral Load | 2003 |
Drug profile: atazanavir (Reyataz, ATV).
Topics: Atazanavir Sulfate; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2003 |
Atazanavir sulphate.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Structure-Activity Relationship | 2003 |
[Are all boosted protease inhibitors the same? Previously treated patients profit too from lopinavir/r].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Organophosphates; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Sulfonamides; Time Factors; Viral Load | 2003 |
Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Indinavir; Oligopeptides; Pyridines | 2004 |
[Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Nelfinavir; Oligopeptides; Oxazines; Pyridines | 2003 |
Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Topics: Atazanavir Sulfate; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Pyrones; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Sulfonamides | 2004 |
Optimizing dosing strategies for the combination of atazanavir plus saquinavir.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Dose-Response Relationship, Drug; HIV Infections; HIV-1; Humans; Oligopeptides; Pyridines; Saquinavir | 2004 |
Identification of I50L as the signature atazanavir (ATV)-resistance mutation in treatment-naive HIV-1-infected patients receiving ATV-containing regimens.
Topics: Atazanavir Sulfate; Base Sequence; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Molecular Sequence Data; Oligopeptides; Point Mutation; Pyridines; Reassortant Viruses; Sequence Analysis, DNA; Virus Replication | 2004 |
[New treatment options for HIV-infected patients].
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2004 |
Atazanavir (Reyataz): new recommendations if combined with tenofovir (Viread) -- and warning on Viagra, Cialis, and Levitra.
Topics: Adenine; Atazanavir Sulfate; Carbolines; Drug Information Services; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Imidazoles; Oligopeptides; Organophosphonates; Organophosphorus Compounds; Piperazines; Purines; Pyridines; Reverse Transcriptase Inhibitors; Sildenafil Citrate; Sulfones; Tadalafil; Tenofovir; Triazines; Vardenafil Dihydrochloride | 2004 |
Acute hepatic cytolysis in an HIV-infected patient taking atazanavir.
Topics: Acute Disease; Atazanavir Sulfate; Chemical and Drug Induced Liver Injury; Female; HIV Infections; HIV Protease Inhibitors; Humans; Middle Aged; Oligopeptides; Pyridines | 2004 |
Pseudoaneurysm of the femoral artery in a HIV-infected man.
Topics: Aneurysm, False; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Femoral Artery; HIV Infections; HIV Protease Inhibitors; Humans; Hyperlipidemias; Indinavir; Male; Middle Aged; Oligopeptides; Postoperative Hemorrhage; Pyridines; Streptococcal Infections; Ultrasonography, Doppler, Color; Vascular Surgical Procedures | 2004 |
Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Female; Gels; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; Saquinavir | 2004 |
[Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].
Topics: Adult; Atazanavir Sulfate; Clinical Trials as Topic; Delayed-Action Preparations; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2004 |
[Long-term tolerance. Favorable lipid profile--favorable effect on development of lipodystrophy?].
Topics: Adult; Atazanavir Sulfate; Cardiovascular Diseases; Clinical Trials as Topic; Delayed-Action Preparations; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin Resistance; Lipids; Long-Term Care; Oligopeptides; Pyridines | 2004 |
[Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir in general practice].
Topics: Atazanavir Sulfate; Delayed-Action Preparations; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2004 |
[Good experiences with saquinavir. Double boosting of protease inhibitors gains significance].
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Synergism; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Saquinavir; Viral Load | 2004 |
[Atazanavir protects lipid metabolism. New PI with favorable metabolic profile].
Topics: Atazanavir Sulfate; Blood Glucose; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipids; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Viral Load | 2004 |
New dosing regimen for atazanavir.
Topics: Atazanavir Sulfate; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; HIV Infections; Humans; Oligopeptides; Pyridines | 2004 |
Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Topics: Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir | 2005 |
Avoid PPIs with atazanavir.
Topics: Area Under Curve; Atazanavir Sulfate; Histamine H2 Antagonists; HIV Infections; Humans; Oligopeptides; Proton Pump Inhibitors; Pyridines | 2005 |
Atazanavir: a novel inhibitor of HIV-protease in haemodialysis.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Failure, Chronic; Male; Middle Aged; Oligopeptides; Pyridines; Renal Dialysis | 2005 |
Simple and simultaneous determination of the hiv-protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir plus M8 nelfinavir metabolite and the nonnucleoside reverse transcriptase inhibitors efavirenz and nevi
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Calibration; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lopinavir; Nelfinavir; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Reproducibility of Results; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Specimen Handling; Spectrophotometry, Ultraviolet; Sulfonamides | 2005 |
Lack of interaction between atazanavir and lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Atazanavir Sulfate; Contraindications; Drug Interactions; Drug Therapy, Combination; Gastroesophageal Reflux; HIV Infections; Humans; Lansoprazole; Male; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines | 2005 |
FDA notifications. BMS issues letter about omeprazole.
Topics: Area Under Curve; Atazanavir Sulfate; Drug Industry; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Oligopeptides; Omeprazole; Pyridines; Randomized Controlled Trials as Topic; Ritonavir; United States; United States Food and Drug Administration | 2005 |
Atazanavir affects saquinavir.
Topics: Atazanavir Sulfate; Biological Availability; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Saquinavir; Severity of Illness Index; Survival Rate; Treatment Outcome; United Kingdom; Viral Load | 2005 |
Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
Topics: Atazanavir Sulfate; Chromatography, High Pressure Liquid; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2006 |
Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Male; Oligopeptides; Pyridines; RNA, Viral | 2005 |
Co-administration of atazanavir with proton-pump inhibitors and H2 blockers.
Topics: Anti-Ulcer Agents; Atazanavir Sulfate; Drug Interactions; Histamine H2 Antagonists; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Retrospective Studies | 2005 |
Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Carbamates; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Saquinavir; Sulfonamides | 2005 |
Unexpected improvement of sexual dysfunction during atazanavir therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Sexual Dysfunction, Physiological | 2005 |
Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Cohort Studies; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines | 2005 |
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Blotting, Western; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genes, Viral; Genetic Vectors; HIV Core Protein p24; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; Oligopeptides; Phenotype; Pyridines; Reverse Transcriptase Inhibitors | 2005 |
Lack of an effect of atazanavir on steady-state pharmacokinetics of methadone in patients chronically treated for opiate addiction.
Topics: Adult; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Methadone; Middle Aged; Oligopeptides; Opioid-Related Disorders; Pyridines | 2005 |
Use of bilirubin as a marker of adherence to atazanavir-based antiretroviral therapy.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Biomarkers; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Patient Compliance; Pyridines; Retrospective Studies; Treatment Outcome; Viral Load | 2005 |
Proton pump inhibitors do not reduce atazanavir concentrations in HIV-infected patients treated with ritonavir-boosted atazanavir.
Topics: Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Male; Oligopeptides; Prospective Studies; Proton Pump Inhibitors; Pyridines; Ritonavir | 2005 |
Can boosted atazanavir induce hyperlipotrophy?
Topics: Aged; Atazanavir Sulfate; Bilirubin; Female; Hepatitis C; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Oligopeptides; Protease Inhibitors; Pyridines | 2006 |
Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2005 |
Rash in an HIV-positive patient.
Topics: Adult; Atazanavir Sulfate; Drug Eruptions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Pyridines | 2005 |
Clinical validation of atazanavir/ritonavir genotypic resistance score in protease inhibitor-experienced patients.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Mutation; Oligopeptides; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
A case of transient hyperphosphatasemia of infancy and early childhood in an HIV-positive adult possibly related to atazanavir.
Topics: Adult; Alkaline Phosphatase; Anti-HIV Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Pyridines | 2006 |
Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Drug Administration Schedule; Drug Interactions; Furans; HIV Infections; Humans; Oligopeptides; Organophosphates; Pyridines; Sulfonamides; Treatment Failure; Viremia | 2006 |
Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Genes, MDR; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Odds Ratio; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk Factors; RNA, Viral; Viral Load | 2006 |
Use of acid-reducing agents in protease inhibitor-based HAART and the potential for negative treatment outcomes.
Topics: Acids; Atazanavir Sulfate; Drug Interactions; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Treatment Outcome | 2005 |
[New data on atazanavir/r]].
Topics: Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome; Viral Load | 2005 |
Human placental transfer of atazanavir: a case report.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Maternal-Fetal Exchange; Oligopeptides; Pregnancy; Pregnancy Complications, Infectious; Pyridines | 2006 |
Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir.
Topics: Atazanavir Sulfate; Buprenorphine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Narcotics; Oligopeptides; Pyridines; Ritonavir | 2006 |
Lack of interaction between atazanavir and proton pump inhibitors in HIV-infected patients treated with ritonavir-boosted atazanavir.
Topics: Antacids; Atazanavir Sulfate; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Oligopeptides; Proton Pump Inhibitors; Pyridines; Ritonavir | 2006 |
Proton pump inhibitor therapy in atazanavir-treated patients: contraindicated?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzimidazoles; Contraindications; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Rabeprazole; Ritonavir | 2006 |
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.
Topics: Aged; Anti-HIV Agents; Anti-Ulcer Agents; Atazanavir Sulfate; Carbamates; Drug Interactions; Esomeprazole; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Organophosphates; Prospective Studies; Proton Pump Inhibitors; Pyridines; Sulfonamides | 2006 |
Some PIs have greater impact than others on heart disease. Patients on atazanavir had less heart problems.
Topics: Atazanavir Sulfate; Heart Diseases; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2006 |
Ritonavir-boosted atazanavir may be efficacious in HIV-infected patients concurrently receiving omeprazole.
Topics: Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Omeprazole; Pyridines; Ritonavir | 2006 |
Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Prospective Studies; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir | 2006 |
The effects of the Roche AMPLICOR HIV-1 MONITOR UltraSensitive Test versions 1.0 and 1.5 viral load assays and plasma collection tube type on determination of response to antiretroviral therapy and the inappropriateness of cross-study comparisons.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Blood Specimen Collection; Cyclopropanes; DNA Primers; Drug Therapy, Combination; Edetic Acid; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Internationality; Nucleic Acid Amplification Techniques; Oligopeptides; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Reagent Kits, Diagnostic; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2006 |
External validation of atazanavir/ritonavir genotypic score in HIV-1 protease inhibitor-experienced patients.
Topics: Atazanavir Sulfate; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Mutation; Oligopeptides; Pyridines; Ritonavir; Species Specificity | 2006 |
A single centre cohort experience with a new once daily antiretroviral drug.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Prospective Studies; Pyridines; Treatment Outcome | 2006 |
Atazanavir and lopinavir/ritonavir: pharmacokinetics, safety and efficacy of a promising double-boosted protease inhibitor regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Combinations; Drug Monitoring; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Failure; Treatment Outcome; Viral Load | 2006 |
Report from the 13th retrovirus conference. Extending the role of atazanavir.
Topics: Atazanavir Sulfate; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Viral Load | 2006 |
Influence of tenofovir, nevirapine and efavirenz on ritonavir-boosted atazanavir pharmacokinetics in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Nevirapine; Oligopeptides; Organophosphonates; Oxazines; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2006 |
[Acute tubulointerstitial nephritis in HIV infection].
Topics: Acute Kidney Injury; AIDS-Associated Nephropathy; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biopsy; Diagnosis, Differential; HIV Infections; Humans; Kidney Tubules; Male; Middle Aged; Nephritis, Interstitial; Oligopeptides; Pyridines | 2006 |
Impact of modelling intra-subject variability on tests based on non-linear mixed-effects models in cross-over pharmacokinetic trials with application to the interaction of tenofovir on atazanavir in HIV patients.
Topics: Adenine; Anti-HIV Agents; Atazanavir Sulfate; Bias; Cross-Over Studies; Drug Interactions; France; HIV Infections; Humans; Likelihood Functions; Nonlinear Dynamics; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2007 |
Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Statistics, Nonparametric | 2006 |
Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection.
Topics: Adult; Aged; Algorithms; Area Under Curve; Atazanavir Sulfate; Bayes Theorem; Dose-Response Relationship, Drug; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Models, Statistical; Oligopeptides; Population; Pyridines; Reproducibility of Results; Ritonavir; Treatment Outcome | 2006 |
Change to a once-daily combination including boosted atazanavir in HIV-1-infected children.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Atazanavir Sulfate; Child; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Male; Oligopeptides; Organophosphonates; Prospective Studies; Pyridines; Ritonavir; Tenofovir; Virus Replication | 2006 |
A prospective evaluation of the effect of atazanavir on the QTc interval and QTc dispersion in HIV-positive patients.
Topics: Antiretroviral Therapy, Highly Active; Arrhythmias, Cardiac; Atazanavir Sulfate; Electrocardiography; Female; Heart Conduction System; Heart Rate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Treatment Outcome | 2006 |
Clinical outcomes associated with concomitant use of atazanavir and proton pump inhibitors.
Topics: Adult; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Oligopeptides; Proton Pump Inhibitors; Proton Pumps; Pyridines; Retrospective Studies; Treatment Outcome | 2006 |
Suppression of HIV-1 protease inhibitor resistance by phosphonate-mediated solvent anchoring.
Topics: Atazanavir Sulfate; Binding Sites; Drug Design; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Models, Molecular; Molecular Structure; Oligopeptides; Organophosphonates; Pyridines; Solvents; Thermodynamics | 2006 |
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.
Topics: Adult; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Dose-Response Relationship, Drug; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lymphocytes; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2006 |
Response to "Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?" by Hill.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Patient Selection; Pyridines; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome | 2006 |
Therapeutic ritonavir-boosted atazanavir plasma concentration and concurrent omeprazole use.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Interactions; Drug Monitoring; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Omeprazole; Proton Pump Inhibitors; Pyridines; Ritonavir | 2006 |
Atazanavir urinary stones in an HIV-infected patient.
Topics: Adult; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Kidney Calculi; Male; Oligopeptides; Pyridines | 2006 |
Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.
Topics: Adult; Aged; Atazanavir Sulfate; Female; Genetic Variation; Gilbert Disease; Glucuronosyltransferase; Haplotypes; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Male; Middle Aged; Oligopeptides; Polymorphism, Single Nucleotide; Pyridines | 2006 |
Identification and structural characterization of I84C and I84A mutations that are associated with high-level resistance to human immunodeficiency virus protease inhibitors and impair viral replication.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Genes, gag; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Mutation; Nelfinavir; Oligopeptides; Pyridines; Ritonavir; Saquinavir; Virus Replication | 2007 |
Atazanavir urolithiasis.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydronephrosis; Male; Oligopeptides; Pyridines; Ureteral Calculi; Urolithiasis | 2006 |
Successful treatment with atazanavir and lopinavir/ritonavir combination therapy in protease inhibitor-susceptible and protease inhibitor-resistant HIV-infected patients.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir | 2006 |
Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Genes, MDR; Genotype; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Logistic Models; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Pyridines; Risk; Ritonavir | 2007 |
Cost effectiveness of lopinavir/ritonavir compared with atazanavir in antiretroviral-naive patients: modelling the combined effects of HIV and heart disease.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Fees, Pharmaceutical; Health Care Costs; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Markov Chains; Models, Statistical; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Ritonavir; Survival Analysis; Survival Rate; Time Factors | 2007 |
Meeting report. Report from ICAAC.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Carbamates; Cyclopropanes; Furans; HIV Infections; Humans; Oligopeptides; Organic Chemicals; Organophosphates; Oxazines; Patient Compliance; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Sulfonamides; Viral Load | 2006 |
Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.
Topics: Adult; Aged; Area Under Curve; Atazanavir Sulfate; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Safety; Saquinavir | 2007 |
Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application.
Topics: Atazanavir Sulfate; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Quality Control; Reference Standards; Reproducibility of Results; Ritonavir; Spectrometry, Mass, Electrospray Ionization; Spectrophotometry, Ultraviolet; Time Factors | 2007 |
Prolonged QT interval and torsades de pointes associated with atazanavir therapy.
Topics: Atazanavir Sulfate; Electrocardiography; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Long QT Syndrome; Middle Aged; Oligopeptides; Pyridines; Risk Assessment; Torsades de Pointes | 2007 |
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B, Member 1; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Polymorphism, Genetic; Pyridines; Pyrimidinones | 2007 |
Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Monitoring; Female; Hepatitis C, Chronic; HIV Infections; Humans; Liver Cirrhosis; Lopinavir; Male; Nevirapine; Oligopeptides; Oxazines; Pyridines; Pyrimidinones; Ritonavir; Severity of Illness Index | 2007 |
Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects.
Topics: Adult; Atazanavir Sulfate; Blood Glucose; Fasting; Female; Glucose Tolerance Test; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lipid Metabolism; Male; Middle Aged; Oligopeptides; Pilot Projects; Prospective Studies; Protease Inhibitors; Pyridines; Retreatment; Treatment Outcome | 2007 |
Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users.
Topics: Alkynes; Atazanavir Sulfate; Benzoxazines; Biological Assay; Buprenorphine; Calibration; Chromatography, Liquid; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Mass Spectrometry; Molecular Structure; Narcotic Antagonists; Oligopeptides; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Substance-Related Disorders; Tandem Mass Spectrometry | 2007 |
Pharmaceutical approach to HIV protease inhibitor atazanavir for bioavailability enhancement based on solid dispersion system.
Topics: Administration, Oral; Animals; Atazanavir Sulfate; Biological Availability; Drug Carriers; Excipients; Fats; HIV Infections; HIV Protease Inhibitors; Male; Oils; Oligopeptides; Powders; Pyridines; Rats; Rats, Wistar; Sodium Dodecyl Sulfate; X-Ray Diffraction | 2007 |
Atazanavir in plasma-exchange treatment.
Topics: Adult; Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Plasma Exchange; Purpura, Thrombotic Thrombocytopenic; Pyridines | 2007 |
Atazanavir-containing renal calculi in an HIV-infected patient.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Calculi; Male; Middle Aged; Oligopeptides; Pyridines | 2007 |
Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.
Topics: Acute Kidney Injury; Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; Fluorescent Antibody Technique; HIV Infections; Humans; Immunohistochemistry; Kidney; Male; Microscopy, Electron; Middle Aged; Nephritis, Interstitial; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Tenofovir | 2007 |
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Topics: Adenine; Adult; Adverse Drug Reaction Reporting Systems; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Hospitalization; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States | 2007 |
The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial.
Topics: Adult; Atazanavir Sulfate; C-Reactive Protein; CD4 Lymphocyte Count; CD8 Antigens; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pilot Projects; Pyridines; Ritonavir; RNA, Viral; Semen; Treatment Outcome; Viral Load | 2007 |
Alopecia associated with ritonavir-boosted atazanavir therapy.
Topics: Adult; Alopecia; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2007 |
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
Topics: Adolescent; Adult; Anti-HIV Agents; Antitubercular Agents; Area Under Curve; Atazanavir Sulfate; Biotransformation; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Rifampin; Tuberculosis | 2007 |
Cushing syndrome and severe adrenal suppression caused by fluticasone and protease inhibitor combination in an HIV-infected adolescent.
Topics: Adolescent; Adrenal Insufficiency; Albuterol; Androstadienes; Anti-HIV Agents; Anti-Inflammatory Agents; Atazanavir Sulfate; Cushing Syndrome; Drug Interactions; Drug Therapy, Combination; Female; Fluticasone; HIV Infections; Humans; Hydrocortisone; Oligopeptides; Pyridines; Ritonavir; Salmeterol Xinafoate | 2007 |
Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Bundle-Branch Block; Drug Monitoring; Electrocardiography; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines | 2007 |
Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.
Topics: Adult; Analgesics, Opioid; Atazanavir Sulfate; Buprenorphine; Drug Interactions; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Substance-Related Disorders | 2007 |
[Insulin resistance in HIV-infected patients receiving long-term therapy with efavirenz, lopinavir/ritonavir and atazanavir].
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Time Factors | 2007 |
Virological failure and subsequent resistance profiles in individuals exposed to atazanavir.
Topics: Atazanavir Sulfate; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Pyridines; Ritonavir; Treatment Failure | 2007 |
Therapeutic drug monitoring of the HIV protease inhibitor atazanavir in clinical practice.
Topics: Adult; Atazanavir Sulfate; Bilirubin; Cohort Studies; Drug Monitoring; Drug Resistance, Viral; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Male; Middle Aged; Mutation; Netherlands; Oligopeptides; Plasma; Pyridines; Retrospective Studies; Treatment Outcome | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Steady-state pharmacokinetics of once-daily fosamprenavir/ritonavir and atazanavir/ritonavir alone and in combination with 20 mg omeprazole in healthy volunteers.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Male; Oligopeptides; Omeprazole; Organophosphates; Proton Pump Inhibitors; Pyridines; Sulfonamides | 2007 |
Atazanavir-associated menorrhagia.
Topics: Adult; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Menorrhagia; Oligopeptides; Pyridines | 2007 |
Treatment of an atazanivir associated grade 4 hyperbilirubinaemia with efavirenz.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Middle Aged; Oligopeptides; Pyridines | 2007 |
Urolithiasis in HIV-positive patients treated with atazanavir.
Topics: Adult; Atazanavir Sulfate; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Oligopeptides; Pyridines; Risk Factors; Urine; Urolithiasis; Water | 2007 |
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Monitoring; Female; Hepatitis C; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pyridines; Pyrimidinones; Substance-Related Disorders; United States | 2007 |
Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bilirubin; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Drug Administration Schedule; Drug Monitoring; Female; HIV Infections; Humans; Male; Oligopeptides; Pyridines; Ritonavir | 2007 |
Early virologic rebound in a pilot trial of ritonavir-boosted atanazavir as maintenance monotherapy.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lopinavir; Oligopeptides; Pilot Projects; Pyridines; Pyrimidinones; Ritonavir | 2007 |
Cost effectiveness of lopinavir/ritonavir tablets compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the UK, France, Italy and Spain.
Topics: Adult; Atazanavir Sulfate; Coronary Disease; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; France; Health Care Costs; HIV Infections; HIV Protease Inhibitors; Humans; Italy; Lopinavir; Male; Markov Chains; Oligopeptides; Pyridines; Pyrimidinones; Quality-Adjusted Life Years; Risk Factors; Ritonavir; Spain; Time Factors; United Kingdom | 2007 |
Evolution of the HIV-1 protease region in heavily pretreated HIV-1 infected patients receiving Atazanavir.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Resistance, Viral; Evolution, Molecular; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Oligopeptides; Phenotype; Phylogeny; Pyridines; Sequence Analysis, DNA | 2008 |
Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Leukocytes, Mononuclear; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir | 2008 |
Reyataz monotherapy study stopped.
Topics: Atazanavir Sulfate; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Viral Load | 2007 |
Atazanavir crystal nephropathy.
Topics: Atazanavir Sulfate; Calcium Phosphates; Crystallization; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney Calculi; Male; Middle Aged; Oligopeptides; Pyridines | 2007 |
Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir.
Topics: Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines; Ritonavir; Saquinavir | 2008 |
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Oligopeptides; Pyridines; Risk Factors | 2008 |
Liver toxicity of antiretroviral combinations including atazanavir/ritonavir in patients co-infected with HIV and hepatitis viruses: impact of pre-existing liver fibrosis.
Topics: Adult; Age Factors; Atazanavir Sulfate; Bilirubin; CD4 Lymphocyte Count; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Cirrhosis; Male; Oligopeptides; Pyridines; Ritonavir; Transaminases | 2008 |
Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Mass Index; Body Weight; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lipids; Male; Metabolic Syndrome; Middle Aged; Oligopeptides; Pyridines; Retrospective Studies; Ritonavir | 2008 |
Progression of Kaposi sarcoma associated with iatrogenic Cushing syndrome in a person with HIV/AIDS.
Topics: Androstadienes; Anti-Inflammatory Agents; Atazanavir Sulfate; Cushing Syndrome; Drug Interactions; Fluticasone; HIV Infections; HIV Protease Inhibitors; Humans; Iatrogenic Disease; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Sarcoma, Kaposi | 2008 |
Urolithiasis under atazanavir boosted and tenofovir therapy: a case report.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; HIV Infections; Humans; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir; Urolithiasis; Viral Load | 2008 |
Atazanavir and lopinavir with ritonavir alone or in combination: analysis of pharmacokinetic interaction and predictors of drug exposure.
Topics: Adult; Aged; Atazanavir Sulfate; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Pilot Projects; Prospective Studies; Pyridines; Pyrimidinones; Ritonavir | 2008 |
Revised package insert for atazanavir.
Topics: Atazanavir Sulfate; Drug Labeling; Histamine H2 Antagonists; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Proton Pump Inhibitors; Pyridines | 2008 |
Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen.
Topics: Atazanavir Sulfate; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Ritonavir; Salvage Therapy; Treatment Outcome | 2008 |
New pediatric dosing recommendations for atazanavir.
Topics: Adolescent; Adult; Atazanavir Sulfate; Capsules; Child; Child, Preschool; Clinical Trials as Topic; Drug Labeling; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Multicenter Studies as Topic; Oligopeptides; Pyridines; Reference Standards; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2008 |
The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors.
Topics: Adult; Area Under Curve; Atazanavir Sulfate; Chromatography, High Pressure Liquid; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Metabolic Clearance Rate; Middle Aged; Oligopeptides; Outpatients; Plasma; Pyridines; Ritonavir; Sex; Tandem Mass Spectrometry | 2008 |
[Acute renal failure associated with the use of tenofovir combined with atazanavir in patients with HIV infection].
Topics: Acute Kidney Injury; Adenine; Anti-HIV Agents; Atazanavir Sulfate; Drug Therapy, Combination; HIV Infections; Humans; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Tenofovir | 2008 |
[Progress toward a once daily regimen. (HA)ART--the art of antiretroviral therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Clinical Trials as Topic; Drug Administration Schedule; Forecasting; HIV Infections; HIV Protease Inhibitors; Humans; Oligopeptides; Pyridines | 2001 |
A new protease inhibitor from Bristol-Myers Squibb.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Industry; Female; HIV Infections; HIV Protease Inhibitors; Humans; Male; Oligopeptides; Pyridines; Viral Load | 2001 |